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General introduction 
CHAPTER 1 
Introduction 
Summary measures of population health combine information on different 
aspects of health to depict a population's health as a single figure. They may be 
used to identify differences in health (e.g. between groups or countries), or 
changes over time (e.g. as a result of policy measures) [1]. The interest in and 
use of these measures has increased over the past decades, and different types 
have been constructed [2]. Although it is theoretically attractive to include 
information on specific diseases in summary measures (for reasons that will be 
discussed later in this chapter), in practice data problems limit the use of disease-
specific summary measures. In this thesis we study practical data problems that 
may restrict the construction of these measures. In the introductory chapter we 
first define summary measures of population health and distinguish different 
types. Then we describe the data problems and the research question they gave 
rise to. We end this chapter with an outline of the thesis. 
Measuring population health 
Health policy makers are concerned with protecting and improving the health of 
a population. To inform decision-making and to evaluate past policy decisions, 
quantitative information is needed on the level of and changes in a population's 
health. Measures that describe the level of health of a population are referred to 
as "indicators of population health". These indicators can cover different aspects 
of health. Some reflect quantitative aspects of the occurrence of fatal and non-
fatal health outcomes, such as mortality rates, life expectancy, incidence and 
prevalence of diseases. Others quantify aspects concerning the quality of life of 
individuals and their ability or disability to function. Health-related quality of 
life measures and health status evaluations provide such information. 
Health indicators, when adopted to inform health-policy making and 
target setting, acquire a normative aspect because health policy focuses on 
improving health outcomes that are measured by the health indicators used [3]. 
In the past, decreasing infant and general mortality was the major challenges for 
health policy. Most health indicators used at that time reflected this focus on 
mortality (e.g. the infant mortality rate and life expectancy at birth) and policy 
targets were formulated in terms of these indicators. As a consequence, health 
policy focused mainly on preventing premature death. However, after the large 
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gains in life expectancy made in the first half of the past century, improving 
quality of life became increasingly important. With longevity achieved for many 
people, the aim of health policy shifted towards improving both quality and 
quantity of life. Since both quality and quantity of life are important, both should 
be incorporated in indicators of population health and indicators based only on 
mortality are no longer sufficient [4, 5]. For this reason, summary measures of 
population health were constructed. 
Summary measures of population health 
Summary measures of population health integrate data on mortality with 
information on non-fatal health outcomes to represent the health of a population 
as a single number [6]. These two types of data are combined using time as a 
common denominator. Time spent in optimal health and time spent in sub-
optimal health can be compared using information on how people value time 
lived in different health states. Thus, not only age-specific data on the 
epidemiology of fatal and non-fatal health outcomes are required as basic input 
to all summary measures, but also information on valuations attached to health 
states. 
Since the first efforts were made to construct this kind of measures [7-
10] many different indicators have been developed, partly within the framework 
of the international network "Reseau Esperance de Vie en Sante" (REVES) [11, 
12]. As a result, there is a range of options in the design of summary measures, 
and many different indicators have been used in different places. For example, 
examples of applications of measures such as the active life expectancy (ALE) 
[13] and the disability-free life expectancy (DFLE) [14, 15] are widespread. 
Another type of measure, the Disability Adjusted Life Years (DALY) [3, 16, 
17], has been used in the Global Burden of Disease Study (GBD) [3] and in 
many subsequent national burden of disease studies (e.g. [18-21]). In the 
following two sections we will make two broad distinctions: between health 
expectancies and health gap measures, and between generic and disease-specific 
summary measures. This will divide summary measures into four broad groups. 
Further diversification, which will not be discussed here, is possible by 
variations in the calculation method; by using different definitions, measurement 
and valuation of health states; and by introducing additional values into the 
indicator (e.g. age-weights and discount rates) [2, 22]. 
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Health expectancy and health gap measures 
Summary measures can be divided into two broad families on the basis of a 
simple survivorship function: health expectancies and health gaps [2]. In Figure 
1.1 the middle curve shows the survival curve for males in the Netherlands in 
1999. For each age it reflects the percentage of men from an initial birth cohort 
that has survived up to that age. The area under this curve (Area A + B) 
represents the male life expectancy at birth in the Netherlands. Health 
expectancies are functions of this area that take into account that a proportion of 
the time lived was spent in less than optimal health (area B). They add the life 
years lived in optimal health (area A) and those lived in less than optimal health 
(area B), giving a lower weight to the latter. The weights assigned to years in 
area B range between 0 and 1, with 1 reflecting optimal health and 0 being 
equivalent to years lost to premature mortality. A well-known example of a 
Figure 1.1. Survivorship curve for men in the Netherlands in 1999. 
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Health Expectancies (HE) and Health Gaps (HG) are calculated as follows: HE = A + 
f(B), and HG = C + g(B), in which the functions f and g assign a weight between 0 and 1 
to years lived in less than optimal health, with optimal health being represented by 1 in 
function f and by 0 in g, and time lost to premature mortality by 0 and 1, respectively. 
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health expectancy measure is the Disability-Free Life Expectancy (DFLE). The 
DFLE combines general life expectancy with information on the prevalence of 
disability within a population (DFLE) [14, 23], assigning all years lived with 
disability (above a certain level) a weight of 0. Other examples are the active life 
expectancy (ALE) [13], the years of healthy life (YHL) [24], and the dementia-
free life expectancy [25]. 
Health gaps on the other hand measure the difference between the actual 
health of a population and some stated norm. For example, in Figure 1.1 the 
proposed norm is reflected by the upper curve, the 75% lowered mortality curve. 
The mortality gap in Figure 1.1 is then represented as area C. Health gaps, apart 
from measuring the mortality gap, can also take into account the fact that not all 
years lived were spent in optimal health. Health gaps are thus functions of the 
areas B and C. They add the years of life lost (area C) and the years of life lived 
in less than optimal health (area B) counting the latter only partially. The weight 
assigned to the years in area B again range between 0 and 1, but with 1 now 
being equivalent to time lost to premature mortality and 0 representing optimal 
health. An example of a health gap measure is the Disability Adjusted Life Year 
(DALY), that was developed within the Global Burden of Disease Study 1990 
(GBD 1990) [3, 16, 17]. 
Generic and disease-specific summary measures 
Depending on the epidemiological input used to construct summary measures, 
we distinguish generic and disease-specific measures. Generic measures are 
based on generic information on mortality, morbidity and health status. An 
example is the DFLE that combines generic life expectancy with generic 
information on disability. All examples of generic indicators (e.g. DFLE, ALE, 
YHL) are health expectancy measures: no generic gap measure has (yet) been 
constructed. The other group of measures, the disease-specific measures, uses 
disease-specific data as input. In this group examples of both health expectancies 
and health gaps can be found. The Disability Adjusted Life Expectancy (DALE) 
[26-28], that uses the inverse health status values of the DALY, is an example of 
a health expectancy measure. The dementia-free life expectancy is another. The 
best-known example in this group, however, is a gap measure: the DALY. 
Measures can be specific for just one disorder, like the dementia-free life 
expectancy, but can also include information for a group or cluster of diseases, 
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as was for example done in the GBD 1990 for the DALY [3, 16, 17] and by 
Barendregt et al. for the DALE [26]. 
The choice between a generic and a disease-specific measure depends 
on its intended use. Generic health expectancy measures have been calculated 
for many countries [29] and provide insight into questions such as: "Are the life-
years gained lived in good health?". Generic measures provide a tool to monitor 
the overall health of a population and, at least theoretically, to detect changes 
therein and compare countries. However, this information is useful to guide 
health policy decisions only if changes or differences in health can be attributed 
to certain diseases or determinants [26]. Policy makers face the difficult task to 
allocate resources and to choose between different intervention and research 
programmes that are mostly disease- or risk factor-oriented. Therefore, disease-
specific information (or disease-cluster-specific) is more useful to inform 
decision-makers. 
The best known disease-specific measure, the DALY, describes the 
burden that a specific disease causes within a population by combining disease-
specific epidemiological frequency data on morbidity and mortality and disease-
specific health status values. For each disease, it is calculated adding the number 
of Years of Life Lost due to premature mortality (YLL) and the number of Years 
Lived with Disability (YLD) [3]. The latter, the years lived with a specific 
disease, are weighted for the severity of the disability that is associated with the 
disease using a set of disease-specific disability weights (DWs). These weights 
are indispensable, as they make the years lived with different diseases 
comparable, enabling the burden of different diseases to be added and to be 
compared (enabling ranking). Ultimately, the addition of the disease-specific 
burdens for all diseases results in a generic estimate of the overall population 
burden. This method, used in the GBD 1990 [3] to estimate the overall 
population burden, is referred to as a bottom-up approach: a generic measure is 
built up from its disease-specific parts. The opposite, the top-down approach, 
refers to a generic population measure being broken down into disease-specific 
components. An example of this is the decomposition of the survival curve into 
underlying causes of death [30]. 
12 
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Data problems of disease-specific summary measures 
From a health policy perspective disease-specific summary measures of 
population health thus have an advantage over generic measures. However, in 
practice, their use may be limited due to their large data requirements. Disease-
specific measures require, for all diseases, disease-specific epidemiological 
frequency data on morbidity and mortality, as well as disease-specific health 
status valuations. Both types of data bring about specific problems to the use of 
disease-specific measures. 
The epidemiological frequency data are not always available and, if they 
are, can be incomplete and/ or of questionable validity. In the Netherlands 
disease-specific prevalence and/ or incidence data are not collected for every 
disease, and when they are, their validity can be affected by selection bias, 
unclear case-definitions, problems with self-reporting and other problems. 
Cause-specific mortality data on the other hand are available in the Netherlands 
(from the cause-of-death registration), but their validity is never perfect as long 
as ambiguity in the primary cause of death exists. 
To remedy some of these problems, models have been developed that 
exploit the causal relationship between the different epidemiological parameters 
for one disease. An example are IPM models (incidence-prevalence-mortality 
models). They exploit the fact that in the causal pathway of every disease 
incidence has to precede prevalence, and disease-specific mortality can only 
follow from having the disease. IPM models have been used both to infer 
missing data from the available information and to check for the internal 
consistency of data. Inconsistencies may be caused by differences in the 
completeness of the data. For example, when more incident cases are missed 
than deaths, incidence and mortality are inconsistent. Also, they may arise when 
the data were derived from different contexts (e.g. in different regions) or were 
measured differently (e.g. with varying case-definitions). Applying inconsistent 
data to an IPM model results in discrepancies between model outcome and data. 
In this way inconsistencies can be detected and the observed data adjusted for 
the inconsistencies. Furthermore, when one parameter is missing, IPM models 
allow it to be calculated from the existing data. The validity and usefulness of 
these models, however, has not been studied yet. 
The key issue of the health status valuations (disability weights in the 
DALY methodology) is that it has to be ensured that they refer to the same 
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health status for which the epidemiological data are collected. They should be 
tailored to the epidemiological case-definition, to guarantee that both refer to 
exactly the same severity level of the disease. This is not always straightforward, 
especially for heterogeneous disorders and diseases with case-definition 
problems. In psychiatric epidemiology, for example, different screening 
instruments use different cut-off points [31], with some including more mild 
cases and others being more stringent. Combining prevalence estimates based on 
a strict instrument with a health status value based on a mild disease description 
will inevitably lead to an underestimation of the problem, and vice versa. 
In the original valuation method of the GBD 1990 disability weights 
(DWs) were derived for a wide range of conditions, but the disease descriptions 
were often not very detailed, making it difficult to tailor them properly to the 
epidemiology. In a Dutch study, the GBD-1990 valuation method was further 
refined [32, 33]. Diseases were divided into disease stages that were more 
homogeneous regarding disability and treatment, for example different severity 
classes (mild! severe) or stages in the disease pathway (initial stage/ end stage). 
Furthermore, a standardised health status description was provided for each 
stage using the EuroQol 5D+C system [34]. This system describes six 
dimensions of health (mobility, self-care, usual activities, pain/ discomfort, 
anxiety/ depression and cognition) in three levels of severity of the problems. 
The distinction of disease stages and the addition of a formal description 
facilitate the tailoring of the DWs to the epidemiology [35]. However, the 
question then becomes how to combine the disease-stage-specific DWs into one 
disease-specific weight. 
Apart from these two data-related problems, several other problems also 
complicate the calculation of disease-specific summary measures. Difficulties 
arise in particular when disease-specific DALY s are combined to estimate the 
overall burden of disease. One problem is caused by co-morbidity of diseases. 
The health status value of having two diseases at the same time is not simply the 
sum of the values associated with each condition separately. For example, co-
morbidity of arthritis and visual problems in older people may exacerbate the 
disability of the separate conditions [36]. Co-morbidity can lead to both higher 
and lower health status values than the sum of the separate values. This should 
be accounted for when the burdens for separate diseases are combined. Another 
problem is that in a bottom-up approach disease-specific measures can not cover 
all morbidity that is present in a population. The number of diseases is large, 
14 
CHAPTER 1 
making it difficult to be exhaustive. Consequently, rare diseases with little 
impact will often be ignored. Furthermore, a decrease in health status can not 
always be linked to a specific disease. Ageing for example may cause a decrease 
in functioning, and some causes of morbidity we may simply not know (yet). 
Adding only the disease-specific components will thus underestimate the total 
burden of disability. Both reasons cause disease-specific summary measures to 
ignore a part of the morbidity that is present in a population: the rest-morbidity. 
The research questions 
As health policy decisions are usually taken at the level of a disease or risk 
factor, there are strong theoretical arguments for the use of disease-specific 
measures. However, the data and methodological problems form clear 
restrictions to their application. The overall research question of this thesis is 
whether useful disease-specific summary measures can be constructed in 
practice. In this context, we focus on the two data problems, because they form 
the first bottleneck in the use of these measures. Before it is possible to study 
any other issues related to disease-specific health indicators, it has to be 
practically feasible to calculate them from the data, making the problems of co-
morbidity and rest-morbidity of secondary importance. Two specific questions 
are addressed: 
1) To what extent are causal disease models valid and useful to check the 
consistency of epidemiological frequency data and to supplement them? 
2) How can disease-stage specific health status valuations be tailored to 
epidemiological frequency data? 
Outline of this thesis 
We explored these two research questions on the basis of empirical data for two 
common diseases in the Netherlands: breast cancer and major depression. We 
chose these disorders for two reasons: they are both important health problems 
and they allow us to study the research questions from different perspectives. 
Breast cancer is important in particular because of the mortality it causes, while 
depression causes mainly morbidity. Also, for breast cancer epidemiological 
data are easily available and regarded as relatively reliable, whereas for major 
depression the data still suffer from several problems. Finally, the disease 
staging for breast cancer and major depression are based on different concepts. 
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For major depression, stages were differentiated according to severity classes 
(e.g. mild, severe), while for breast cancer phases in the disease pathway were 
used (e.g. diagnosis and therapy, metastasised). 
The research in this thesis consists of two parts. In part A we address the 
first research question: the validity and usefulness of disease models. This 
question can best be studied using data for a disease with well-described 
epidemiology. As cancer incidence and mortality are registered on a regular 
basis in the Netherlands and are regarded as relatively reliable, such data provide 
a good basis for studying this question. Chapter two therefore studies the 
validity and usefulness of IPM models using relatively reliable and complete 
data sets on breast cancer and three other common types of cancer. The results 
of these analyses showed us that time-trends in the epidemiological frequency 
data bias the outcome of these models. For breast cancer many additional 
epidemiological data (e.g. survival, prevalence, etc.) are available, allowing us to 
quantify, in chapter three, the impact of data problems and trends on the model 
for breast cancer. The last chapter of part A, chapter four, describes an 
application of a disease model to the less well monitored epidemiology of major 
depression to obtain internally consistent estimates for the epidemiological 
parameters of major depression. 
The second part of this thesis, part B, is concerned with tailoring health 
status valuations to the epidemiology and assessing their impact on the resulting 
summary measure. Since tailoring is a problem especially in diseases that are 
heterogeneous and/ or have unclear case-definitions, we thought it relevant to 
study this problem for major depression. In the Netherlands, the Netherlands 
Mental Health Survey and Incidence Study (NEMESIS) provided a good 
database for major depression with information on both prevalence and health 
status by severity class. These data enabled us to use the severity classes in the 
tailoring of the DWs to the epidemiology. In chapter five we compare disability 
between the severity classes. Chapter six uses this information to derive health 
status values per severity class that we subsequently used in a burden of major 
depression calculation. A comparison of the results with studies using non-
tailored values gives an impression of the importance of health status values on 
the overall burden of disease calculation. For breast cancer the health status 
valuations can be tailored using a modelling approach. This approach is used in 
chapter seven to calculate and compare the burden of breast cancer in six 
16 
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European countries and to study its sensitivity to variations in health status 
values. 
Chapter eight, the general discussion, integrates and discusses the 
results from these studies. 
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PART A 
The validity and usefulness of disease 
models 

The use of models in the estimation of 
disease epidemiology 
Michelle E. Kruijshaar, Jan J. Barendregt, Nancy Hoeymans. The use of models 
in the estimation of disease epidemiology. Bulletin of the World Health 
Organization 2002; 80 (8): 622-628. 
CHAPTER2 
Summary 
Objective 
To explore the usefulness of incidence-prevalence-mortality (IPM) models in 
improving estimates of disease epidemiology. 
Methods 
Two artificial and four empirical data sets (for breast, prostate, colorectal, and 
stomach cancer) were employed in IPM 
models. 
Findings 
The internally consistent artificial data sets could be reproduced virtually 
identically by the models. Our estimates often differed considerably from the 
empirical data sets, especially for breast and prostate cancer and for older ages. 
Only for stomach cancer did the estimates approximate to the data, except at 
older ages. 
Conclusion 
There is evidence that the discrepancies between model estimates and 
observations are caused both by data inaccuracies and past trends in incidence or 
mortality. Because IPM models cannot distinguish these effects, their use in 
improving disease estimates becomes complicated. Expert opinion is 
indispensable in assessing whether the use of these models improves data quality 
or, inappropriately, removes the effect of trends. 
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Introduction 
Quantitative descriptions of disease epidemiology, such as incidence, prevalence 
and mortality, by age and sex, are essential inputs for burden of disease studies 
and cost-effectiveness analyses of interventions. Such studies serve as an 
important source of information for policy-making, planning, and research 
prioritization in health care. Empirical observation is obviously the gold 
standard for obtaining epidemiological information, but empirical data are often 
incomplete or of dubious validity. In addition, the validity of estimates tends to 
vary even for an individual disease. For example, in instances where incidence is 
more difficult to observe than mortality, more incident cases than deaths are 
likely to be missed. In this case, therefore, data on incidence are less complete 
than those on mortality, making these two parameters internally inconsistent. 
One way to circumvent these data limitations is to exploit the causal 
structure of the disease process: incidence has to precede prevalence, and cause-
specific mortality can only follow being diseased. Incorporating the causal 
structure into a mathematical model makes it possible to calculate data that are 
missing from the observational set and to check for the internal consistency of 
observations. An example of the first of these procedures is the back-calculation 
of (unobserved) human immunodeficiency virus (HIV) infection from data on 
the incidence of acquired immunodeficiency syndrome (AIDS) [1]. 
The Global Burden of Disease 1990 study, and many subsequent 
national burden of disease studies, made extensive use of DisMod, a generic 
mathematical disease model, which was specially designed to supplement 
observational data and check for internal consistency [2]. Previously we have 
employed a conceptually similar disease model to calculate unobserved 
incidence data [3]. The present article explores the usefulness of such generic 
disease models that describe the relation between incidence, prevalence and 
mortality (IPM models) for improving estimates of disease epidemiology. We 
consider whether these models calculate the correct results and, if so, how useful 
these results are. Our approach is to apply two IPM models (DisMod and our 
own model) to two artificial data sets known to be complete and consistent and 
to four high-quality empirical data sets for cancers, drawn from Dutch registries. 
The ability of the IPM models to describe adequately the data sets serves as an 
indicator of their usefulness. 
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Methods 
Artificial data sets 
In order to demonstrate that the models can calculate the correct results, we first 
used them with internally consistent data (formal validity). Data sets for breast 
and colorectal cancer were generated by MISCAN, a microsimulation model for 
the evaluation of screening programmes [4, 5]. MISCAN creates a cohort of 
hypothetical individuals, each of whom has a risk of developing cancer, and, 
once the disease is present, a survival drawn from a lognormal distribution. 
Incidence, prevalence and mortality data generated by this model are, by 
definition, complete and internally consistent. 
Empirical data 
We applied the IPM models to national incidence and mortality data for breast 
cancer (ICD-9 code 174), prostate cancer (ICD-9 code 185), colorectal cancer 
(ICD-9 codes 153 and 154) and stomach cancer (ICD-9 code 151). Data 
averaged for 1991-95, specified by sex and 5-year age group (up to ;:::95 years), 
were used. Statistics Netherlands (CBS) collects mortality data by cause-of-
death on a continuous basis using information from death certificates. Incidence 
data are collected continuously by the Dutch Cancer Registry (NKR), which 
receives its information from nine regional cancer centres. These data are based 
on pathology reports, complemented by national hospital admission data; death 
certificates are not used as an additional source. 
The cancer registries do not estimate prevalence data on a regular basis. 
The Regional Cancer Centre South (IKZ) determined the prevalence of the 
specific cancers for which incidence has been determined for the eastern part of 
the coverage area on 1 January 1993: for all incident cases registered in the 
region from 1970 until 1992 the population registry was checked to determine 
whether the persons concerned were still alive. For the same region we obtained 
the regional mortality and incidence rates from IKZ, averaged for 1991-95. 
Mortality data for this region originated from the CBS database (region: COROP 
36 and 37). Regional data were specified by sex and 5-year age group (up to ;:::85 
years). 
!PM models 
Both DisMod and our model are based on the conceptual disease model depicted 
in Figure 2.l.The population is described as being in different states, while 
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transition hazards determine how people move from one state to another. Within 
a population, individuals can be either susceptibles or cases. Cases may die from 
their disease, while both cases and susceptibles are at risk of dying from other 
causes. There are consequently three transition hazards: incidence, case-fatality, 
and all other mortality. DisMod also includes remission as a fourth transition 
hazard, but for our analysis we set this hazard to zero since cure is not taken into 
account in the registered cancer prevalence. The framework in Figure 2.1 shows 
that the number of cases can be calculated by following an initially disease-free 
cohort over time and applying the transition hazards. Under the important 
assumption made in the IPM models that there are no trends in the transition 
hazards, time is equal to a patient 's age. The models thus permit calculation of 
prevalence at a certain age from the prevalence at the previous age and the 
mortality and incidence in the age interval. 
Although they are based on this common conceptual model, the actual 
model calculations differ. DisMod uses a set of linear differential equations that 
describe the transitions between the states. The solution of the equations is 
approximated by using the finite differences method. Incidence and case-fatality 
hazards are required as input parameters, and we approximated them using rates. 
Case-fatality rates were calculated from mortality data and the prevalence 
calculated from our own model (see below and Annex). Since DisMod cannot 
calculate data for age groups over 90 years and can only handle a limited 
number of age groups, we specified 5-year age groups from 15 years to 89 years. 
The calculation is performed using a competing risk life table [6]. General 
mortality data for the Netherlands for 1991-95 reported by CBS were specified. 
Figure 2.1. Schematic representation of a Markov model for cancers 
Susceptibles Incidence Cases Case-fatality Cause-specific 
.... .... (S) ~-h··· .................. ~ (C) ... deaths (F) 
Remission 
I ... All other ... 
All other mortality deaths (G) ... 
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Our model gives an exact solution based on an analytical solution of a 
continuous time Markov process [7]. We refer to it here as the analytical model. 
Using a spreadsheet we implemented the formula for the calculation of 
prevalence from incidence and mortality probabilities (see Annex). Mortality 
and incidence rates per 5-year age group up to ~95 years served as input. We 
first interpolated these data to 1-year age groups up to ~95 years and then 
converted them to probabilities (see Annex for formulas and methods). Apart 
from the different calculation method (approximate versus exact), the analytical 
model thus also differs from DisMod in the way it treats mortality. Mortality 
probability relates to the total population, whereas case-fatality, used in DisMod, 
concerns only prevalent cases. In the event of inconsistent data, the mortality 
probability may exceed the predicted prevalence, resulting in negative 
prevalence estimates in the analytical model, which is not possible if case-
fatality is used. 
The models were assessed by comparing the calculated prevalence with 
the observed data. We extrapolated the observed prevalence data from ~85 years 
to ~95 years by applying the cubic-spline methodology and using life-table 
derived mean ages of 89.6 years and 90.8 years, for men and women aged ~85 
years, respectively. 
Results 
Application of the internally consistent MISCAN data to the models resulted in 
prevalence estimates that were virtually identical to those generated by 
MISCAN and to one another. When the observed data were applied the results 
of the two models were also practically identical. The reproducibility of 
MISCAN data and the consistency of the results from the two models suggest 
that they calculated the correct results. 
The prevalences calculated from national data by the analytical model 
are shown with the observed prevalences in Figures 2.2-2.5. The model 
estimates increase with age, at first exponentially, but subsequently at a slower 
pace. At ages >80 years the estimates reach a maximum and then decline. The 
decline at older ages is most apparent for stomach cancer, the calculated 
prevalence decreasing to zero or even to negative values; the smallest decline is 
that for breast cancer. 
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Figure 2.2. Observed and estimated prevalence of female breast cancer by 
age. Empirical data (broken line) are from the IKZ region and were interpolated from 5-
to 1-year age groups and extrapolated for ages >85 years using the cubic-spline method. 
Model estimates (solid line) are calculated from national incidence and mortality data 
using the analytical modeL 
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Figure 2.3. Observed and estimated prevalence of prostate cancer by age. 
Empirical data (broken line) are from the IKZ region and were interpolated from 5- to 1-
year age groups and extrapolated for ages >85 years using the cubic-spline method. 
Model estimates (solid line) are calculated from national incidence and mortality data 
using the analytical modeL 
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Figure 2.4. Observed and estimated prevalence of colorectal cancer, by age 
and sex. Empirical data (broken lines) are from the IKZ region and were interpolated 
from 5- to 1-year age groups and extrapolated for ages >85 years using the cubic-spline 
method. Model estimates (solid lines) are calculated from national incidence and 
mortality data using the analytical modeL 
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Figure 2.5. Observed and estimated prevalence of stomach cancer, by age 
and sex. Empirical data (broken lines) are from the IKZ region and were interpolated 
from 5- to 1-year age groups and extrapolated for ages >85 years using the cubic-spline 
method. Model estimates (solid lines) are calculated from national incidence and 
mortality data using the analytical modeL 
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The predicted prevalences are nearly always larger than the observed ones. 
However, stomach cancer is exceptional in this respect in that the estimate 
approximates to the observed value, except for ages >85 years. For prostate and 
breast cancer the discrepancy is large (depending on age, the model calculations 
are up to about two and three times larger, respectively), while for colorectal 
cancer it is intermediate (up to about 1.5 times larger). 
Discussion 
The results from the artificial data sets support the validity of the IPM models: 
despite the difference of a lognormally distributed survival in MISCAN and a 
piecewise exponentially distributed survival in the IPM models, the latter are 
able to reproduce the MISCAN prevalence very well. In addition the two IPM 
models produce virtually the same results, a further indication of validity. 
Nevertheless, when registered incidence and mortality data were used, the 
predicted prevalence differed considerably from that observed, and for stomach 
cancer impossible results were produced. Three possible reasons for these 
discrepancies are considered below. 
Regional differences 
The regionally observed prevalence data, to which the national prevalence 
estimates are compared, may not be representative of the national situation. 
Breast cancer screening was introduced in the IKZ region between 1993 and 
1997, whereas in the rest of the Netherlands it was introduced around 1990. 
Cause-specific prostate cancer mortality is unequally distributed [8]. We 
explored the influence of regional differences by applying regional incidence 
and mortality data to the model. A comparison of the results of these 
calculations (not shown) with the empirical data revealed that the differences 
between estimates and observations were similar, and, if anything, somewhat 
larger than the discrepancies we found on using national data in the models. The 
regional variation in disease epidemiology therefore could not explain the 
differences. 
Past trends 
Because both models are based on the assumption that incidence and mortality 
are in a steady state, the occurrence of trends in incidence or mortality would 
lead to discrepancies between the model estimates and the observations. 
Prevalence is a stock variable, comprising all past incident cases that are still 
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alive. It is therefore dependent on incidence and case-fatality from the past as 
well as the present. 
Cancer incidence has a tendency to rise for the tumours we studied, 
because of increased awareness and screening, and for other, unknown, reasons 
[9, 10]. The incidence of breast cancer, for example, is presumed to show a 
secular trend of 1% per year [11], on top of which an additional increase is 
imposed because of the introduction of breast cancer screening around 1990 in 
the Netherlands. A notable exception to this rising incidence is presented by 
stomach cancer, for which there has been a long-term secular decline [9, 10]. 
Cancer mortality, meanwhile, remains relatively stable [9, 10, 12-14], 
except for stomach cancer and female colorectal cancer, for which it has 
declined. With increasing incidence and constant mortality, prevalence increases 
over time but does so less rapidly than incidence, since it also includes persons 
who became incident in the past. Consequently, applying current incidence and 
mortality to the model produces estimates that are higher than the observations. 
The largest deviations were seen concordantly for breast cancer and prostate 
cancer, the two cancers for which the rise in incidence has been most apparent, 
mainly because of screening. 
In an additional analysis old incidence data for breast cancer were used 
in the model in order to check whether trends could explain the discrepancies. 
The risk of mortality for breast cancer patients remains elevated for more than 
20 years after diagnosis. We therefore used regional incidence data for 1968-72 
[12], obtaining an estimated prevalence close to the observed value for 1993. 
This shows that the trend in incidence may indeed cause a difference. 
Nevertheless it cannot explain the discrepancy entirely: the average incidence 
that cases prevalent on 1 January 1993 were exposed to lies somewhere between 
the 1991-95 and the 1968-72 incidences. Although we believe the effect of the 
trends in incidence is considerable, other factors evidently also play a role. 
Data inaccuracies 
Inaccuracies in the epidemiological estimates are the third possible reason for 
the differences between observations and model predictions. Statistics on 
mortality by cause-of-death in the Netherlands are assumed to be reliable, 
although no studies are known in which the completeness of the death registry 
has been investigated in absolute terms. Compared with other European 
countries, in the Netherlands the detection fraction for cancer as a cause of death 
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is high [15]. Furthermore, it has been argued that deaths from cancer in general 
are not likely to be missed [16], although misclassification between cancers may 
occur for older age groups. Thus it is unlikely that underregistration of cancer 
deaths is a causative factor in our generally higher prevalence estimates, 
especially with regard to young and middle-aged people. Nevertheless, the 
underestimation of mortality remains a possible explanation for discrepancies. 
Since we did not include excess mortality from other diseases in our model we 
implicitly assumed it to be zero. However, cancer patients also suffer from an 
increased risk of dying from diseases other than cancer [17]. We believe that, in 
addition to the effect of trends, the impact of ignoring this factor makes an 
important contribution to the discrepancies. 
At older ages, where multiple medical problems are frequent and 
pathological examinations are performed relatively infrequently, 
misclassification of cancer deaths may lead to the overregistration of deaths for 
the more frequent types of cancer. This would cause prevalence estimates to be 
too low and could contribute to the decline of our prevalence estimates at older 
ages. 
Cancer incidence data in the Netherlands are reliable. Nevertheless, 
because they are based on pathology and hospitalization data, those incident 
cancer cases that did not undergo a pathological examination and were not 
hospitalized would be systematically excluded from registration. It has been 
estimated that this would lead to an underregistration of 1.3-1.6% [18, 19]. 
Moreover, some cases that are included in pathology or hospitalization registries 
are missed. This non-systematic exclusion has been estimated to occur in 2.2% 
of cases [19]. A completeness of approximately 96.2%is thus achieved, which is 
comparable to the level of completeness in several other national cancer 
registries [19]. This incompleteness seems to be concentrated in the highest age 
groups; one study suggested that missed incident cases mostly related to elderly 
persons with cancer of the digestive tract [18], although this was not confmned 
in another study [19]. The underregistration of incidence may help to explain the 
impossible negative prevalence calculated for stomach cancer and the decline in 
the estimates for colorectal cancer at older ages (Figure 2.4 and 2.5). 
Underregistration cannot, however, explain the finding that the 
prevalence estimates are generally higher than the observations for the other age 
groups. Multiple malignancies can contribute to this. The incidence registry 
counts the number of malignancies, whereas the prevalence data are based on 
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the number of persons with a malignancy. Consequently, a person with multiple 
malignancies in the same organ is counted more than once in the incidence data 
but only once in the prevalence data. For breast and colorectal cancer such 
multiple malignancies may be present, and can account for up to 10% and 15%, 
respectively, of the incident cases (J.-W. Coebergh, personal communication, 
2000). This would make our prevalence estimate too high and would explain 
part of the differences, but not more than the 10% or 15% by which the 
incidence is overestimated. 
The incompleteness of prevalence data could also be a factor 
contributing to the higher estimates. Although based on regional incidence data, 
prevalence data may be somewhat less complete because cancer registration was 
less complete in its early years than more recently [19]. Since only old cases are 
underestimated in this way, prevalence is only affected if the survival time is 
long. Furthermore, this underestimation might be diminished by the opposite 
phenomenon: overestimation of prevalence resulting from incomplete 
ascertainment of survival status. The latter incompleteness would be very small, 
however, since deaths are unlikely to be missed, although problems may arise 
when persons have moved out of the country. We believe that the 
underestimation of prevalence data is not large and that it is unlikely to explain a 
large part of the differences. 
Conclusion 
The test with the artificial data supports the formal validity of IPM models. 
However, the confrontation with the four empirical data sets of presumed high 
quality shows that, in practice, there may be large discrepancies between 
measurements and calculations. The discrepancies are likely to be attributable in 
considerable measure to past trends in incidence but also to data inaccuracies, 
the most important source of which seems to be underestimation of mortality as 
a result of ignoring excess mortality from other causes. 
The model cannot distinguish between the effects of trends and the 
effects of data inaccuracies. Separating these effects would require a dynamic 
model that describes the disease processes over time, and could incorporate the 
effects of past trends. Unfortunately, such a model would be much more 
complex. Moreover, since the trends would have to be quantified, more input 
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data would be required, and these have proved difficult to obtain. Consequently, 
a dynamic analysis is often not feasible. 
In practice use of IPM models such as DisMod occurs particularly when 
data are incomplete andJor of low quality. In such circumstances it is impossible 
to distinguish between the apparent inconsistencies that represent real data 
problems and those that are attributable to past trends. This complicates the use 
of such models in improving estimates of disease epidemiology. Considerable 
judgement has to be exercised when the disadvantage of forcing data to comply 
with the assumption of a steady state is weighed against the goal of reducing the 
unreliability of the data. Expert knowledge on disease epidemiology and 
registries remains indispensable for guiding this process. 
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for age n by averaging the results of two successive ages. This can be given in 
either 1-year or 5-year age groups. 
The DisMod model 
The DisMod model can be downloaded from the Internet (at URL: http:// 
www.hsph.harvard.edu/organizations/bduldismod/index.html). (Two versions of 
DisMod are available at this URL -we used DisMod I in our analyses.) For this 
model the same assumptions of steady state, constant hazards in the age interval 
and independence of other-cause mortality are required. 
We approximated input hazards by rates. The appropriate input formats 
were calculated using the following expressions: 
CFRn =-LN[1-{(mn -rn *(1- Pn))! Pn}], ifmn<pm otherwise 0 eq.{3} 
rn = [IRn * (1-exp(- CFRn-1 ))- CFRn-1 * (1-exp(- IRn ))]![IRn- CFRn-1 ], 
where CFRn is the case-fatality rate for age group n and rn is the probability of 
making two transitions in age group n (the other parameters are mentioned 
above). 
Conversions to the appropriate input formats were made by using the 
interpolated data (1-year age intervals). We used the prevalence calculated by 
the previous model to compute case-fatality. Because the formula for calculating 
rn requires the CFRn as input data, and vice versa, we used the case-fatality rate 
of the previous age (CFRn.J) in this calculation. This produced a slight deviation. 
We then back-transformed the input data to 5-year age groups. DisMod 
was then used to calculate annual incidence and mortality rates and mean 
prevalence per 5-year age group. 
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Abstract 
Background: 
Health policy and planning depend on quantitative data of disease epidemiology. 
However, empirical data are often incomplete or are of questionable validity. 
Disease models describing the relationship between incidence, prevalence and 
mortality are used to detect data problems or supplement missing data. Because 
time trends in the data affect their outcome, we compared the extent to which 
trends and known data problems affected model outcome for breast cancer. 
Methods: 
We calculated breast cancer prevalence from Dutch incidence and mortality data 
(the Netherlands Cancer Registry and Statistics Netherlands) and compared this 
to regionally available prevalence data (Eindhoven Cancer Registry, IKZ). 
Subsequently, we recalculated the model adjusting for 1) limitations of the 
prevalence data, 2) a trend in incidence, 3) secondary primaries, and 4) excess 
mortality due to non-breast cancer deaths. 
Results: 
There was a large discrepancy between calculated and IKZ prevalence, which 
could be explained for 60% by the limitations of the prevalence data plus the 
trend in incidence. Secondary primaries and excess mortality had relatively 
small effects only (explaining 17% and 6%, respectively), leaving a smaller part 
of the difference unexplained. 
Conclusion: 
IPM models can be useful both for checking data inconsistencies and for 
supplementing incomplete data, but their results should be interpreted with 
caution. Unknown data problems and trends may affect the outcome and in the 
absence of additional data, expert opinion is the only available judge. 
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Background 
Estimates of disease-specific incidence, prevalence and mortality, specified by 
age and sex, are important information to health care policy and planning. They 
are essential inputs to cost-effectiveness analyses and burden of disease 
calculations. Empirical data, however, are often difficult to obtain or are of 
questionable validity. To remedy some of these data problems, disease models 
have been developed that describe the relationship between the epidemiological 
parameters, by exploiting the causal structure of a disease. Incidence, 
prevalence, mortality models (IPM models) formalise the relationship between 
the three parameters, using the fact that incidence has to precede prevalence, and 
that cause-specific mortality can only follow disease. IPM models have been 
used frequently both to supplement missing data and to study the agreement 
between different epidemiological data [1-4]. Our previous study supported the 
formal validity of IPM models, but when the modelling was applied to empirical 
data on four types of cancer, the model calculations differed to a large extent 
from the empirical data [5]. For breast cancer the difference was particularly 
large. It was argued that these discrepancies may indicate inconsistencies in the 
data, but that they may also be caused by time trends. 
When the data for one disease are not in accordance with each other, 
they are internally inconsistent. Inconsistencies may be caused by differences in 
the completeness of the data. For example, when more incident cases are missed 
than deaths, incidence and mortality are inconsistent. Also, inconsistencies may 
arise when the data were derived from different contexts (e.g. a different region) 
or measured differently (e.g. varying case-definitions). Applying inconsistent 
incidence and mortality to an IPM model will result in under- or overestimating 
prevalence, and thus in discrepancies between model estimations and empirical 
prevalence data. Time trends, on the other hand, may cause the data to appear 
inconsistent in a steady state model, while in fact they are not. Because 
prevalence is the resultant of incident cases from the past, it cannot react 
instantaneously to changes in incidence and case-fatality, but only with a certain 
delay. It is possible to account for the effects of time trends in a dynamic model, 
but this requires additional input data on the nature and size of the trends, which 
are not available for most diseases. Often, we do not even know whether a trend 
is present or not, and the researcher faces a dilemma what to do with the 
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discrepancies. Adjusting observed data for apparent inconsistencies that are in 
fact the consequence of past trends would rather defeat the purpose of IPM 
models. 
For breast cancer in the Netherlands the discrepancy between observed 
prevalence and prevalence calculated from incidence and mortality was 
particularly large [5]. Fortunately, for breast cancer several data problems are 
known, and, in addition, there is a tentative estimate of the trend in incidence. 
This allowed us to quantify the relative contribution of the trend and several 
known data problems on the discrepancy and to throw some light upon the 
researcher's dilemma. Even though prevalence of breast cancer is not a very 
useful epidemiological measure, it does allow us to illustrate the difficulties in 
the use of IPM modelling because of the relative abundance of data. 
Methods 
General approach 
We calculated the point-prevalence of breast cancer in the Netherlands and its 
95% confidence interval from national incidence rates and cause-specific 
mortality rates using the IPM model described by Barendregt et al. [6]. We 
compared it to regional prevalence data. To determine the separate effects of 
trends and known data problems we next recalculated the model: 
1) incorporating the incompleteness in the prevalence data (see below), 
2) adjusting for a trend in incidence, 
3) adjusting for double counting of incident women with secondary primaries, 
and 
4) taking excess mortality from non-breast cancer deaths into account. 
For point c a single cohort model was used, while for a, b, and d it was necessary 
to use a multi-cohort model that takes into account both age and calendar time. 
We estimated the proportion of the difference that was explained by each of the 
recalculations from the overall differences in the number of prevalent cases 
using 1993 population figures and summing over all age groups. 
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!PM model 
Our model is based upon the conceptual disease model depicted in Figure 3.1 
and was described in Kruijshaar et al. [5]. Briefly, the model describes a 
population as being in two states: diseased or susceptible, while transition 
hazards determine how people move from one state to another. Following an 
initially disease-free cohort over time and applying the transition hazards, the 
number of cases can be calculated. Under the important assumption of a steady-
state situation, time is equivalent to age. The model then allows the calculation 
of prevalence at a certain age from the prevalence at the previous age and the 
transition hazards. By assuming furthermore equal mortality from other causes 
in cases and susceptibles, prevalence at exact age n can be calculated from 
incidence and cause-specific mortality probabilities using formula 1a in the 
Appendix [6]. 
Baseline calculation 
First, we calculated prevalence from national incidence and mortality rates of 
female breast cancer (ICD-9 code 174) for 1991-1995, averaged by five-year age 
groups up to 85+. Incidence data obtained from the Netherlands Cancer Registry 
(NKR) are based on pathology and hospital admission data, and the mortality 
data from Statistics Netherlands (CBS) on death certificates. To enable 
comparison with the prevalence data we used incidence rates excluding in-situ 
tumours. Incidence and mortality rates were first interpolated to one-year age 
groups using the cubic-spline method and then converted into probabilities (see 
the Appendix for formulas). A 95% confidence interval of the calculated 
Figure 3.1. A Markov model for cancers 
Susceptibles Incidence Cases Case-fatality Cause-specific 
(S) ~·--·····-- .......... ~ .. (C) ... deaths (F) 
Remission 
I ... All other ... 
All other mortality 
.. deaths (G) 
... 
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prevalence was obtained by parametric bootstrapping assuming a Poisson 
distribution for numbers of incident cases and deaths in each age group. The 
@risk software programme [7] was used to simulate 10000 iterations by Monte 
Carlo sampling. 
The Regional Cancer centre South (IKZ) was the only cancer registry in 
the Netherlands that has estimated prevalence. The IKZ determined prevalence 
for a specific part (the core region) of the region South at 1-1-1993 by checking 
the vital status of all incident cases registered in the region since 1970 against 
the municipal population administration and the National Death Index. If a 
person had moved to another municipality in the Netherlands, data from that 
municipal population administration was used (under Dutch law, registration 
with the municipal population administration is obligatory within five days of 
changing address). In case of migration to another country, a case was lost to 
follow up. In-situ tumours are not included. For more information on these data 
we refer to Coebergh et al. [8]. A 95% confidence interval around these data (by 
five-year age group up to 85+) was calculated assuming a binomial distribution 
(see formula 2 in the Appendix). Point estimates and confidence intervals were 
interpolated to one-year age groups as described in the Appendix. 
Limitations of the prevalence data 
Prevalence registered by the IKZ does not include patients diagnosed before 
1970 and is consequently underestimated. To quantify the effect of this, we 
created a dynamic model, incorporating a parameter y that represents the number 
of years prior to incidence. Prevalence in the reference year yO, was calculated 
from prevalence in the 23 years prior to yO (see Appendix). 
Also, prevalence data refer to a specific region only, whereas the model 
calculations are based on national input. We showed in our previous study [5], 
that differences between regional and national incidence and mortality rates 
hardly affected the calculated prevalence. Therefore, we did not further examine 
this here. 
Trend in incidence 
Next, we estimated the effect of a trend of increasing incidence on the calculated 
prevalence. While incidence increased, the population mortality rate for breast 
cancer has remained approximately the same in the Netherlands [8-12], thus 
case-fatality must have declined. Coebergh et al. have estimated the yearly rise 
in incidence in the region South between 1975 and 1986, to be approximately 
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one percent [13]. The effects of screening are not included in this estimate, as it 
was not introduced until later, but effects of other types of increased case finding 
were included -if present. 
We estimated the effect using the dynamic model described above, 
decreasing incidence by one percent for each additional year y prior to the year 
of reference (see Appendix). We assumed the trend was present up to 95 years 
before the year of reference. Sensitivity to the trend was inspected, by applying a 
50% higher and lower trend (1.5% and 0.5%) as input values. 
Double counting incident women with a secondary primary 
The NKR registers the number of incident tumours, whereas prevalence refers to 
women. Women are thus counted twice, if they have a second primary tumour in 
their breast (SP). The percentage of SPs by age group were provided for 1991-
1995 by the IKZ. We estimated the incidence of women with breast cancer, by 
subtracting the age-specific proportion SP from the reported incidence rate and 
recalculated our model. 
Excess mortality from non-breast cancer deaths 
Breast cancer patients have been shown to be at increased risk of dying from 
other causes of death [14], although with longer survival (>20 years) they may 
experience a decreased risk [15]. Cause-specific mortality data thus 
underestimate the total excess mortality from breast cancer. We adjusted for this 
estimating excess mortality from duration-specific relative survival data 
assuming a lognormal survival distribution from breast cancer and a proportion 
not dying from breast cancer (proportion cured) [16], as described in the 
Appendix (formula 5). Relative survival data, i.e. excess mortality over and 
above the background mortality, were reported by the IKZ registry for three 
cohorts (1970-1979, 1980-1986 and 1987-1992) for ages < 70, and> 70 [8]. 
Because survival improves over time, we used survival probabilities at one, 
three and five years after incidence of the youngest 1987-1992 cohort. As longer 
follow-up was not available for this cohort, survival at 10 and 20 years was 
estimated using the conditional 10 and 20-year survival in the older cohorts. 
Fitting the lognormal model allowed us to estimate the cumulative probability of 
excess mortality with time after incidence, from which we calculated the yearly 
mortality probability (see Appendix). 
We extended our baseline model to include duration (see Appendix for 
the mathematical description): prevalence at age n, d years after incidence was 
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calculated from the prevalence at the previous age and year. Summation across 
all years d provided age-specific prevalence. 
Results 
In our baseline calculation we estimated the prevalence of breast cancer from 
national incidence and cause-specific mortality data. The results of this are 
shown in black in Figure 3.2 (solid line), together with the regional data (dotted 
line), while the total number of calculated prevalent cases and the difference 
with the IKZ are shown in Table 3.1. Both the IKZ and calculated prevalence 
increased exponentially with age to about age 47, but thereafter they started to 
diverge. The model calculations increased linearly to a prevalence of 9.2% at 
Figure 3.2. Calculated prevalence and prevalence data of breast cancer by 
age. Baseline calculation and separate effects of known data problems and trend. 
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age 85, while the IKZ prevalence increased more slowly and levelled off to 
3.7%. At age 55 the calculated prevalence was 1.5 times higher than the data, 
increasing to 2.5 times at age 85, a difference in total number of cases of 86%. 
The 95 % confidence interval for the calculated prevalence was narrow, due to 
the high numbers of breast cancer incidences and deaths. The uncertainty in the 
prevalence data was larger. From age 48 upward the confidence intervals did not 
overlap. 
Figure 3.2 and Table 3.1 also show the effects of the known data 
problems and trend in incidence (coloured lines). First, excluding cases that 
became incident more than 23 years before the year of reference had the largest 
effect and altered the age pattern. Prevalence increased with age more slowly, 
levelling off to a maximum of 4.4% at age 78, and declining thereafter. The total 
number of prevalent cases was 53% higher than the IKZ prevalence, explaining 
39% of the difference between calculated and IKZ prevalence. Second, 
incorporating a secular trend in incidence in the calculation of prevalence 
resulted in a lesser increase with age, levelling off after age 70, without reaching 
Table 3.1. Comparison of the total number of prevalent cases of breast 
cancer, estimated in different ways, and 1993 prevalence data. 
Total number of % difference from %of the gap 
cases estimated 1993 data explained 
1993 data 123216 0.0 0.0 
Baseline 66370 85.6 100.0 
Combined 89169 34.4 59.9 
>1970 101268 52.6 38.6 
1% trend 103943 56.6 33.9 
SP 113440 70.9 17.2 
Mortality 119769 80.5 6.1 
Baseline: baseline calculation, combined: adjusting for one-% trend and excluding 
incident cases of before 1970, > 1970: excluding incident cases of before 1970, 1% trend: 
estimating the effect of a secular trend in incidence, SP: adjusting for secondary 
primaries, mortality: including excess mortality from non-breast cancer deaths. 
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a plateau. The secular trend of one percent decreased the discrepancy with 44% 
(ranging between 49% and 18% for 50% higher and lower estimates of the 
trend). Third, adjusting for double counting of incident women with a second 
primary tumour of the breast (SP) had a smaller effect. The percentage of SP did 
not exceed nine percent for any age group. Subtracting this percentage from the 
incidence rate explained 17% of the difference. Fourth, taking excess mortality 
from non-breast cancer deaths into account made a difference of six percent. 
The combined effect of restricting the duration of prevalence and the 
trends, shown in Figure 3.3, resulted in a 60% decrease of the difference 
(ranging between 70% and 50% for a 50% higher or lower trend). At age 85 the 
calculations touched upon the upper confidence limit of the data. 
Figure 3.3. Calculated prevalence and prevalence data of breast cancer by 
age. Baseline calculation and the effect of both the secular trend and restricting 
prevalence. 
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Discussion 
We quantified the separate effects of known data problems and a trend in 
incidence on IPM model calculations of breast cancer prevalence, and inspected 
their influence on the discrepancy between model estimations and prevalence 
data. Two factors had a major effect on the estimated prevalence: the limitation 
of the IKZ prevalence data including only incident cases since 1970, and the 
trend in incidence. Together, they accounted for a major part (60%) of the 
discrepancy. Still, their combined effect leaves a part of the discrepancy 
unexplained. The effects of adjusting for double counting of incident women 
with secondary primaries of the breast and of taking excess mortality from non-
breast cancer deaths into account were smalL Consequently, the combined effect 
of all four factors does not explain the entire difference. Either unknown data 
problems are present contributing to the remaining difference, or we 
underestimated some of the effects. 
The two factors with the largest effects could influence the calculations 
because prevalence is a stock variable: it contains cases that became incident in 
the past. The long survival time of breast cancer explains why these two factors 
can exert such a strong influence. The time lag after which prevalence fully 
reflects a change in incidence is determined by the rate at which the pool of 
prevalent cases is replaced by new cases, which, in turn, depends on the survival 
time. The underestimation of the prevalence data due to its limitation to incident 
cases after 1970 may be as large as 44% at age 85, but is lower on average, as 
the effect increases with age. When the effect is calculated additional to 
adjusting for the trend in incidence, it is also smaller: 24% at age 85. In a small 
part of the IKZ region prevalence can be based upon incidence registration since 
1958 [9]. These data are indeed higher than the IKZ data for the larger region 
indicating the data will improve with longer follow-up in the future. 
The estimated trend in incidence and the effect of adjusting for it are 
subject to some uncertainty for several reasons. First, the one percent trend is an 
average figure; its magnitude differs with age and calendar year. Second, the 
regional estimate may deviate somewhat from the national trend. Furthermore, it 
is a rounded figure. Nevertheless, as the results of the sensitivity analysis 
showed that increasing or decreasing the trend by 50% altered the percentage 
explained by a combined effect (of limiting prevalence and the secular trend) by 
only 10%-points, we expect these three effects to be small. The estimated one 
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percent may also be too low because it does not include the effect of the 
introduction of screening around 1990 in the Netherlands. We estimated this 
effect in an additional analysis, increasing the estimated one to five percent for· 
the last four years. The additional effect of screening was very small. Finally, we 
may have overestimated the effect assuming that a one percent trend was present 
many years before the period for which it was estimated (1975 to 1986). 
Assuming no trend before 1975 in an extra analysis increased the calculated 
prevalence by almost 10% at age 85, but inspection of the incidence rates since 
1958 for the smaller part of the IKZ region showed that incidence has increased 
since 1958 [9]. The effect of assuming no trend before 1960 was negligible. 
The effects of adjusting for secondary primaries and excess mortality 
were only small, but this is not surprising. The proportion of women with a 
secondary primary in the breast did not exceed nine percent, preventing a much 
larger change in the calculated prevalence. Also, the relative risk of breast 
cancer patients to die from other causes of death is not that high, and may even 
inverse with longer follow-up [14, 15]. 
Thus, although the effect of the trend may be somewhat uncertain, other 
unknown data problems are likely to cause the remaining difference between 
calculated and IKZ prevalence. One possible explanation for the remaining 
deviation could be that when the cancer registries started completeness of 
incidence was not as high as it is now. As a result the prevalence is 
underestimated by the IKZ. On the other hand, IKZ prevalence was determined 
by checking population administrations, which involves matching of the 
registrations, which is never 100% accurate. Therefore, some deaths may have 
been missed and individuals inaccurately assumed to be alive, resulting in an 
overestimation of the IKZ prevalence. How large both counteracting effects are, 
is difficult to determine. An additional explanation may be found in variation 
between national and regional all-cause mortality, as the equations in our model 
are based on the assumption of similar background mortality. A higher 
background mortality in the IKZ region would decrease the discrepancy, but we 
expect only a minimal effect as the differences in all-cause mortality will be 
minor. Additional reasons for overestimating incidence or underestimating 
mortality (both resulting in overestimating prevalence) are difficult to think of. 
Cancer incidence data in the Netherlands are reliable with a completeness of 
96.2 % around 1990 [17], and probably even higher in the years thereafter. 
Furthermore, mortality by cause-of-death statistics of the Netherlands are 
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assumed to be reliable and, compared to other European countries, the detection 
fraction for deaths from cancer is high [18]. The causes of the remmmng 
discrepancy thus remain uncertain. 
Conclusion 
Even when data are regarded as relatively reliable, as was the case for breast 
cancer in the Netherlands, data problems may be present. 1993 prevalence data 
for breast cancer in the IKZ region are underestimated, as they do not include 
incident cases before 1970. Our analyses show the importance of using IPM 
modelling to detect data problems. However, we also showed the trend in 
incidence to have a large effect on the model estimations for breast cancer, 
complicating the use of IPM models. 
IPM models can be useful both for checking for data inconsistencies and 
for supplementing incomplete data, but in both cases there remains the need for 
careful interpretation of the results. In the all too common situation where, 
unlike for breast cancer, no data on the size and nature of trends are available, 
the effects of trends cannot be estimated. Furthermore, unknown data problems 
may affect the model estimations in unknown directions. In the absence of 
additional data the researcher is faced with the dilemma of how to interpret 
model discrepancies, and expert opinion is the only available judge. 
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APPENDIX 
The steady state IPM model 
Assuming a steady state situation and equal other-cause mortality for cases and 
non-cases, prevalence at exact age n, can be calculated from incidence and 
cause-specific mortality data, using [ 6]: 
(1a) 
where mn-I is the mortality probability of age group n-1; and in is incidence 
probability of susceptibles of that age group. The formula gives an exact 
solution of a continuous time Markov process. 
The input parameters for this formula are mortality probability at age 
group n and the incidence probability of susceptibles at that age group. We 
interpolated incidence and mortality rates from five-year to one-year age groups 
using the cubic-spline method adopting a mean age of 90.8 for women aged 85 
and over that was derived from a life table corresponding to general mortality. 
We assumed these rates approximate the hazards fairly well. Hazards were then 
converted to probabilities: 
probability n = 1- EXP( -hazard n) . (lb) 
The incidence rate among susceptibles was calculated from national incidence 
hazards using the prevalence of the previous age group, resulting in a slight 
deviation: 
JRn.susceptibles = JRn.national /(1- P n-1) ' (1c) 
where IRn.susceptible is the incidence rate among susceptibles, and IRn.national the 
incidence rate within the national population. 
Confidence interval for prevalence data 
Assuming prevalence data are binomially distributed, their 95 % confidence 
interval can be calculated from [19]: 
CI95n =sin[arcsin.JP: ±1.96~1!(4Nn)r, (2) 
with Nn representing the total number of women in age-group n: Nn = Cn + Sn . 
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A dynamic IPM model 
The baseline IPM model is extended to incorporate the parameter y, the number 
of years prior to the reference year: 
Pn.y = lf;revn-Ly+1 - mortn_1 + incin_1 * (1- prevn-Ly+l )J!(l- mortn_1 ). (3) 
To correct for the fact that more than 23 years before the year of reference 
incidence was not measured, incidence, and thus prevalence, was set to zero for 
y>23. To correct for a one-% trend in incidence, incidence was decreased by 
one-% for each additional year prior to the reference year (maximum 95): 
Pn,y = [prevn-Ly+l -mortn-! +incin-! *0.99A(y+l)*(l- prevn-Ly+l)J!(l-mortn-!). (4) 
Describing survival from breast cancer as lognormally distributed with 
a proportion cured 
We estimated excess mortality with breast cancer from duration-specific relative 
survival data assuming a lognormal survival with a proportion cured [16]. 
When RSurvn,d is the relative survival in age-group n, d years after incidence, Cn 
is the proportion cured for that age-group, and fln and IJn are the parameters of 
the cumulative lognormal distribution (Logndist), the model can be described as: 
(Sa) 
Fitting this model to the survival data allows the estimation of the cumulative 
mortality at different years dafter incidence. Non-cumulative mortality at exact 
d years after incidence is calculated by: 
mortyrn.d = (1- en)* (Logndist[un ,0' n ,d + 1]- Logndist[un, 0' n ,d]. (5b) 
A duration specific IPM model 
Prevalence at age n, d years after incidence can be calculated from the 
prevalence at the previous age and year, using: 
for d=O, and (6a) 
Summation across all years d results in an estimate of age-specific prevalence: 
(6b) 
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Abstract 
Objective 
Measurement of lifetime prevalence of depression in cross-sectional surveys is 
biased by recall problems. We estimated it indirectly for two countries using 
modelling and quantified the underestimation in the empirical estimate for one. 
Method 
We used a microsimulation model to generate population-based epidemiological 
measures of depression. We fitted the model to 1- and 12-month prevalence data 
from the Netherlands Mental Health Survey and Incidence Study (NEMESIS) 
and the Australian Adult Mental Health and Well being Survey. 
Results 
The lowest proportion of cases ever having an episode in their life is 30% of 
men and 40% of women, for both countries. This corresponds to a lifetime 
prevalence of 20% and 30%, respectively, in a cross-sectional setting (aged 15-
65). The NEMESIS data were 38% lower than these estimates. 
Conclusion 
Modelling enabled us to estimate lifetime prevalence of depression indirectly. 
This method is useful in the absence of direct measurement, but also showed that 
direct estimates are underestimated by recall bias and by the cross-sectional 
setting. 
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Introduction 
Major Depression (MD) is a debilitating [1-6] and prevalent disease, which is 
among the top five leading causes of burden of disease worldwide [7, 8]. In 
recent community surveys, four to ten percent of the general population was 
shown to experience an episode of MD within a year [9-13]. Another way to 
express the prevalence of MD is lifetime prevalence, which is defined as the 
proportion of people ever having experienced at least one episode. Ideally this 
would be measured based on completed life courses, but since community 
studies have to rely on self-report, this is not possible. In practice, studies 
measure a cross-sectional life time prevalence, ignoring incident cases that 
appear after the survey takes place. Two recent surveys reported lifetime 
prevalences of over 15% [10, 11]. 
These recent surveys rely on structured diagnostic interviews that use 
the respondents' reporting of depressive symptoms to diagnose MD. To collect 
lifetime prevalence data, respondents have to recall the presence and co-
occurrence of symptoms retrospectively over their past lifetime, possibly many 
years after they occurred. In such an assessment, problems with recall are not 
uncommon [ 14-19]. A comparison of cross-sectional and longitudinal data 
suggested that lifetime prevalence based on recall may be severely 
underestimated [20]. Furthermore, one study found that 25 years after admission 
for MD, 50% of the patients were not detected by the Composite International 
Diagnostic Interview (CIDD, the interview used in the recent surveys [21]. This 
recall problem was an important reasons to refrain from measuring lifetime 
prevalence in the Australian Mental Health and Well being Survey (personal 
communication). 
Instead of collecting lifetime prevalence empirically, it can also be 
estimated indirectly, using a modelling approach. It can be reconstructed from 
survey data, which are less prone to recall bias, such as 1- and 12-month 
prevalence. This approach enables us to check the extent to which existing 
measures of lifetime prevalence are underestimated by recall bias, but also 
provides an estimate in the absence of data. 
In this study we indirectly estimate the lifetime prevalence of MD on 
data from the Australian Adult Mental Health and Well being Survey [9] and the 
Netherlands Mental Health Survey and Incidence Study (NEMESIS) [10]. In 
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addition to providing an estimate for Australia, where empirical data is missing, 
a comparison of the indirect estimate with the empirical NEMESIS data 
provides a quantification of recall bias. 
Methods 
The data 
The three-wave longitudinal NEMESIS survey was based on a random sample 
drawn from the Dutch general adult population, aged 18 to 64 [10, 22]. Using 
the CIDI [23, 24] version 1.1, diagnoses were derived according to third revised 
version of the Diagnostic and Statistical Manual of Psychiatric Disorders (DSM-
III-R) [25]. We used 1- and 12-month prevalence data from wave I (1996). Total 
incidence (of both first and recurrent cases) in the 12 months between wave I 
and II were used to check the model outcome. For consistency with the 
incidence data, prevalence data were derived from the sample that participated in 
both wave I and II (5018 people) and exclusion criteria were not applied. 
The cross-sectional Australian Mental Health and Well being survey was 
based on a household sample of adults 18 years and older. Using the CIDI 
version 2.1, 1-month and 12-month prevalence was assessed for 1997. Both 
DSM-N and ICD-10 diagnoses were available. To be consistent with the Dutch 
data, we used the DSM diagnoses, without application of exclusion criteria, and 
excluding subjects older than 65. 
The weighted data of the surveys were used. For more information on 
the methods, sampling and response we refer to Bijl et al. [22] and Andrews et 
al. [9]. For both studies 95% confidence intervals around the prevalence data 
were calculated assuming a binomial distribution, using: 
CI95 a = sin[arcsin ~ ± 1.96~11(4N a) r , where Pa is the prevalence at age-
group a and Na the total number of persons at that age-group [26]. 
The model 
To allow for the large degree of heterogeneity that is seen in MD, we used a 
microsimulation approach. This technique describes the disease process of an 
individual in terms of probabilities and their distributions [27]. Individual life 
histories are generated by random drawings from these distributions. Adding a 
large number of life histories creates a population from which population based 
epidemiological measures, such as lifetime prevalence and number of episodes, 
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can be derived. 
We defmed distributions for all the relevant transitions. The following 
algorithm creates a life history for each person in the population: 
1. First an age at death is drawn from the observed survival curve (Statistics 
Netherlands and Australian Bureau of Statistics). 
2. A second random draw from a uniform distribution determines whether the 
person is susceptible for depression or not (parameter "susceptible"). If so 
we continue with point 3, else all years are lived free of MD. 
3. From a Weibull distribution, a standard distribution to model 'time to 
failure', age at first incidence is drawn (parameters: al and ~1). Ifthis age is 
lower than the age at death, we continue with point 4, else all years are lived 
free of MD. 
4. We assumed the duration of a depressive episode to be lognormally 
distributed [28] (parameters: f.! and o). Random draws are made until the 
episode lasts at least two weeks. If age at death is higher than age at 
incidence increased with duration, we continue with point 5, else the 
duration of the episode is reduced to last until death. If it becomes shorter 
than two weeks, it is dropped. 
5. From a second Weibull time until a repeat episode is drawn (parameters: a2 
and ~2). Eight weeks, by definition the a minimum period between episodes 
is added to the randomly drawn time to the next episode. If the age of 
incidence is lower than age at death, we continue with point 6, else all 
remaining years are lived free of MD. 
6. Points 4 and 5 are repeated until the age at death is reached. 
The model is thus defined by seven parameters. 
Fitting the model to survey data 
First we fitted the parameters of the lognormal distribution to sex-specific mean 
duration of episodes (u) calculated from 12- and 1-month prevalence from: 
365 * Pw h . th d . f . d . d u = + 2i- w+ 1 , w ere u IS e mean uratwn o ep1so es m ays; Pw 
y*n 
the 1-month prevalence, y the 12-month prevalence, i the minimum length of 
episode minus 1 day (13 days); w the length of the observation window (30.4 
days for 1-month prevalence); and n the mean number of incident episodes of 
average duration per year for people being 12-month prevalent. We assumed n is 
one. Next, we fitted the remaining five parameters to the prevalence data 
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specified by 5-year age group and sex. The fitting procedures used Neider and 
Mead's downhill simplex method [29]. 
The available data do not provide sufficient restrictions for only one 
optimal fit. Various combinations of lifetime prevalence and lifetime number of 
episodes lead to the same 1- and 12-month prevalence, although the number of 
combinations is restricted by the age pattern of the prevalence data. We choose 
those fits with the lowest lifetime prevalence in order to estimate the minimum 
extent of the underestimation. 
A cross-sectional estimate and excess mortality 
The model provides age-specific and a cohort estimate of lifetime prevalence. 
To enable comparison with the survey data we calculated a cross-sectional 
estimate averaging the age-specific model results for ages 15-64, weighting for 
the relative population size of the respective age groups in the Dutch 1996 
(Statistics Netherlands) and Australian 1997 (Australian Bureau of Statistics) 
population. 
We examined the effect of excess mortality of persons with a history of 
depression. Using a relative risks on total mortality (RR) we adjusted the 
survival curve for people with one or more episodes. We recalculated the fitted 
model using a RR of 1.81 that was reported in a meta-analysis of community 
studies [30], and an arbitrary higher value of 4. 
Results 
Figure 4.1 depicts the Dutch and Australian 12-month prevalence data by age 
and their 95% confidence intervals (95%CI); figure 4.2 the 1-month data. For all 
age groups the prevalence data are higher for women than for men, an 
observation that is consistently reported in the literature [31]. The rates fluctuate 
with age, with the 1-month prevalence having a similar, but lower, pattern than 
the 12-month prevalence. Between the two countries, the age-patterns are 
comparable, although the rates in Australia are on average higher than in the 
Netherlands. This does not necessarily relate to a true difference in the 
prevalence between these countries; differences in the version of the CIDI, DSM 
and the use of a lifetime or 12-months questionnaire as reference point may also 
cause such differences. Moreover, the 95% confidence intervals (95%CI) around 
the data are wide. 
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Figure 4.1. Twelve-month prevalence of Major Depression for the Netherlands 
and Australia: model outcome and data for men and women by age. 
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Figures 4.1 and 4.2 also show the modelled prevalence. For most age groups 
modelled prevalence falls within the 95%CI of the data. For the Netherlands, the 
data at age 40-45 are not reproduced well, while for Australia the data at age 50-
55 and the 12-month data for the youngest age group are markedly higher than 
the model outcome. 
In table 4.1 and 4.2 we give the model results for, respectively, mean 
duration and number of episodes and compare these to findings from community 
studies. Modelled mean episode duration is approximately 24 weeks, except for 
Australian men where it is 5-6 weeks longer. These estimates agree well with the 
number of weeks reported in several community surveys (Table 4.1), except for 
those reported by Kendler et al. and Spijker et al. [32, 33]. The mean number of 
episodes predicted by the model is around 7-8, but 13 for Australian women 
(Table 4.2). Our estimates are similar to the results from two community surveys 
that reported the number of depressive episodes (Table 4.2). 
For both countries the model estimates that approximately 30% of men 
and 40% of women experience one or more episodes of MD during their entire 
lifetime (Table 4.3). In a cross-section of the modelled population aged 15-65, 
this is equivalent to a lifetime prevalence of 20% and 30%, respectively, which 
is higher than reported in recent community surveys (Table 4.3). The Dutch 
NEMESIS data are on average 38% lower than the cross-sectional model 
estimates ({model-data}/model*lOO%). Lifetime prevalence by age is shown for 
the Netherlands in Figure 4.3 (model estimates follow a similar pattern for 
Australia, survey data are not available). The model estimates increase with age 
until they reach a plateau, while the NEMESIS increase to a lower level and 
decline after age 45-50. The difference between the data and the model increases 
with age, with the data being approximately 70% lower at age 60-64. Figure 4.3 
also depicts the results of adjusting for excess mortality from depression (a 
similar pattern was found for Australia). As can be seen from this graph, this had 
little effect on the model estimates. 
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Figure 4.2. One-month prevalence of depression for the Netherlands and 
Australia: model outcome and data for men and women by age. 
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Table 4.1. Mean episode duration (in weeks): model results and literature. 
Study Men Women Both sexes 
Modelling the Netherlands 24.6 23.8 24.1 
Modelling Australia 29.5 24.4 25.8 
ECA (USA) [28, 34] 26 27 * 
NCS (USA) [11, 28] * * 23 
Lewinsohn et aL (adolescents) [35] * * 26 
Kendler et aL (twins) [32] * * 12 
Spijker et al. (the Netherlands) [33] * * 36 
ECA: Epidemiologic Catchment Area 
NCS: National Comorbidity Survey 
*: these data are not reported 
Table 4.2. Mean number of episodes: model results and literature. 
Study Men Women Both sexes 
Modelling the Netherlands 6.8 7.7 7.3 
Modelling Australia 8.0 12.8 11 
NCS [3] * * 10.8 
Andrews et al (twins) [36] * * 8 
*: these data were not reported 
Table 4.3. Lifetime prevalence (percentage): model results and literature. 
Study Men Women Both sexes 
Modelling the Netherlands (cohort) 29.8 42.4 36.2 
Ditto (cross-section) 17.8 32.2 25.1 
NEMESIS [10] 10.9 20.1 15.4 
Modelling Australia (cohort) 27.2 43.4 35.4 
Ditto (cross-section) 20.1 23.4 27.4 
ECA [13] * * 5.8 
NCS [11] 12.7 21.3 17.1 
*: these data were not reported 
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Discussion 
We estimated lifetime prevalence of major depression indirectly using a 
modelling approach and found that approximately 30% of men and 40% of 
women suffer from one or more episodes of MD during their life in the 
Netherlands and Australia. The cross-sectional equivalent of this (20% and 30%, 
respectively) is higher than reported in community surveys. The Dutch survey 
data (NEMESIS) are 38% lower than the model estimates, indicating a 
potentially large recall bias. The model replicated the data to which it was fitted 
well. The plausibility of the model is supported by the similarities between the 
outcomes of the two countries and a comparison to literature findings. 
Figure 4.3. Lifetime prevalence of depression for the Netherlands: data and 
model outcome by age. 
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The model outcomes (prevalence, average duration, number of episodes) are 
mostly similar between the two countries and, apart from the well-described sex 
difference in the prevalence of MD, also between sexes. Two exceptions are the 
duration of episodes in Australian men and their number in Australian women. 
These higher estimates can be explained by the fact that the 1- and 12-month 
prevalence data were higher in the Australian than in the Dutch survey. To fit to 
these higher data the model can increase its current prevalence estimates in three 
ways: by increasing the number of susceptibles (i.e. lifetime prevalence), the 
duration of episodes, or their number. Episode duration was fixed, because we 
calculated it from 1- and 12-month prevalence. In Australian men, the ratio 
between these two variables was smaller than in the other three calculations, 
explaining the higher estimate. For Australian women, with an estimate of 
episode duration similar to the Dutch estimates, the only remaining variable to 
change is the number of episodes, as we reported the fit with the lowest lifetime 
prevalence. 
The model-generated results are (mostly) in agreement with data from 
the international literature. The estimated mean duration of episodes of around 
24 weeks is similar to results from several community studies in the USA [28, 
35]. The higher estimate of the Dutch study may be due to the inclusion of sub-
threshold cases and of dysthymic patients [33], the lower estimate of Kendler et 
al. [32] to the exclusion of persons with episodes lasting over a year. Also the 
number of episodes is comparable to the literature. This agreement with the 
literature contributes to the plausibility of the model, but more information, for 
example on the number of episodes encountered lifetime, will help to further 
pinpoint the model results. 
The lifetime prevalence estimates are the only results that differ from 
the international literature. We have presented here the lowest estimates of 
lifetime prevalence that are consistent with the 1- and 12-month prevalence data 
from NEMESIS and the Australian survey. The lower lifetime prevalence 
figures reported by NEMESIS are thus inconsistent with the current prevalence 
data from the same study. There are two major sources for this inconsistency. 
Firstly, the NEMESIS estimates are not based on completed life-courses. It is 
not possible to obtain such information in a cross-sectional setting. Secondly, 
problems in the recall of symptoms and their timing will lower the number of 
reported lifetime cases in NEMESIS. After correcting the model estimates for a 
cross-sectional setting the NEMESIS data are still 38% lower than these 
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estimates, a difference that increases with age. Recall bias may explain this 
underestimation. Taking into account that the average time of recall in the 
survey will be smaller than the 25 years studied by Andrews et al. our 38% is 
not far off from the 50% underestimation reported by Andrews et al. [21]. 
The increased risk of mortality in persons with a history of MD can not 
explain a large part of this underestimation. A recent meta-analysis estimated the 
RR of mortality to be around 1.81 [30], but even taking into account a much 
higher RR of four hardly changed the average percentage of underestimation 
(35% at RR=4). The effect is only seen at the older ages where lifetime 
prevalence decreases. Thus, although excess mortality decreases the 
underestimation at higher ages, across all ages the underestimation of the data 
remains approximately similar. 
One point that may be seen as a drawback of this study is that we did 
not include trends over time into the model. Several authors have suggested that 
incidence of (first episodes of) MD has increased over time [37]. A trend of 
increasing incidence would cause the lifetime prevalence rates at a certain age to 
be higher in younger cohorts than in older ones and may be an explanation for 
the observed decrease in the NEMESIS lifetime rates after age 45, which is not 
seen in our modeL However, such a trend should have only little influence on 
our model estimates, as it also effects the level of current prevalence by age. 
Thus, by fitting the model to current prevalence data, the effect of an increase in 
incidence is already partially included in the modeL We therefore expect the 
trend in incidence, like excess mortality, not to detract from our higher overall 
estimates of lifetime MD prevalence. 
Conclusion 
Based on Dutch and Australian 1-month and 12-month prevalence data, we 
estimated that approximately 30% of men and 40% of women suffer from one or 
more episodes of MD during their life. Lifetime rates observed in cross-sectional 
surveys are much lower. Two important reasons for this are that these surveys 
ignore cases that become incident after the time of the survey and that self-
reported symptoms and their timing may be biased by recall problems. We 
showed the Dutch data to be underestimated through recall bias by at least 35%. 
We expect excess mortality and trends in incidence to have little influence on 
this estimate. The large recall problem poses questions to the measurement of 
lifetime prevalence in cross-sectional surveys. 
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Summary 
Background 
Information on the distribution of disability associated with Major Depression 
(MD) across different groups of patients is of interest to health policy and 
planning. We examined the associations of severity and type (a single or 
recurrent episode) of MD with disability in a Dutch general population sample. 
Methods 
We used data from the first wave (1996) of the Netherlands Mental Health 
Survey and Incidence Study (NEMESIS). MD 'severity' and 'type' were 
diagnosed with the help of the Composite International Diagnostic Interview 
according to DSM-Ill-R criteria. SF-36 scores, days ill in bed and days absent 
from work were taken as indicators of disability. The differences in these 
variables were studied by means of variance and regression analysis. 
Results 
Recurrent MD was found not to be associated with more disability than single 
episode MD. Higher 'severity' classes were associated with more disability. 
However, the degree of disability between 'moderate' and 'severe' MD differed 
only very slightly. The difference in disability between non-depressed and 
mildly depressed individuals had a larger effect than between each successive 
pair of 'severity' classes. 
Conclusions 
Three groups of MD can be distinguished based on the associated degree of 
disability: 'mild', 'moderate to severe' and 'severe with psychotic features'. In 
the future, these groups can be used to describe the distribution of disability in 
the depressed population. The marked difference between 'mild' MD and no 
MD suggests that 'mild' cases should be considered relevant. 
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Background 
Recent community surveys reveal an alarmingly high prevalence of Major 
Depression (MD) in several developed countries [1-4]. In addition, the impact of 
MD on the daily functioning of the individual is strong [5-7], and the limitations 
in well-being and functioning of patients have been shown to be equal to or 
greater than those of several major chronic medical conditions [8-11]. The 
distribution of disability across the depressed population, however, has received 
little attention. Identifying differences in the extent of disability between sub-
groups of depressed patients may prove useful to health policy and planning and 
may help to interpret the high prevalence figures. 
Cases of depression are often classified into sub-groups according to the 
criteria of the American Psychiatric Association (AP A) to facilitate treatment 
planning in the clinical situation. The third Revised Version of the Diagnostic 
and Statistical Manual of mental disorders of the APA (DSM-III-R) [12] 
classifies episodes of MD into two 'types', namely 'single' and 'recurrent'. 
Furthermore, an episode is labelled by level of 'severity': 'mild', 'moderate', 
'severe', 'severe with psychotic features' and MD of 'unspecified severity'. 
'Severity' is defined according to the DSM-III-R by the number of depressive 
symptoms and the limitations in social, emotional and professional functioning 
that these symptoms cause [12]. The more severe the label assigned to an 
episode, the greater the likelihood that the episode will be associated with more 
disability, although empirical evidence to support this is lacking. Furthermore, in 
clinical practice it is often assumed that recurrent MD has a larger impact on 
functioning than single MD, but this has not been documented in the literature. 
It has been suggested that, despite the use of standardised diagnostic 
criteria, milder cases of MD are identified in community surveys compared to 
clinical settings [13]. If less disability is associated with mild cases diagnosed in 
a community setting, compared to those in the clinics, the question is whether 
they are still of public health concern. This could be investigated by comparing 
the extent of disability associated with 'mild' MD in community surveys to non-
MD. 
Our study focussed on the following assumptions: 1) that recurrent MD 
is associated with more disability than single MD, 2) that higher 'severity' 
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classes are associated with more disability, and 3) that individuals with 'mild' 
MD experience distinctly more disability than non-depressed individuals. 
To study these assumptions, we analysed how disability differed 
according to MD 'type' and 'severity', and between mildly depressed and non-
depressed individuals. We studied this for the Dutch population using data from 
the Netherlands Mental Health Survey and Incidence Study (NEMESIS) [14], in 
which MD 'type' and 'severity' were diagnosed using the Composite 
International Diagnostic Interview (CIDI) [15]. Disability was defined as 
limitations in the physical, psychological and social domains of functioning. 
Materials and methods 
Study sample 
Data were collected in the Netherlands Mental Health Survey and Incidence 
Study (NEMESIS). The methods used have been described elsewhere by Bijl et 
al. [4, 14]. Briefly, the survey was based on a three-stage, stratified random 
sample drawn from the Dutch general adult population, aged 18 to 64. An initial 
sample was drawn from a population of 90 Dutch municipalities, stratified by 
urbanicity and province, the next from a population of private households 
(addresses from post office registers) and a third from a population of 
individuals (most recent birthday). The survey was prospective: the interviews 
were taken in 1996, 1997 and 1999. We used cross-sectional unweighted data 
obtained on individuals diagnosed with MD in 1996. 
The interviews were spread over the entire year 1996 to compensate for 
seasonal influences. A maximum of ten attempts were made at various times and 
on various days to contact interviewees who were initially unavailable. This 
increased the response rate, and reduced selection bias due to short-term 
institutionalisation. The response rate for the sample was 69.7%, yielding a 
study population of 7076 persons, of whom 439 had been diagnosed with MD 
within the past year and 204 within the past month. Investigation of the non-
responders (i.e. refusals) revealed no evidence of selectivity (43% of non-
responders could be assessed). The study sample (n=7076) was shown to be 
representative of the Dutch adult population in terms of gender, civil status, and 
degree of urbanisation of the place of residence. The 18-24 year age group was 
slightly underrepresented. 
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Instruments/ variables measured 
The Composite International Diagnostic Interview (CIDI; version 1.1, 
computerised) [ 4, 14-16] was the diagnostic interview used to establish the 
diagnoses of MD and to classify MD 'type' and 'severity' based on the DSM-
III-R [12]. The CIDI is a structured interview developed by WHO. It can be 
administered by trained non-clinicians. The validity and reliability of this 
instrument have been shown to be good for all psychiatric diagnoses including 
MD [17]. However, its capacity to classify MD by 'type' and 'severity' has not 
been validated. 
Disability has been operationalised in different ways [18-21]. In the 
International Classification of Impairments, Disabilities and Handicaps (ICIDH, 
[18]) disability is restricted to disturbances at the level of the individual, as 
distinct to the level of the human organism (impairment) and in the societal 
context (handicap). In the International Classification of Functioning, Disability 
and Health (ICF, [19]) that has recently succeeded it, disability is, however, used 
in a broader sense, covering limitations in all levels of functioning. We used 
disability in its broader meaning. We defined disability as limitations in 
physical, psychological and social functioning. Disability was measured using 
the Short-Form-36 Health Survey (SF-36) [22, 23], an instrument reported to 
provide good reliability and validity [23]. Furthermore, it has proven to be able 
to distinguish different severity levels of MD in the elderly [24]. The 36 items of 
the SF-36 are grouped into eight health scales: physical functioning, role 
limitations due to physical problems, bodily pain, general health, vitality, social 
functioning, role limitations due to emotional problems and mental health. The 
scoring algorithm recommended by Ware & Sherbourne was adhered to [22], in 
which scores are distributed between 0 and 100, the latter representing optimal 
health. 
We included two other indicators of disability to reflect some of the 
economic consequences of depression as well: the number of days spent in bed 
due to psychiatric, drug or alcohol related problems (days ill in bed), and the 
time missed from work due to these problems (absence days). In both cases, the 
data collected referred to the past 12 months (measured in number of days) and 
to the past month (five classes: 0 days, 1-3 days, 4-7 days, >1week, <1 month, 
the whole time). 
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We included sex, age (in 10-year age groups) and socio- economic status (SES) 
as demographic confounders in our analyses. We used educational attainment 
(four levels) as a proxy for SES. Other confounders included were adverse early 
life experiences, the presence of chronic somatic conditions, and the presence of 
other psychiatric disorders. These variables were found to be associated with 
MD in an earlier study [7] and may affect an individual's functioning. The 
variable 'adverse early life experiences' consisted of self-reported emotional 
neglect, psychological abuse, physical abuse or unwanted sexual approaches on 
more than one occasion prior to age 16. The presence of chronic somatic 
conditions during the previous 12 months was assessed by a list of 31 chronic 
somatic conditions, based on the Health Interview Survey of Statistics 
Netherlands [25]. Only those somatic conditions that were reported to be treated 
or monitored by a doctor were included in the analyses. 'Other psychiatric 
disorders' included anxiety disorders, substance dependence or abuse (including 
alcohol), dysthymia, bipolar disorder, eating disorders and schizophrenia, as 
diagnosed by the CIDI. 
The CIDI provides diagnoses of MD (and presence of other psychiatric 
disorders) in the past month and year (and lifetime). Because we were not only 
interested in the extent of the problems during an episode, but also after this 
episode (residual disability), we used the sample of individuals diagnosed with 
MD in the past year in our analyses. The variables days ill in bed and absence 
days, and the two comorbidity confounders that refer to the past year were used. 
The SF-36 scores, however, reportedly measure the health situation during the 
past month. Although, the sample of individuals prevalent in the past month 
corresponds better with the SF-36 data, there are two additional reasons why we 
did not use it. First, this does not improve the correspondence with the timings 
of 'severity' and disability. 'Severity' is assessed by the CIDI for a severe -or 
the most severe- period of an episode, which may easily have occurred before 
the last month as the average duration of an episode is 4-6 months. Second, the 
number of individuals depressed in the last month was too small to reveal 
significant results in the comparison of the separate 'severity' classes. To 
examine whether the relationships differ using this sample, we repeated the 
regression analyses (see below), using variables and confounders that refer to the 
last month (except presence of somatic disorders), and inspected the beta-
coefficients. 
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Statistical analyses 
We used em-square analysis to study the association between 'type' and 
'severity' ofMD. 
Analyses of variance (ANOV A) were performed to study the 
associations of 'type' and 'severity' with each of the ten indicators of disability. 
We constructed ten models in whlch 'type' and level of 'severity' constituted the 
independent variables and one of the disability indicators the dependent variable. 
The confounders were adjusted for in the analyses. 
To test for a trend of increasing disability with recurrent 'type' and 
increasing 'severity', we used linear regression analyses, adjusting for the same 
confounders. 
When 'severity' was found to be statistically significant in the ANOV A, 
we tested whlch successive pairs of severity classes differed from each other by 
means of ANOV A. We corrected for the same confounders, but 'type' was not 
included in the analysis. To assess whether statistically significant differences in 
these tests were meaningful, we estimated effect sizes (d) using Cohen's 
guidelines to interpret the size of the effect: 0.2<=d<0.5 for a small, 0.5<=d<0.8 
for a moderate and d>=0.8 for a large effect [26]. 
In the same way, we compared mean SF-36 scores, days ill in bed, and 
absence days between individuals with 'mild' MD and without MD, and 
between those with MD and without MD. We also estimated effect sizes as 
described above. The statistical package used was SAS (version 6.12 [27]). 
Results 
The study population 
The characteristics of the total sample of the NEMESIS survey, and of the 
individuals diagnosed with MD in the past year and month are shown in Table 
5.1. The unweighted prevalence of MD in the last year in the total NEMESIS 
sample was 6.2%. The generally reported prevalence of MD weighted for sex, 
age, urbanicity and marital status is 5.8% (NEMESIS [4]). Compared to non-
depressed individuals, depressed individuals were significantly more likely to be 
female, to report more adverse early life events, somatic disorders and to have a 
low level of educational attainment. Of individuals who were diagnosed with 
MD 69% was diagnosed with a non-affective psychlatric disorder, compared to 
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only 18% of non-depressed individuals, a significant difference. Depressed 
individuals reported significantly higher levels of disability: the mean SF-36 
scores were lower (higher SF-36 scores indicate a better health status), whereas 
the mean number of days ill in bed and mean number of absence days were both 
higher. For most variables, these patterns seemed more pronounced for MD in 
the past month (Table 5.1 ). 
Disability according to 'type' and 'severity' 
Table 5.2 shows the mean SF-36 scores, mean number of days ill in bed and 
mean number of absence days (all unadjusted), broken down according to 'type' 
Table 5.1. Characteristics of the study population. 
Population: Total MD in the MD in the 
population last year last month 
Number (prevalence in %) 7076 (100) 439 (6.2) 204 (2.9) 
Confounders 
%Females 53.4 67.0 66.7 
Mean age in years (SD) 41.2 (12.2) 39.7 (11.0) 41.5 (11.1) 
% Educational level: high 27.3 23.0 21.6 
% Adverse early life 28.7 56.3 59.3 
experience 
% Chronic somatic 41.0 51.9 57.4 
condition(s) (treated) 
% Psychiatric disorder( s) 21.1 69.0 74.5 
other than MD 
Disability indicators 
Mean SF-36 scores (sd) 
Physical functioning 91.3 (16.5) 85.6 (20.9) 81.2 (23.5) 
Role limitations, physical 85.1 (30.5) 70.5 (40.0) 63.4 (42.8) 
Bodily pain 84.8 (22.0) 73.6 (27.5) 68.0 (29.0) 
General health perception 73.9 (18.2) 62.4 (22.0) 55.7 (22.4) 
Vitality 71.1 (18.6) 51.1 (22.4) 40.3 (20.4) 
Social functioning 89.3 (18.4) 71.4 (25.8) 62.5 (26.6) 
Role limitations, emotional 91.9 (23.8) 61.3 (42.1) 42.6 (41.7) 
Mental health 81.5 (15.3) 59.8 (22.3) 46.6 (19.8) 
Mean# of days ill in bed (sd) 0.6 (8.3) 5.0 (23.2) 
% with >0 days ill in bed 3.8 16.5 9.3 
Mean# of absence days (sd) 4.2 (31.1) 32.9 (81.9) 
% with >0 absence da~s 6.6 33.7 17.6 
a The number of days in the last month were measured categorically (five levels), and no 
mean value could be calculated. SD, standard deviation 
82 
CHAPTERS 
and 'severity', and according to 'type' alone. Inspecting this Table, it seems that 
mean SF-36 scores were somewhat lower (i.e. worse) for depressed individuals 
diagnosed with a single episode than for individuals with recurrent episodes of 
MD, and the mean number of absence days somewhat higher. Split up by 
'severity' class, the scores for single 'severe' MD looked particularly worse for 
all ten indicators compared to recurrent 'severe' MD. 
For higher 'severity' classes, it seems that the mean SF-36 scores were 
somewhat lower and the mean number of days ill in bed and absence days 
higher. This pattern, however, does not appear for 'moderate' and 'severe' MD. 
The scores of the latter two 'severity' classes seem to lie close together, as also 
appears from Figure 5.1, which shows the (unadjusted) mean scores of the 
indicators by 'severity'. 
The mean scores of single and recurrent MD of 'unspecified severity' 
are also given in Table 5.2, but we excluded these groups of persons from 
further analysis because they could not be categorised accurately into one of the 
four other 'severity' classes. 
Association of 'type' and 'severity' 
Chi-square analysis of MD 'severity' versus 'type' revealed no significant 
relation (p=0.486); the distribution of cases across the 'severity' classes did not 
differ significantly between single and recurrent episode MD. 
Association of 'type' and 'severity' with disability 
In the analysis of variance we adjusted for sex, age, educational attainment, 
adverse early life experience, presence of chronic somatic conditions and 
presence of other psychiatric disorders. 'Type' of MD was not significantly 
different for any of the disability indicators. The 'severity' classes, on the other 
hand, differed significantly on all SF-36 scales, days ill in bed and absence days 
(p<O.OS). 
Direction of the association 
In the regression analysis we adjusted for the sameconfounders. There was no 
significant trend with 'type' of MD. A positive linear trend with 'severity' was 
found for all SF-36 scales, for the number of days ill in bed and for absence days 
(p<0.05). 
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Table 5.2. SF-36 scores, number of days ill in bed and absence days according to 'type' and 'severity' class: means and sd. 
12-Month diagnosis Disability indicator Numbers 
SF-363 Other observed 
Physical Role Pain General Vitality Social Role Mental Days ill Absence 
functioning limitations health functio- limitations health in bed days 
(f!h_ysical) PerceEtion ning (emotional) 
Single MD, total 83.9 67.9 73.1 60.8 50.8 70.9 60.8 58.7 4.8 37.0 240 
(22.8) (44.0) (28.0) (22.9) (23.4) (26.9) (42.6) (24.1) (23.3) (89.4) 
Single 'mild' 92.2 85.5 82.1 70.8 62.1 85.3 78.0 67.6 0.2 0.3 50 
(14.0) (29.1) (22.3) (18.1) (19.2) (18.2) (33.4) (20.1) (1.0) (1.4) 
Single 'moderate' 85.4 70.4 76.3 57.8 51.2 76.2 68.0 66.5 6.0 48.8 49 
(21.2) (41.0) (27.7) (21.8) (22.7) (24.4) (40.2) (19.9) (26.9) (87.1) 
Single 'severe' 81.4 67.4 68.3 59.3 46.5 64.4 57.5 52.0 3.8 53.9 70 
(26.1) (40.3) (29.5) (23.1) (23.7) (26.7) (43.1) (25.3) (22.0) (109.3) 
Single psychotic 75.3 44.2 62.8 51.3 39.2 52.7 34.4 48.5 18.6 81.3 30 
(24.6) (44.9) (30.9) (26.6) (23.0) (27.7) (42.4) (25.0) (43.5) (129.5) 
Single not specified 82.4 61.6 74.1 61.3 52.1 71.7 56.1 57.4 0.6 8.3 41 
(23.9) (43.0) (27.0) (23.1) (23.2) (28.3) (45.0) (24.8) (2.0) (39.6) 
Recurrent MD, total 87.7 73.6 74.0 64.3 51.4 72.0 62.0 61.1 5.3 28.1 199 
(18.1) (38.8) (27.1) (20.8) (21.3) (24.4) (41.6) (19.9) (23.3) (71.8) 
Recurrent 'mild' 93.6 80.9 86.3 72.8 56.2 76.9 66.0 63.6 0.7 1.0 47 
(8.5) (35.4) (17.9) (18.0) (21.4) (20.4) (40.2) (18.8) (2.6) (2.8) 
Recurrent 'moderate' 86.4 77.9 71.6 63.6 51.6 72.2 65.4 61.5 3.2 30.1 52 
(20.3) (35.6) (29.3) (17.1) (21.3) (24.2) (42.8) (20.3) (17.0) (72.6) 
Recurrent 'severe' 88.5 74.1 71.5 66.5 53.1 71.9 63.0 61.9 4.2 42.5 54 
(16.5) (38.8) (25.3) (19.1) (20.1) (26.0) (39.7) (20.3) (18.2) (86.4) 
Recurrent psychotic 76.8 45.0 57.0 50.0 39.8 54.3 45.0 49.8 31.2 74.7 20 
(22.1) (44.1) (31.7) (27.1) (21.1) (26.0) (44.9) (21.1) (55.9) (111.6) 
Recurrent not speci- 86.0 73.1 75.2 56.7 47.7 76.5 59.0 62.9 0.5 7.2 26 
fied (22.0) (39.3) (28.3) (23.4) (21.1) (21.8) ( 42.5) (17.4) (1.5) (27.7) 
Total MD 85.6 70.5 73.6 62.4 51.1 71.4 61.3 59.8 5.0 32.9 439 
(20.9) (40.0) (27.5) (22.0) (22.4) (25.8) (42.1) (22.3) (23.2) (81.9) 
Standard deviations (sd) are shown in brackets. Psychotic, 'severe MD with psychotic features'; not specified, MD of 'unspecified severity'. 
"The SF-36 scales are scored from 0-100, 100 representing optimal health. 
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Figure 5.1. Unadjusted mean disability scores by 'severity' class. 
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We compared disability between the adjoining pairs of 'severity' classes, 
adjusting for the same confounders, and studied the relevance of significant 
differences, using effect size estimation. In Table 5.3, the means and effect sizes 
are reported; effect sizes of non-significant differences are not interpreted. 
'Mild' and 'moderate' MD differed significantly in four SF-36 scales and in 
absence days. The effect sizes were small (4x) and moderate (lx), respectively. 
'Moderate' and 'severe' MD differed only in mental health, a difference with a 
small effect size. Between 'severe' MD and 'severe with psychotic features' four 
SF-36 scales differed significantly, and also days ill in bed. The effect sizes were 
small (4x) and moderate (lx), respectively. 
Comparison with non-depressed persons 
Table 5.4 shows the results of the comparisons between non-depressed and 
depressed individuals and between non-depressed and 'mildly' depressed 
subjects, adjusted for confounders. As a group, depressed individuals differed 
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from non-depressed individuals on all disability indicators, although the effect of 
the difference in physical functioning was not meaningful. 'Mild' MD on the 
other hand differed significantly from non-MD in vitality, social functioning, 
role limitations due to emotional problems and mental health; four SF-36 scales 
that reflect psychological and social functioning. The effect sizes were moderate 
(lx), small (1x) and large (2x), respectively. 
The effects of the differences between 'mild' MD and non-MD were 
larger than the differences between the subsequent 'severity' classes reported 
above, which had a small effect nine out of 11 times and never had a large 
effect. In addition to the differences in indicators of psychological and social 
functioning between 'mild' MD and non-MD, differences also emerged with 
respect to indicators reflecting physical functioning and economical 
consequences (physical functioning, role limitations due to physical problems, 
pain, general health and days ill in bed and absence days) between the 
successive 'severity' classes. 
Regression analyses based on last month prevalence 
We repeated the regression analyses using the sample of individuals diagnosed 
with MD in the past month (204 individuals). 'Type' remained insignificant. 
According to 'severity' disability differed less significantly in nine of the 
indicators to the extent that no significant differences could be observed in two. 
The regression coefficients were nevertheless larger, except for role functioning 
due to emotional and due to physical problems. 
Discussion 
We compared disability as measured by the SF-36, numbers of days ill in bed 
and number of absence days, between MD 'type' (single and recurrent) and 
'severity', diagnosed according to the DSM-III-R. Recurrent episode MD was 
not found to be associated with more disability than single episode MD. Higher 
'severity' classes on the other hand ('mild', 'moderate', 'severe' and 'severe 
MD with psychoses') were associated with increasing levels of disability, 
although not all classes differed significantly from each other. 'Mild' MD 
showed distinctly worse scores than non-MD in indicators that represent 
psychological and social functioning. 
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Table 5.3. Comparison of disability indicators between successive 'severity' 
classes: raw mean scores, effect sizes and their interpretation. 
Variable Means Effect Interpre-
Mild Moderate Severe Ps~chotic size tation 
Mild versus moderate MD 
SF-36 
Physical functioning 92.89 85.94 0.32 small 
Role limitations (physical) 83.25 74.26 0.15 ns 
Pain 84.12 73.89 0.28 small 
General health 71.75 60.74 0.47 small 
Vitality 59.23 51.44 0.29 small 
Social functioning 81.20 74.16 0.21 ns 
Role limitations (emotional) 72.16 66.67 0.17 ns 
Mental health 65.65 63.92 0.02 ns 
Other 
Days ill in bed 0.41 4.56 0.21 ns 
Absence days 0.60 39.08 0.76 moderate 
Moderate versus severe MD 
SF-36 
Physical functioning 85.94 84.51 0.07 ns 
Role limitations (physical) 74.26 70.33 0.15 ns 
Pain 73.89 69.70 0.12 ns 
General health 60.74 62.48 0.14 ns 
Vitality 51.44 49.39 0.11 ns 
Social functioning 74.16 67.66 0.24 ns 
Role limitations (emotional) 66.67 59.89 0.06 ns 
Mental health 63.92 56.33 0.29 small 
Other 
Days ill in bed 4.56 3.98 0.07 ns 
Absence days 39.08 48.88 0.05 ns 
Severe versus severe MD with psychotic features 
SF-36 
Physical functioning 84.51 75.90 0.38 small 
Role limitations (physical) 70.33 44.50 0.42 small 
Pain 69.70 60.50 0.09 ns 
General health 62.48 50.82 0.42 small 
Vitality 49.39 39.40 0.33 ns 
Social functioning 67.66 53.30 0.36 ns 
Role limitations (emotional) 59.89 38.67 0.44 small 
Mental health 56.33 49.04 0.17 ns 
Other 
Days ill in bed 3.98 23.71 0.67 moderate 
Absence days 48.88 78.59 0.17 ns 
Effect sizes are interpreted according to Cohen's guidelines: with cut-off values of 0.2, 
0.5 and 0.8 for small, moderate and large effects, respectively. Effect sizes are adjusted 
for sex, age, educational attainment, adverse early life experience, presence of chronic 
somatic conditions and presence of other psychiatric disorders. 
ns, the difference was not significant and the effect size, therefore, not interpreted. 
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Table 5.4. Comparison of disability indicators between 'mild' MD and non-
MD and between MD and non-MD: raw mean scores, effect sizes and their 
interpretation. 
Variable Means Effect Interpre-
No MD MD Mild MD size tation 
No MD versus MD 
SF-36 
Physical functioning 91.72 85.61 0.18 no effect 
Role limitations (physical) 86.11 70.49 0.30 small 
Pain 85.50 73.55 0.28 small 
General health 74.64 62.38 0.39 small 
Vitality 72.40 51.05 0.84 large 
Social functioning 90.45 71.40 0.75 moderate 
Role limitations (emotional) 93.91 61.34 1.16 large 
Mental health 82.93 59.79 1.13 large 
Other 
Days ill in bed 0.33 5.01 0.45 small 
Absence days 2.34 32.92 0.84 large 
No MD versus mild MD 
SF-36 91.72 92.89 0.12 ns 
Physical functioning 86.11 83.25 0.02 ns 
Role limitations (physical) 85.50 84.12 0.03 ns 
Pain 74.64 71.75 0.05 ns 
General health 72.40 59.23 0.55 moderate 
Vitality 90.45 81.20 0.37 small 
Social functioning 93.91 72.16 0.85 large 
Role limitations (emotional) 82.93 65.65 0.95 large 
Mental health 
Other 
Days ill in bed 0.33 0.41 0.07 ns 
Absence da2:s 2.34 0.60 0.20 ns 
Effect sizes are interpreted according to Cohen's guidelines: with cut-off values of 0.2, 
0.5 and 0.8 for small, moderate and large effects, respectively. Effect sizes are adjusted 
for sex, age, educational attainment, adverse early life experience, presence of chronic 
somatic conditions and presence of other psychiatric disorders. 
ns, the difference was not significant and the effect size, therefore, not interpreted. 
In contrast to what we expected, our findings do not support the general idea that 
episodes of recurrent MD are associated with more disability than a single 
episode. This finding is based on the insignificant association of 'type' in the 
ANOVA and the insignificant chi-square analysis. The latter indicates that 
individuals suffering from recurrent MD were not more likely to have a higher 
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'severity' labeL One may argue against our fmding that we did not test for the 
interaction between 'type' and 'severity'. To examine its effects we included it 
in additional analyses. It was not significant except for the mental health scale, 
indicating that disability varies similarly between the 'severity' classes for single 
and recurrent MD, except for the variation in mental health. Another demur 
might be that our dependent variables do not cover all aspects of disability, 
thereby concealing possible existing differences. Because at least all three 
domains of disability were represented in our variables, this, in our view, is not a 
major shortcoming. Also, the temporality of a diagnosis of a single episode of 
MD may be seen as a problem. This diagnosis may later change to recurrent 
MD, which means that the single MD group could well contain a certain number 
of misclassified cases, obscuring possible differences in 'type'. Whereas 
obviously, therefore, no conclusive evidence was obtained regarding the 
differences between the underlying 'true type', assuming such a thing exists, our 
analyses did show that having experienced more than one episode was not 
associated with more disability than experiencing a first - perhaps sole - episode. 
This lack of difference in degree of disability can be explained in 
several ways. Firstly, it may be due to a response shift on the SF-36. Individuals 
with recurrent MD may adapt to their situation, causing them to make positive 
adjustments to their assessment of disability as compared to the first episode. A 
second factor could be differences in treatment-seeking behaviour. If individuals 
with recurrent MD are more often successfully treated, this can decrease their 
disability, diminishing differences with single MD. Thirdly, frequent episodes 
may well still be associated with more disability. Our study was restricted to 
examining differences between a single episode and recurrent episodes of MD, 
rather than by frequency. Finally, recurrent MD could still be associated with 
more disability in a clinical setting, where this idea was formed. Differences 
between a community setting, which was studied here, and a clinical setting may 
explain the outcome. Further study is needed to determine which of these 
explanations plays a role. Despite similar levels of disability, other parameters, 
such as prognosis and response to therapy, may still differ with 'type'. 
We did find a relation between MD 'severity' level and disability: a 
higher level of 'severity' was associated with more disability. This is consistent 
with the DSM-III-R criteria for MD 'severity'. The observation that limitations 
in physical functioning were not associated with 'mild' MD, but only with 
higher levels of 'severity' also corresponds with this definition. Not each 
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increase in 'severity' coincided with more disability. 'Moderate' and 'severe' 
MD seemed to be associated with a similar level of disability: only a difference 
in mental health was found. Because the items of the mental health scale are 
rather similar to the DSM criteria for MD and hence closely related to the CIDI 
diagnosis of MD, we believe it is not an appropriate measure of disability in our 
study. 
Individuals diagnosed with 'mild' MD differed substantially from non-
depressed individuals on indicators that represent psychological and social 
functioning. Moreover, these differences showed larger effect sizes than the 
differences between the successive levels of 'severity'. Apparently, 'mild' MD 
causes major disability, which can be exacerbated by higher levels of 'severity'. 
We believe for this reason that although less severe cases may well be detected 
in a community setting compared to a clinical setting [13], these mild cases are 
nonetheless still relevant. This is consistent with the literature describing 
considerable disability to be associated even with subthreshold levels of 
depression in the community [5, 6, 28, 29]. The results reported by Henderson et 
al. [30] are also in line with this idea. Although they report 14% of MD cases in 
a community survey to be free of disability, 86% of cases did have limitations in 
ability to work and perform role-activities. Moreover, while Henderson et al. 
[30] limited their definition of disability to these latter two indicators, our study 
showed that 'mild' cases report limitations in indicators other than these. In view 
of our results the sceptisisms about using fully structured interviews [31] may be 
seen from a different perspective. Although the SCAN, a semi-structured 
interview administered by clinically trained interviewers, has been reported to 
detect less MD cases than the CIDI [31], the additional cases detected by the 
CIDI may still be relevant. 
Three factors may detract from our conclusions. The first concerns the 
representativeness of the sample, which could be questioned for two reasons. In 
the first place, homeless and long-term institutionalised individuals are not 
included in the sample, so that some very severely depressed individuals may be 
missed. In the second place, selective non-response may also have caused under 
representation of severely depressed persons. As a result of such under 
representation the extent of the disability in the highest 'severity' group may be 
underestimated. This may be countered by the argument that inspection of the 
non-responders showed that their psychiatric morbidity did not differ from the 
responders [4, 14], although only 44% of the non-responders were available for 
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this analysis. Furthermore, the number of patients institutionalised with MD for 
more than a year is a relatively small group (1620 affective psychoses (first 
diagnosis) in general psychiatric hospitals in the Netherlands in 1993 [32]). We 
therefore assume that the sample is an adequate representation of the Dutch 
population of depressed individuals. 
A second possible drawback is the fact that our analyses were 
performed on a sample that had been diagnosed with MD during the past year, 
whereas the SF-36 is designed to assess disability over the period of the past 
month. The approximate 50% of individuals that are no longer suffering from 
MD may obscure the relation between the SF-36 scores and 'severity' or 'type'. 
For this reason we repeated our regression analyses using the sample of 
individuals diagnosed with MD during the last month. Although the disability 
indicators differed less significantly with 'severity', the larger regression 
coefficients indicate that the relation between 'severity' and disability is even 
stronger when the month prevalent sample was used. The less significant p-
values in the analyses of variance can be explained by the low numbers of cases 
included. The relation with 'type' remained insignificant. In fact, our finding 
that recurrent MD was not associated with more disability is strengthened by the 
use of the year prevalent sample. It may well be that recurrent MD is associated 
with more residual disability instead of with more disabling episodes of MD. 
Using the year prevalent sample we incorporated such residual disability into the 
analysis, and showed that even when it is taken into account, levels of disability 
are similar for single and recurrent MD. 
A third limitation to our study is the use of cross-sectional data. Because 
we were only interested in how burdensome it is for individuals to have a 
depressive episode within a certain time frame (i.e. a year), not in their future 
prospects of disability, using cross-sectional data suffices. Longitudinal data, 
nevertheless, may provide further insight into the difference between single and 
recurrent depression MD, as a subject can be more disabled not only by having a 
higher degree of disability, but also by having the same degree of disability for a 
longer period of time. 
Conclusion 
The DSM-ill-R diagnosis of 'severity' classes provides information on the 
disability associated with MD. Diagnosis of MD 'type', on the other hand, did 
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not. Consequently, the diagnosis of 'severity' can be used to estimate the 
distribution of disability in the depressed population, information that is 
important for health policy and planning. Broken down according to disability 
level, only three groups of MD could be distinguished: 'mild', 'moderate to 
severe', and 'severe MD with psychotic features'. A simplification of the DSM 
'severity' classes could be considered. The distinct difference in disability 
between 'mild' MD and no MD suggests that 'mild' cases are relevant. This is 
important information for interpreting the high prevalence figures from 
community surveys. 
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Abstract 
Context: 
The high burden of major depression is caused by high prevalence figures in 
combination with a high disability weight. The available weights, however, 
seem to be based on clinical descriptions of functioning, rather than on 
information of depression-associated disability within the community. 
Objective: 
To investigate whether this has led to an overestimation of the burden of 
depression. 
Design: 
Disability information from a Dutch mental health survey was used to 
distinguish different severity-classes of major depression and determine their 
proportional prevalence. We obtained expert valuations for each class and 
calculated an overall disability weight, weighting for the proportional 
prevalence. 
Results: 
Overall and severity-specific weights were very similar to other studies, but the 
overall DW was 73% higher than the weights used in the Dutch Burden of 
Disease Study, in which proportional prevalence was based on expert opinion. 
Conclusions: 
This study provides no indication to suspect that the disability and burden of 
depression have been overestimated. The Dutch example shows the importance 
of tailoring the disability weights to the epidemiological data. 
96 
CHAPTER6 
Introduction 
The importance of mental disorders and particularly of major depression (MD) 
as a cause of disease burden was one of the major findings of the Global Burden 
of Disease Study 1990 (GBD 1990) [1]. World-wide, depression accounted for 
nearly 11% of the disability and 4% of the total disease burden. The measure of 
burden of disease used in this study, the Disability-Adjusted Life-Year (DALY), 
combines the number of life years lost due to premature mortality and the 
number of years lived with disability using a set of disease-specific disability 
weights (DW s ). Years lived with a specific disease are weighed for the severity 
of the disability that is associated with the disease using DW s. 
In several national burden of disease studies that followed the GBD-
1990, the prominent burden of MD was replicated [2-4]. The prominence of MD 
reflects both the high prevalence figures found in community surveys [5-7], and 
the strong effects of MD on functioning and well-being [7-11]. 
In the original DALY methodology of the GBD-1990 DWs were 
determined by health experts. While the epidemiological estimates such as 
incidence or prevalence were hardly debated, the valuation method used to 
derive the DWs, the use of expert values and the universality of the DWs, have 
been criticised [12, 13]. For depression and other mental disorders, there are 
additional problems specific to the field of mental disorders that concern the 
DWs. 
One problem is that the estimates of the burden of depression are based 
on prevalence data from community surveys. This requires the DW s for 
depression to reflect the situation in the community. However, much of the 
empirical information on the functional effects of MD relates to clinical cases. 
Population surveys, on the other hand, may include milder cases of depression 
than those found in clinical settings [14], and DWs may as a consequence be 
overestimated. Having a low mortality component [1-4], the burden of MD 
relies heavily on the DWs and prevalence estimates, and the effect of 
overestimating the DW will be large. 
The aim of this study was to investigate whether accurate tailoring of 
the DWs to the prevalence data decreases the estimated burden of depression. To 
study this we needed information on the distribution of disability among the 
depressed cases in the community. Previously, we examined this using data from 
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a Dutch general population sample [15]. Disability was defined as limitations in 
the physical, psychological and social domains of functioning. Three clusters of 
"severity" could be distinguished: "mild", "moderate to severe" and "MD with 
psychotic features" [15]. We derived DWs for these three severity-classes, 
compared the DWs with other studies, and calculated the burden of depression 
using these tailored DW s. 
Methods 
Derivation of Disability Weights 
Disease selection, staging and description 
We presented five disorders for valuation: MD, obsessive compulsive disorder, 
cancer of the oesophagus, prostate cancer and vision disorders. We included 
disorders other than MD to prevent accentuating MD. Each disease was 
subdivided into assumed homogeneous stages regarding disability, treatment and 
prognosis. In total 18 disease stages were valued: the three severity-classes of 
MD (see introduction), 3 stages for oesophageal cancer, 2 for obsessive 
compulsive disorder, and 5 for the other two disorders. 
For each disease stage, a lay text and a standardised generic description 
of the functional health status was provided. An example is shown in Figure 6.1. 
We used the EuroQol 6D5L to describe the generic health status [ 16, 17]. This 
system describes six dimensions (6D) of health: mobility, self-care, usual 
activities, pain! discomfort, anxiety/ depression and cognition, in five levels (5L) 
of severity of the problems. The first, third and fifth levels are identical to the 
EuroQol 6D3L; two intermediate levels are inserted. 
For MD we based the lay text on the DSM-ill-R criteria for MD and 
"severity" of MD. EuroQol descriptions were based on the reported disability in 
the Netherlands Mental Health Survey and Incidence Study (NEMESIS) [8, 15]. 
From this study we used as indicators of disability the eight scales of the Short-
Form-36 Health Survey (SF-36) [18], the number of days spent in bed due to 
psychiatric, drug or alcohol related problems, and the number of days not able to 
work due to these problems. We used a formal algorithm (available from the 
authors on request) to map these disability data on the EuroQoL 6D5L 
classification. 
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Figure 6.1. Example of a disease stage description. 
Depression 
Depression is divided into the following stages: 
1. mild, 
2. moderate to severe, 
3. severe with psychotic features. 
We now ask you to value: 
Patients with moderate to severe depression 
These people experience one or more depressive episodes within a year. 
During these periods they go through permanent feelings of sadness or 
emptiness and a permanent loss of interest or pleasure in nearly all 
activities. They have problems eating and/ or sleeping and feel worthless or 
guilty. They may have thoughts of death. 
In a year in which one or more episodes are experienced their condition is: 
No problems in walking about 
No problems with self care 
ee Some problems with performing usual activities 
(e.g. work, study, housework, family or leisure activities) 
n Moderate pain or discomfort (fatigue) 
•• Moderately anxious or depressed 
•• Some cognitive impairments 
(memory, concentration, desorganisation, IQ-level) 
The descriptions for obsessive compulsive disorder and oesophageal cancer 
were adopted from a previous study: the Dutch Disability Weights Study 
(DDW) [19]. We recoded their EuroQol 6D3L descriptions into 6D5L. The 
descriptions and resulting values for prostate cancer and vision disorders will not 
be discussed here. 
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Valuation procedure and respondents 
The valuation procedure was largely copied from the DDW Study [19]. In brief, 
we employed medical doctors with sufficient knowledge of the consequences of 
a broad range of diseases. A convenience sample of 75 doctors was contacted, 
26 of whom had previously participated in similar studies [19, 20]. 
A written postal questionnaire was used. We replicated the DDW's 
"interpolation" procedure [19], in which subjects were asked to interpolate 
disease stages on a disability scale. The scale ranges between 0 (worst 
imaginable health state) and 100 (best) and was formally calibrated with PTO-
derived weights for 16 conditions. On the scale we replaced the conditions 
"mild MD" and "severe vision disorder" by disorders with comparable DW s 
("mild to moderate panic disorder" and "grade 3-4 arthritis"). 
The duration of a disease stage to be valued was defined universally as 
one year. For MD, with its episodic character, we asked the respondents to 
value: "a year in which one or more depressive episodes took place". The 
general description then showed the average health status for individuals who 
had an episode of MD in the last year. 
Analyses of the interpolation data 
For each disease stage, we calculated the DW from: 1-mean_ value/100. We 
examined the reliability of the valuations by 1) checking the compliance with the 
imposed ordering of the stages of mental disorders ("mild", "moderate", 
"severe"); 2) inspecting the Spearman rank correlation and inter-rater reliability 
among respondents; and 3) estimating the proportion of total variance that was 
attributable to the disease stages applying generalisability theory (G-study) [21, 
22]. 
We also studied possible associations of age, sex, current profession 
(GP, psychiatrist, researcher, other), and having medical experience (less versus 
more than 1 year) with the valuations in a regression analysis. All analyses were 
performed in SAS version 6.12 [23]. 
Comparison to the Dutch Disability Weights Study (DDW) 
We compared our DWs for MD with those from the DDW. Because respondents 
of the two studies were not independently drawn, standard statistical testing does 
not apply. Nevertheless to get an impression of the differences we compared the 
95% confidence intervals. We also compared the weights for obsessive 
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compulsive disorder and oesophageal cancer, to estimate the level of retest-
variability. 
Burden of Disease 
An overall weight for MD 
An "overall" average DW for MD was calculated from the severity-specific 
DWs, weighting for their proportional prevalence. Prevalence data for the three 
severity classes were obtained from the NEMESIS study. The residual 
prevalence of cases with "unspecified severity" in this study was proportionally 
distributed over the classes, excluding "MD with psychotic features", as we 
assumed these cases were unlikely to be missed. 
Calculation 
We calculated the burden of MD in the Netherlands in 1996 from the number of 
years lived with disability (YLD) only. We ignored mortality, because mortality 
from depression is typically low, and was also not included in the Dutch 
National Burden of Disease Calculation for 1994 [3] (suicide was measured 
separately in this study). 
We estimated YLDs for MD by multiplying 1-month prevalence and the 
overall DW with 1996 population data from the Netherlands Bureau of 
Statistics. Month prevalence figures were used as estimates of point prevalence. 
For adults aged 18-64 years we obtained 1996 prevalence data from the 
NEMESIS study [6]. We supplemented these for 13-17 year olds using 1993 
figures [24] and for those aged over 65 using 1992/3 prevalence data [25]. The 
6-month prevalence measured for the adolescent group was converted to 1-
month prevalence using the ratio of 1 to 6-month prevalence from the NEMESIS 
study. 
Comparison with previous estimates 
We compared the overall DW with weights from four studies: the Dutch 
National Burden of Disease Calculation for 1994 [3], the GBD-1990 [1], the 
Australian Burden of Disease Study [2], and a study by Andrews et al. [26]. 
Both the Dutch and Australian Burden of Disease Studies used severity-specific 
weights from the DDW to calculate an overall DW, but applying different 
proportional distributions of the severity-classes. We compared the number of 
DALY s lost to MD in the Netherlands in 1996 calculated using our tailored DW 
and the one from the Dutch Burden of Disease Study. 
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Results 
Derivation of Disability Weights 
Description of MD classes 
The formal and lay descriptions of the three severity-classes of Major 
Depression (MD) are given in Table 6.1. 
Respondents 
In total 49 medical experts participated (24 men and 25 women), a response rate 
of 64%. The mean age was 46.6 years (SD 8.8), the mean number of years of 
medical experience 12.2. Of the respondents, 53% was involved in direct patient 
care (14 GPs, 5 psychiatrists and 7 others), 35 %worked in medical research and 
12% had other health-related professions or was retired. 
Analyses 
The top part of Table 6.2 shows the DWs and their 95% confidence intervals 
(95%-CI) for the three classes of depression. The rank-order implied by the 
severity-specific classes of the psychiatric disorders (mild/ moderate/ severe/ 
severe with psychotic features), was complied with, except by one respondent 
who valued "MD with psychotic features" equal to "moderate to severe". 
Respondents largely agreed with each other on the ranking of the 18 disease 
stages: the mean Spearman correlation coefficient was 0.83. Also, individual 
valuations correlated well with the rest: Pearson correlation coefficients were 
larger than 0.8 except for one. 
In the variance component analysis, 76% of total vanance was 
explained by the disease stages. Respondents contributed another 6%, while a 
residual 18% remained unexplained. Regression analyses showed that age, sex, 
current profession, and not having medical experience could not significantly 
predict the scores of the 18 disease stages. 
Comparison to the Dutch Disability Weights Study (DDW) 
In the top part of Table 6.2 we also provide the DWs for MD obtained in the 
DDW [19]. Our severity-class descriptions and the number of classes differed 
from the DDW. Our EuroQol descriptions were generally less severe than in the 
DDW. Our DWs fell within the range of the 95%-CI of the DDW values, except 
for "moderate to severe" MD, where it is in between the 95%-Cls of the two 
separately valued classes. 
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Table 6.1. Descriptions of the three severity-classes (stages) of major 
depression (MD). 
MD class ''mild" (EuroQol 6D5Ldescription: 112222) 
These people experience one or more depressive episodes within a year. During 
these periods they go through permanent feelings of sadness or emptiness or a 
permanent loss of interest or pleasure in nearly all activities. They can have 
problems eating or sleeping and can feel worthless or guilty. They may have 
thoughts of death. 
MD class ''moderate" to "severe" (EuroQol 6D5Ldescription: 113333) 
These people experience one or more depressive episodes within a year. During 
these periods they go through permanent feelings of sadness or emptiness and a 
permanent loss of interest or pleasure in nearly all activities. They have 
problems eating and! or sleeping and feel worthless or guilty. They may have 
thoughts of death. 
MD class "severe with psychotic (EuroQol6D5Ldescription: 214444) 
features" 
These people experience one or more depressive episodes within a year. During 
these periods they go through permanent feelings of sadness or emptiness and a 
permanent loss of interest or pleasure in nearly all activities. Furthermore, they 
experience delusions and hallucinations. They have problems eating and 
sleeping and feel worthless or guilty. They have thoughts of death. 
*1. no problems, 2. a few problems, 3. some/ moderate problems, 4. severe problems, 5. 
very severe problems/ inability. The six digits correspond to the six dimensions of the 
EuroQol 6D: mobility, self-care, usual activities, pain! discomfort, anxiety/ depression, 
and cognition. 
Also shown in Table 6.2 are the DWs for obsessive-compulsive disorder and 
cancer of the oesophagus. Our descriptions for these disorders were taken from 
the DDW. Re-valuation of these stages resulted in new average values that fell 
within the 95%-Cis of the DDW, except for severe obsessive-compulsive 
disorder. 
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Table 6.2. Disability Weights obtained in the present study and comparison to the Dutch Disability Weights Study. 
Disease stage This study DDW 
EuroQol DW 95%CI EuroQol DW 95% CI 
Major Depression: 
"Mild" 112222 0.19 0.16-0.22 113131 0.14 0.09-0.19 
"Moderate" to "severe" 113333 0.51 0.46-0.55 
Moderate 133133 0.35 0.27-0.42 
Severe 335353 0.76 0.56-0.97 
"With psychotic features" 214444 0.84 0.80-0.88 335355 0.83 0.75-0.92 
Cancer of the oesophagus 
Stage of diagnosis and pdmary therapy (pt) 112441 0.52 0.48-0.57 112441 * 0.53 0.36-0.70 
State after intentionally curative pt 113331 0.42 0.37-0.46 113331 0.38 0.25-0.51 
Irradically removed I disseminated carcinoma 114451 0.82 0.79-0.84 114451 * 0.73 0.61-0.86 
Obsessive-compulsive disorder 
Mild to moderate 113133 0.30 0.26-0.33 113133 0.24 0.17-0.32 
Severe 133155 0.76 0.71-0.82 133155 0.56 0.38-0.74 
DW: Disability Weight; DDW: Dutch Disability Weights Study [19]. 
*For these stages the DDW descriptions gave two descriptions in EuroQol6D3L, each with 50% possibility. We recoded these into EuroQol 6D5L 
levels by averaging the two descriptions, thereby using the two additional levels (level 2 and 4) of this system. 
CHAPTER6 
For MD the differences with the DDW weights do not appear to be larger than 
for the identically described disorders. Most new weights fell within the DDW's 
95%-Cls, and the absolute differences with the DDW for MD (0.01 and 0.05) 
were smaller than for the other diseases (between 0.01 to 0.20). For all three 
disorders, our 95% confidence intervals were smaller than in the DDW. 
Burden of disease 
Overall DW for depression 
Table 6.3 shows how we calculated an average disability weight for MD. 
Weighting for the prevalence distribution of depressive cases across the severity-
classes we calculated an overall DW of 0.46. 
Burden of Disease 
We estimated that a total of 151,137 disability adjusted years were lost to MD in 
1996 in the Netherlands; 9.7 per 1000 persons (total population of 15,5 million). 
Per 1000 men 6.8 DALY s were lost to MD and per 1000 women 12.6. 
Comparison to previous estimates 
In Table 6.4 we compare the overall weight for MD to other studies. Our 
estimate is similar to the GBD weight and close to the weights from two 
Australian studies. However, our overall weight for MD is 73% higher than the 
one used in the 1994 Dutch National Burden of Disease Calculation. In that 
study the severity-specific weights from the DDW were combined to an overall 
DW for MD using expert estimations of the proportional prevalence of the 
severity-classes: 60% for "mild", 30% "moderate", 9% "severe" and 1% for 
"severe with psychotic features. Although our severity-specific DWs did not 
differ largely from the DDW, the NEMESIS data on the proportional 
distribution of the severity-classes that we used to combine them (see Table 6.3) 
were very different. 
Using the DW from the National Burden of Disease Study [3] the 
estimated number ofDALYs lost to MD (excluding dysthymia) is 5.6 per 1000 
persons, 42% lower than the number calculated using the tailored DW. 
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Table 6.3 Calculation of the average disability weight for Major Depression. 
Severity-class of depression % of prevalence* DW 
"Mild" 26.7** 0.19 
"Moderate" to "severe" 61.9** 0.51 
"Severe with psychotic features" 11.4 0.84 
Total MD 100 0.46 
DW: Disability Weight, MD: major depression. 
*Prevalence data obtained from the Netherlands Mental Health Study and Incidence 
Survey (NEMESIS) [6, 15]. **Including MD of "unspecified severity". 
Discussion 
We derived DWs for MD that are tailored to the level of MD-associated 
disability observed in a community sample in the Netherlands. For the separate 
severity-classes of MD our DWs did not deviate largely from the Dutch 
Disability Weights Study (DDW) [19]; even though our health status 
descriptions were more severe. Our overall weight for MD was similar to those 
used in several burden of disease studies [1, 2, 26]. Due to differences in the 
estimated proportional prevalence of the severity-classes, nevertheless, our 
overall DW was 73% higher than the one used in the 1994 Dutch National 
Burden of Disease Calculation [3]. As a result, we estimated that per 1000 
persons 9.7 years lived with disability (YLDs) were lost to MD in the 
Netherlands in 1996. 
We derived DWs for three severity-classes of depression providing 
descriptions of the health states that were based on information obtained in a 
Dutch community survey [8, 15]. Because our health status descriptions in 
EuroQol (based on self-reported disability in the survey) were on average 
somewhat less severe than the ones provided in the DDW (based on case-
definition and expert opinion), we expected our DWs to be lower (i.e. indicating 
less disability) than the DDW weights. Nevertheless, the differences between the 
two studies did not appear significant. Similar weights for depression were also 
found in an Australian study [27], in which the health status was provided as 
Short Form-12 (SF-12) descriptions, that were obtained from the Australian 
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Table 6.4. Comparison of the overall disability weights for depression from different studies, and how they were derived. 
Study, country DW (method) Severity-classes Distribution across classes DW 
This study, the Netherlands New 3 severity classes: "mild", "moderate to Dutch survey data* 0.459 
(ip-PTO) severe", "severe with psychotic features". 
GBD-1990, EME [1] GBD 2 classes: treated versus untreated. expert estimation 0.469 
(PTO) 
Dutch National Burden of DDW 4 Severity classes: "mild", "moderate", expert estimation 0.266 
Disease Calculation [3] (PTO & ip) "severe", "severe with psychotic features". 
Australian Burden of DDW 3 Severity classes: "mild", "moderate", SF-12 cut-off scores in 0.41 (m) 
Disease Study [2] (see DDW) "severe". Australian survey** 0.37 (f) 
Andrews et al., Australia New 3 Severity classes: "mild episode", SF-12 cut-off scores in 0.417 
[26, 27] (PTO) "moderate episode", "severe episode". Australian survey** 
DW: Disability Weight; PTO: person trade-off; ip-PTO: interpolation on a PTO calibrated disability scale; GBD-1990: Global Burden of Disease 
Study 1990; EME: established market economies; DDW: Dutch Disability Weights Study; m: male; f: female. 
*The Dutch Survey data were derived from The Netherlands Mental Health Study and Incidence Survey [6, 15]. 
**The Australian Survey data were collected in The Australian National Mental Health and Wellbeing Survey [7]. 
CHAPTER6 
Mental Health Survey [7]. Apparently, the health status description has only 
little effect on the valuation, and the disease-stage label is much more important. 
Our overall DW was similar to those used in the GBD and in two 
Australian studies. Their correspondence suggests that there is no reason to 
suspect that DWs for MD, which are not tailored to the community situation, are 
overestimated. Therefore, the high burden of depression as estimated in the 
GBD and several national studies does not appear to be overrated due to an 
overvaluation of the DWs. On the contrary, in the Dutch 1994 National Burden 
of Disease Calculation the burden of depression seems to be too low as a result 
of underestimating the overall DW. In the latter study the proportional 
distribution of the severity-classes was based on expert opinion. The proportion 
of "mild" cases estimated by experts was much higher than the NEMESIS 
survey data suggest. This altered the overall DW severely (73%), showing us the 
importance of the quantitative epidemiological information in burden of disease 
calculations. The overall DW for depression was more sensitive to the 
distribution of disability across the depressed population, than to differences in 
health status descriptions. 
Three remarks may be put forward to detract from our conclusions. 
Firstly, our generic health status descriptions were based on disability reported 
by people who were depressed in the past year. Thus, not all cases included were 
currently depressed, and disability estimated in this way is less severe than when 
only current cases had been included. However, there were three reasons why 
we did not use current cases only. Firstly, it enabled us to include residual 
disability, secondly to increase the number of observations and, thirdly, to 
provide a description of the health status in a year. The last reason is important, 
as the time-frame for which health states were valued was, as in most valuation 
studies, one year. The fact that disability is possibly underestimated in this way 
only strengthens our conclusion that DWs for MD were not overestimated in 
previous studies. 
Secondly, the use of these descriptions of health status over the past 
year has further implications. Strictly speaking, DWs for these "annual-profiles" 
cannot be compared to the ones from the DDW that were derived for a whole 
year living with the health status at the actual moment of a depressive episode. 
Furthermore, to calculate the burden of MD, the annual-profile DWs should be 
multiplied with an annual prevalence. However, we compared with the DDW 
and used estimates of point-prevalence. Our rationale for this was that 
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respondents seem to respond mainly, or entirely, to the provided disease-stage 
label, not paying much attention to the generic health status descriptions and 
annual profile. 
Thirdly, if the respondents mainly valued their idea of the average 
"mild", or "moderate" case of depression, it is not possible to tailor the severity-
specific DWs to the community setting. Should the robustness of the DWs lead 
us to believe that the burden of depression is not overestimated, or are expert 
opinions insensitive to the subtle differences in the descriptions provided? 
Nevertheless, irrespective of this stand the tailoring of the overall DW using the 
proportional distribution of the classes, and the importance of the 
epidemiological data. 
Conclusions 
Our study provides no indication that previously estimated DWs were 
overestimates because they were not tailored to the community setting. Our 
tailored DWs were similar to most other studies, including the GBD and do not 
decrease the estimated burden of depression. These results strengthen the 
validity of the high estimates of the burden of depression. This study 
furthermore points out the importance of obtaining sound epidemiological data 
in burden of disease studies. 
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Abstract 
Background: 
The burden of breast cancer expressed in Disability Adjusted Life Years 
(DALYs) was compared for six European countries and its sensitivity to 
different sources of variation examined. 
Methods: 
DALY s were calculated using country-specific epidemiological data and 
European Disability Weights. Epidemiological data for 1996 were obtained for 
Denmark, England and Wales, France, the Netherlands, Spain and Sweden. 
Disability weights were empirically derived. 
Results: 
Denmark and the Netherlands lost the largest number of DALY s (approximately 
1100 DALYs per 100,000 women). They were followed by England (87% of the 
Danish burden), France (72%), Sweden (68%) and Spain (67%). 70 to 80% of 
the burden was caused by mortality. Cross-national variation in disease 
epidemiology was the largest source of variation in the burden of breast cancer. 
Variation in disability weights and uncertainty in epidemiological data had 
smaller effects. 
Conclusion: 
To compare the burden of breast cancer and most other types of cancer mortality 
rates provide sufficient information. 
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Introduction 
Breast cancer is an important health problem among women in developed 
countries. In the Global Burden of Disease Study 1990 (GBD 1990) [1] it was 
among the ten leading causes of burden of disease for women in the established 
market economies. The summary measure used in this study, the Disability 
Adjusted Life-Year (DALY), combines the burden caused by premature 
mortality and non-fatal health outcomes into one figure. In the GBD 1990 study 
the DALY is calculated by summing the number of years of life lost (YLL) and 
the number of years lived with disability (YLD) attributable to a specific 
disease. The estimations are based on disease-specific epidemiological 
frequency data, expert derived disability weights (DW) and demographic data. 
The DWs weigh the years lived with a specific disease by the severity of the 
disability associated with it. 
The DALY concept is criticized on many points. The use of universal, 
expert derived DWs has raised much debate regarding the reliability of the 
DALY, [2-5] while the reliability and availability of the epidemiological data 
have commonly been taken for granted. Recently, the stability of DWs was 
investigated in the European DWs study (EDW) [6]. Prior to this study, no 
country-specific DWs were available except for the Netherlands [7], and 
national burden of disease studies used either the GBD 1990 DWs, the Dutch 
weights or a combination of both [8-10]. 
Another point of concern is the potentially low sensitivity of the DALY 
to reflect true variation in the light of the error variation. True variation is caused 
by true differences in epidemiology, DWs or demography over time or place, 
whereas causes of error variation are sampling and measurement error, and 
incomparability in both epidemiological data and DWs. Between European 
countries we may expect true variation in the burden of breast cancer for three 
reasons. First, as a result of differences in exposure to risk factors (e.g. age at 
first pregnancy [11]), variation in screening practices and therapeutic 
management, the epidemiological frequency data differ. Secondly, due to cross-
national variation in preferences for health states, DWs of breast cancer may 
differ. Thirdly, the countries differ in population size and structure. 
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The objective of this paper is twofold: 
1. To compare the burden of breast cancer in six European countries. 
2. To assess the relative impact of the three sources of variation on the estimated 
DALY s for breast cancer, and, specifically, of the DW s. 
Methods 
General approach 
We compared the burden of female breast cancer between Denmark (Dk), 
England and Wales (E&W), France (Fr), the Netherlands (Nl), Spain (Sp) and 
Sweden (Sw) for the year 1996. This was the most recent year for which 
epidemiological frequency data were available for most countries. We computed 
YLLs using a standard expected years of life lost. [1, 12] YLDs were obtained 
applying an incidence perspective; meaning incidence and duration were 
multiplied. DALY s were the summation of the age-specific YLLs and YLDs. 
In the EDW project DWs were derived for five phases of breast cancer: 
(1) diagnosis and primary breast conserving therapy; (2) diagnosis and 
mastectomy; (3) clinically disease-free without permanent sequelae; (4) 
clinically disease-free with major permanent sequelae; and (5) recurrent or 
disseminated disease (for a description and DWs see Addendum I). We 
calculated YLDs for each phase, necessitating the estimation of incidence and 
duration for each phase. 
We calculated the burden of breast cancer from: 
1) epidemiological frequency data on incidence and mortality, 
2) DWs from the EDW project, 
3) demographic data, 
4) additional data to estimate incidence and duration of the five phases, and 
5) a model to combine these data into a burden of disease calculation. 
The baseline calculations used country-specific epidemiological data, European 
DWs and a standard European population (I). Additional calculations were done 
with alternative epidemiological frequency data (II), country-specific DWs 
instead of European DWs (III), and country-specific demographic data (IV), to 
explore the effects of uncertainty in the epidemiological estimates (II), of 
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introducing cross-national variation in DWs (III) and m demography (IV), 
respectively. 
Incidence and mortality data 
National incidence and cause-specific mortality data of female breast cancer 
(ICD-10: C-50) were collected for each country per 5 year age group up to 85+. 
Incidence numbers refer to the number of tumours and not women. Because 
women may experience a second primary tumour in their breast, incidence was 
adjusted for double counting of persons using estimates of the percentage of 
secondary breast cancer primaries (SPs). ASP was defined as a new tumour in 
the breast of a woman who had been diagnosed with a malignancy in the breast 
before. Information on the data and their sources can be found in Addendum II. 
To study the sensitivity of the DALY to uncertainty in the 
epidemiological information, we increased the Dutch mortality rates by 5% in an 
additional calculation, and used regional registrations of incidence as an 
alternative to hospital discharge data for Spain. 
Disability weights 
In the EDW project, disability weights were derived from health professionals 
and non-health professionals in five countries (232 participants in total) using 
the time trade-off method and a visual analogue scale. For a description of the 
methods see Essink-Bot et al. [6] Empirical DWs were not derived in Denmark. 
For the remaining five countries country-specific weights were derived for the 
five phases of breast cancer (see Addendum I). European weights were 
calculated based on the pooled data of the five countries. 
Demographic data 
The European standard population, obtained from the World Health Statistics 
Annual 1990 [13], has a total population size of 100,000. We collected 
population numbers and total mortality data per 1 year age group for each 
country. Information on these data and the data sources are given in Addendum 
II. 
Additional data 
To estimate the incidence of each phase of breast cancer data were collected on 
the proportion of incident cases diagnosed as metastasized (M1) and on the 
proportion of women undergoing total mastectomy. We used one estimate for all 
age groups. Data sources are provided in Addendum II. For England, cancer 
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epidemiologists suspected the data on the percentage Ml to be too low, and we 
used a maximum estimate they provided in an alternative calculation. 
Phase-specific duration was in part estimated from a study by the 
Munich cancer registry [14]. The diagnosis and therapy phase was assigned a 
duration of one year. The duration of the remaining phases was back calculated 
using the total disease duration (see below). The disease-free phase was allowed 
to last a maximum of five years. For more information see Addendum III. 
Calculation of the burden of breast cancer 
Incidence and mortality rates were obtained by dividing age-specific numbers by 
the midyear population. Incidence rates for France were extrapolated from 75+ 
to 85+ using cubic-spline methodology [15] and life-table derived mean ages of 
87 and 93 for age groups 75+ and 85+, respectively. The proportion of SPs was 
subtracted from the incidence rates. 
Next, the average total disease duration by age was estimated using the 
DisMod II software [ 16, 17], interpolating the rates to 1 year age groups (a good 
approximation of the transition hazards) using cubic-spline methodology. To 
obtain incidence hazards among susceptibles we divided incidence by 
prevalence, calculated using the model described by Barendregt et al. [18]. Both 
models were specified for a situation without remission and assumed that no 
time trends in the transition hazards exist. 
Subsequently, incidence was distributed over the five phases of breast 
cancer using a model that describes different pathways that incident patients 
may pass through over time (see Addendum IID. Briefly, the total proportion of 
patients dying from breast cancer (non-survivors) was first estimated by dividing 
the total number of breast cancer deaths and incident cases, after standardising 
them to the European standard population. Second, assuming that death from 
breast cancer is always preceded by metastasis or local recurrence, we calculated 
the proportion of non-survivors with and without metastasis at diagnosis using 
the percentage Ml. Third, survivors and MO non-survivors were distributed into 
those with and without permanent sequelae, assuming that the proportion of 
cases with permanent sequelae can be approximated by the proportion of women 
undergoing mastectomy treatment. In each pathway several phases may be 
passed through over time. 
YLDs were calculated for each phase in each pathway by multiplying 
pathway-specific incidence, phase-specific duration and DW, with population 
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numbers in each age group. Summation resulted in estimates of total YLDs by 
age. 
YLLs were calculated using standard expected years of life lost derived 
from the standard West Level 26 life-table and estimates of mean age at death 
per 5 year age group (Drs T. Vos, department of human services). Standard 
years of life lost were multiplied by mortality rates and population numbers to 
yield YLLs. Summation of YLDs and YLLs produced the country specific 
DALYs. 
Results 
Country-specific epidemiological data 
Figures 7.1 and 7.2 show the observed mortality and incidence rates for each 
country by age. Mortality increased with age. Highest rates were reported for 
Denmark and the Netherlands, followed by England and Wales, while the lowest 
were seen in Sweden and Spain. 
The incidence rates in figure 7.2 show an initially exponential increase 
with age, which changes around age 50 for most countries (Clemmensen's hook). 
Figure 7 .1. Breast cancer mortality rates by age for women in six European 
countries. 
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For some countries, another interruption of the exponential increase can be seen 
around age 65, while at the highest age groups incidence starts to decline except 
in England and Wales. The Spanish incidence rates were lower than in other 
countries from age 40-45 onwards. The 1996 Spanish hospital discharge data 
decreased after age 50, while the averaged regional estimates used as alternative 
data (dotted line) continued to increase up to age 75. 
The proportion of M1 cases ranged between 2% (Sweden) and 6% (the 
Netherlands). For England and Wales cancer epidemiologists expected the 
registered 2.5% to be an underestimate, and estimated it to be maximally 10%. 
This maximum was used as an alternative. Therapy practice (mastectomy versus 
breast-conserving therapy) differed somewhat between countries. In England 
and France, respectively 32% and 35% of women underwent total mastectomy. 
In other countries the percentage ranged between 43% (Sweden) and 59% 
(Spain). Because cancer registration experts suspected no large deviations, 
Dutch regional data on the percentage SP were used for all countries except 
Spain. The percentage increased with age to nearly 10% in age group 70-75. In 
Spain, experts estimated SP as close to zero. 
Figure 7 .2. Breast cancer incidence rates by age for women in six European 
countries. 
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The burden of breast cancer I: epidemiological frequency data as the only 
source of variation 
The number of DALY s calculated from country-specific epidemiological data, 
European DWs and a standard European population are shown by age for each 
country in figure 7.3. The total number of DALYs, YLDs and YLLs are given 
by country in table 7.1 and figure 7.4. Denmark and the Netherlands lost the 
highest number of years to breast cancer, followed by England and Wales (87% 
of the Danish burden), France (72%), Sweden, (68%) and Spain (67%). DALYs 
lost to breast cancer peak at around age 50. Table 7.1 also provides the 
percentage of DALY s attributable to mortality: in Sweden the lowest proportion 
of DALY s was attributable to YLLs: 70%. 
The burden of breast cancer II: replacing some uncertain epidemiological data 
by alternative data 
For England and Wales, the Netherlands and Spain the burden was calculated 
assuming alternative epidemiological data. The results and changes with the 
original calculations are depicted in table 7.2 (top). The largest deviations from 
the baseline estimates were observed for Spain where the hospital discharge data 
Figure 7.3. Population standardized DALYs for breast cancer by age in six 
European countries. 
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were replaced by regional incidence rates. As a result, YLLs decreased by 
almost 30% and the number of DALYs by 8.5%. For the Netherlands, the 
mortality rates were increased by 5%. This increased the number of DAL Ys by 
6.3%. Varying the proportion of patients metastasised at diagnosis (Ml) in 
England and Wales increased the number of YLD by only 0.2%. Using the 
higher mortality rates for the Netherlands caused the burden of breast cancer in 
the Netherlands to become slightly larger than in Denmark. 
The burden of breast cancer III: cross-national differences in epidemiological 
data andDWs 
Table 7.2 (middle) presents results for the calculations with baseline 
epidemiological data using country-specific DWs. Denmark is not shown here, 
as no country-specific DWs were available. Sweden showed the largest change: 
the number of YLDs was 22% lower, resulting in a decrease in DALYs of 7%. 
For the other countries, the differences in YLDs and DALY s were smaller. 
Some changes appeared in the ranking of countries on DALY s, but only where 
the original differences in DALY s were small. 
Figure 7.4. Total DALYs, YLDs and YLLs for breast cancer by country 
(standardized) 
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The burden of breast cancer N: cross-national differences in epidemiological 
data and demographic data 
DALYs computed from country-specific population figures, European DWs and 
the baseline epidemiological data by age are shown in table 7.2 (bottom). Total 
population size for each country was scaled to 100,000 to allow comparison. The 
number of DALY s increased for all countries: the difference ranging between 
4.6 and 14.9% for Spain and Sweden, respectively. As a result, Sweden came 
fourth and France fifth in the ranking of the burden of breast cancer. The age 
pattern also changed and varied between countries, the number of DALYs still 
increased sharply towards age 50, but decreased more slowly thereafter (data not 
shown). 
Discussion 
The burden of breast cancer was compared in six European countries: Denmark, 
England and Wales, France, the Netherlands, Sweden, and Spain, and the 
relative effects of variation in epidemiology, in disability weights (DWs), and in 
demography on the estimated burden studied. Taking into account only 
Table 7.1 Breast cancer DALYs, YLLs and YLDs calculated for six 
European countries. Baseline calculation. Cross-national differences in 
epidemiological data. 
Baseline epidemiological data, European DW, standard EU population 
Denmark England France Netherlands Sweden Spain 
and Wales 
DALY 1102.2 961.2 801.4 1071.0 745.1 741.9 
YLL 868.8 768.5 606.4 818.2 520.9 526.7 
YLD 233.4 192.8 195.0 252.8 224.1 215.3 
%YLL 78.8 79.9 75.7 76.4 69.9 71.0 
DWs: disability weights; EU: European; % YLD: percentage of DALYs that is 
attributable to morbidity. 
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Table 7.2 Breast cancer DALYs, YLLs and YLDs calculated for six 
European countries. Additional calculations. Alternative epidemiological 
data, cross-national differences in DWs, cross national differences in 
demographic data 
Denmark England France Netherlands Sweden Spain 
and Wales 
Alternative epidemiological data, European DW, standard EU population 
% Ml Mortality Incidence 
DALY 961.7 1138.7 678.7 
YLL 768.5 886.9 526.7 
YLD 193.2 251.9 152.1 
Change in comparsion with baseline calculation (%) 
DALY 0.0 6.3 -8.5 
YLL 0.0 8.4 0.0 
YLD 0.2 -0.4 -29.4 
Baseline epidemiological data, country specific DW, standard EU population 
DALY 975.0 763.7 1120.2 695.1 764.1 
YLL 768.5 606.4 818.2 520.9 526.7 
YLD 206.6 157.3 302.0 174.2 237.4 
Change in comparsion with baseline calculation (%) 
DALY 1.4 -4.7 4.6 -6.7 3.0 
YLL 7.2 -19.4 19.5 -22.3 10.3 
YLD 
Baseline epidemiological data, European DW, country-specific population 
figures (scaled) 
DALY 1219.0 1044.4 846.6 1125.3 856.2 
YLL 958.2 830.2 637.3 857.2 595.9 
YLD 260.8 214.2 209.3 268.1 260.2 
Change in comparsion with baseline calculation (%) 
DALY 10.6 8.7 5.6 5.1 14.9 
YLL 10.3 8.0 5.1 4.8 14.4 
YLD 11.8 11.1 7.3 6.1 16.1 
DWs: disability weight; EU: European. 
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differences in breast cancer epidemiology, relatively more DALYs were lost in 
Denmark and the Netherlands, followed by England and Wales. Spain lost the 
smallest number of DALY s to breast cancer. Cross-national variation in disease 
epidemiology was the largest source of variation in the burden of breast cancer. 
Additional variation resulting from introducing differences in population 
structure was smaller. The smallest effects resulted from uncertainty in the 
epidemiological data and using country-specific DWs. 
The major part of the burden (at least 70%) was caused by premature 
mortality (YLLs). Consequently, the estimated burden of breast cancer reflected 
mainly mortality. To determine in which country the burden of breast cancer 
was largest, a simple inspection of the epidemiological frequency data would 
have sufficed: the differences in mortality rates could predict the rank order of 
the countries accurately. The use of a composite health indicator such as the 
DALY seems unnecessary to compare the problem of breast cancer between 
these European countries. Although this may seem surprising, it is in line with 
the rationale behind the construction of the DALY, which was to compare the 
burden of different diseases within one region, not of one disease between 
different regions. 
DWs have raised a lot of debate regarding their reliability and 
comparability between countries [3]. The European disability weights project 
showed that variation in DWs between countries could only, in very small part, 
be explained by country-related effects and that the ranking of disease stages 
was very similar between countries [6]. The additional variation introduced 
using country-specific DWs (maximally 7%, Sweden) did not exceed the effect 
of uncertainties in the epidemiological data (6% for the Netherlands and 9% for 
Spain), and was smaller than the additional variation attributable to demography 
(up to 15%) and the variation resulting from cross-national differences in disease 
epidemiology (up to 33%). Therefore, using country-specific weights adds little 
additional information to comparison of the burden of breast cancer between 
these European countries. A similar conclusion was drawn with respect to the 
burden of dementia [ 6]. 
Even though we attempted to obtain reliable epidemiological data, these 
data are not perfect. Moreover, due to differences in registration practices, data 
source (expert opinion, hospital or cancer registration), coverage (regional 
versus national), case-definition and sometimes even the year of reference, 
comparability between countries may be limited. Nevertheless, the variation due 
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to uncertainty in the epidemiological data was small (maximally 9%, Spain). 
Breast cancer mortality data are believed to be rather reliable. In each country 
cause-specific mortality was registered on a regular basis with national 
coverage, increasing the comparability between countries. On the other hand, 
mortality data have a large influence on the burden of breast cancer; a small 
change often changed the ranking order between countries. 
Comparability of the incidence data between countries is more limited, 
as we relied on different data sources (cancer registrations and hospital statistics) 
with different coverage (regional and national) and case-definitions (in situ 
tumours were included for England and Spain, but not for the other countries). 
Also, we were uncertain about the incidence estimates for Spain, because of the 
large discrepancy, especially in the age pattern, between the rates based on 1996 
hospital discharge data and the older regional registration data. The former rates 
were higher at younger ages, which may be explained by a cohort effect of a 
trend of increasing breast cancer incidence, but can also be caused by 
overestimation resulting from referral shortly after diagnosis. Furthermore, for 
women over 65 the 1996 rates were lower than the older rates, which is unlikely 
considering the trend in incidence and the usually observed increase with age. 
The data on the proportion of tumours metastasised at diagnosis (Ml), 
of women undergoing mastectomy, and of secondary primaries (SP) were not 
readily available and therefore obtained from many different sources including 
expert opinion. Nevertheless, we believe these data have little effect on the 
estimated DALY. A different proportion Ml for England hardly affected the 
estimated burden. These data affect only the number of YLDs and only by 
altering the average DW through the distribution over the different disease 
phases. Likewise, the proportion of women undergoing mastectomy will have 
little effect. The percentage SP directly affects incidence, but, as it was small, its 
effect will also be small. 
Conclusions 
A large fraction of the burden of breast cancer was attributable to premature 
mortality (70% or more), causing this burden to reflect mainly mortality. To 
compare the burden of breast cancer in different countries a simple inspection of 
the mortality rates would have sufficed. As most types of cancers have a large 
mortality component we believe this conclusion can be extrapolated to most 
126 
CHAPTER 7 
other types of cancer. Using country-specific DWs will add little information to 
the comparison of their burden. However, for a disease that causes mainly 
morbidity, such as several psychiatric disorders, the effect of variation in DWs 
may be larger. 
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ADDENDUM I 
Description of phases of breast cancer. 
The phases of breast cancer that were weighted in the European Disability 
Weights [1] project were provided with a lay text and a standardised generic 
description of the functional health status. For the generic description the 
Euroqol-5D (EQ-5D) classification system of health status (mobility, self-care, 
usual activities, pain I discomfort and anxiety I depression) was used and 
extended with a sixth dimension of cognitive functioning (EQ-5D+C) [6]. Each 
dimension had three levels of the general form 1 = no problems, 2 = some 
problems, and 3 = severe problems. 
phase 1. 
• Patient is initially diagnosed with breast cancer and undergoes breast-
conserving surgery with subsequent local radiotherapy and chemotherapy, 
during a 6-month period. In the following 6 months the patient experiences 
some pain and discomfort from the wound. The surgery is intentionally 
curative, but there is the shock of the cancer diagnosis and uncertainty about 
lasting cure. 
• EQ-5D+C during the 1st 6 months: no problems in walking about, no 
problems in washing or bathing, some problems in performing usual 
activities, some pain or discomfort, moderately anxious or depressed, no 
cognitive impairment. 
EQ-5D+C during the 2nd 6 months: no problems in walking about, no 
problems in washing or bathing, no problems with performing usual 
activities, some pain or discomfort, moderately anxious or depressed, no 
cognitive impairment. 
phase 2. 
• Patient IS initially diagnosed with breast cancer and undergoes radical 
mastectomy (total removal of the breast and adjacent tissues), with or 
without subsequent radiotherapy and/or chemotherapy, during a 6-month 
period. In the following 6 months the patient experiences discomfort and 
pain from the wound (initially), disfigurement and scarring, and a swollen 
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arm. The surgery is intentionally curative, but there is the shock of the 
cancer diagnosis and uncertainty about lasting cure. 
• EQ-5D+C during the 1st 6 months: no problems in walking about, some 
problems in washing or bathing, some problems in performing usual 
activities, some pain or discomfort, moderately anxious or depressed, no 
cognitive impairment. 
EQ-5D+C during the 2nd 6 months: no problems in walking about, no 
problems in washing or bathing, some problems with performing usual 
activities, some pain or discomfort, moderately anxious or depressed, no 
cognitive impairment. 
phase 3. 
• Patient who has undergone breast conserving therapy and local radiotherapy 
and/or adjuvant chemotherapy for breast cancer more than one year ago, 
who now only experiences some discomfort; there are no signs of tumour 
recurrence. 
• EQ-5D+C: no problems in walking about, no problems in washing or 
bathing, no problems in performing usual activities, some pain or 
discomfort, moderately anxious or depressed, no cognitive impairments. 
phase 4. 
• Patient who has undergone a radical mastectomy with or without radiation 
therapy and/or chemotherapy for breast cancer, more than one year ago. The 
permanent after effects consist of discomfort and pain from disfigurement 
and scarring, and a swollen arm. There are no signs of tumour recurrence. 
• EQ-5D+C: no problems in walking about, no problems in washing or 
bathing, some problems in performing usual activities, some pain or 
discomfort, moderately anxious or depressed, no cognitive impairments. 
phase 5. 
• Patient with breast cancer, who has local recurrence of the disease and/or 
spread elsewhere (to the bone, brain or liver), requiring chemotherapy 
and/or radiotherapy. The patient spends a large amount of time on treatment 
and experiences anxiety and major discomfort (e.g., due to side effects of 
chemotherapy). 
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• EQ-5D+C: some problems in walking about, some problems in washing or 
bathing, unable to perform usual activities, some pain or discomfort, very 
anxious or depressed, no cognitive impairments 
Weights derived in the European Disability Weights project 
In the European Disability Weights project, Disability Weights (DWs) were 
derived from health and non-health professionals using time trade-off (TTO), 
person trade-off (PTO) and a visual analogue scale (VAS). Because derivation 
of VAS scores does not include an explicit trade-off, VAS scores are not 
considered suitable for direct use as disability weights. Disease stages for which 
only VAS scores were available were transformed to TTO scores using: 
ITO= (1- (1-VAS fa) [6], in which a differs between countries. The resulting 
weights are given in Table 7 A.I. 
Table 7 A.I. European and country-specific disability weights. 
Phase of breast cancer country 
EU E&W Fr NL Sp Sw 
- diagnosis and primary breast 0.27 0.32 0.21 0.30 0.32 0.19 
conserving therapya 
- diagnosis and radical mastectomya 0.37 0.38 0.37 0.41 0.47 0.26 
-clinically disease-free without 0.18 0.19 0.15 0.20 0.23 0.12 
. 1 b maJor permanent seque ae 
- clinically disease-free with major 0.30 0.32 0.22 0.35 0.35 0.22 
permanent sequelae a 
- recurrent or disseminated disease a 0.61 0.60 0.64 0.70 0.58 0.53 
EU: the pooled European weights, obtained by pooling the data from the five countries 
a: VAS scores were obtained and transformed using a transformation formula 
b: TTO scores were obtained 
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Table 7A.II A. Epidemiological frequency data: data source and reference year by country. 
Country Data Year Source 
Mortality by 5-year age-groups up to 85+ 
Denmark Numbers of cause-specific deaths 1996 Danish Cause of Death Registration, National Board of Health; 
(NBH) Denmark 
England& Wales Numbers of cause-specific deaths 1996 Office for National Statistics (ONS) 
France Numbers of cause-specific deaths 1996 National Institute of Health and Medical Research France; 
Numbers of prior year (alternative) 1995 National Institute of Health and Medical Research France 
Netherlands Numbers of cause-specific deaths 1996 Statistics Netherlands (CBS) 
Spain Numbers of cause-specific deaths 1996 National Institute of Statistics Spain (INE) 
Sweden Numbers of cause-specific deaths 1996 National Board of Health and Welfare Sweden (Socialstyrelsen) 
Table 7 A. II A. Continued 
Incidence by 5-year age-groups up to 85+ 
alternative: used as additional data source, because different years or sources showed very different patterns; % SP: percentage of secondary breast 
cancer primaries; n.a.: year is not applicable, as the estimates concern expert opinions, NL: estimates from the Netherlands were used. 
1 incidence numbers (to 75+) were estimated from regional incidence data (around 1990), mortality (1994) and population figures ( 1995) [ 19]. 
2
: Zaragoza 1986-1990, Tarragona 1988-1992, Navarra 1987-1991, Murcia 1988-1992, Mallorca 1988-1992, Granada 1988-1992, Basque Country 
1988-1991, Asturias 1988-1991, Albacete 1991-1992. Average age-specific rates were weighted for total population size of each registration area. 
Table 7A.ll B. Epidemiological frequency data: data source and reference year by country. 
Country Data Year Source 
Demography by one-year age-groups 
Denmark Population numbers, 1996 Statistics Denmark; 
total mortality 1996 Danish Cause of Death Registration, NBH Denmark 
England& Wales Population numbers, 1996 Office for National Statistics (ONS); 
total mortality 1996 Office for National Statistics (ONS) 
France Population numbers, 1996,1995 National Institute of Statistics and Economic Studies France; 
total mortality 1996 National Institute of Statistics and Economic Studies France 
Netherlands Population numbers, 1996 Statistics Netherlands (CBS); 
total mortality 1996 Statistics Netherlands (CBS) 
Spain Population numbers, 1996 National Institute of Statistics Spain (INE); 
total mortality 1996 National Institute of Statistics Spain (INE) 
Sweden Population numbers, 1996 Statistics Sweden (SCB); 
total mortality 1996 National Board of Health and Welfare Sweden (Socialstyrelsen) 
Table 7A.ll C. Additional epidemiological data: data source and reference year by country. 
Country Data Year Source 
Additional data all age-groups combined 
Denmark %M1 1990-1995 Danish Cancer Registry, NBH Denmark; 
%mastectomy 1990-1995 Danish Cancer Registry, NBH Denmark 
England& Wales %M1 1996 West Midlands Regional Cancer Registry; 
% M 1 (alternative) n.a. Expert opinion; 
%mastectomy 1998-1999 Hospital episode statistics, ONS 
France %M1 n.a. Expert opinion; 
%mastectomy, ages <70 and > 70 <=1998 Database of hospital admissions, IN SEE 
Netherlands %M1 1995-1997 Comprehensive Cancer Centre Amsterdam (IKA); 
%mastectomy 1995-1997 Comprehensive Cancer Centre Amsterdam (IKA) 
Spain %M1 1996 Granada Regional Cancer Registry; 
%mastectomy 1997 Clinical hospital discharges data set [20] 
Sweden %M1 n.a. Expert opinion 
%mastectomy n.a. Expert opinion 
%Ml: proportion of incident cases that are metastasised at diagnosis; % mastectomy: proportion of women undergoing mastectomy; n.a.: year is 
not applicable, as the estimates concern expert opinions; alternative: used as additional data source, because cancer epidemiologists suspected the 
data on the %Ml to be low. alternative: used as additional data source, because different years or sources showed very different patterns. 
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General approach 
Different phases of breast cancer are weighted differently. In order to calculate 
Years Lived with Disability (YLDs) using the incidence method, data on the 
incidence and duration of each of these phases are needed. Therefore we used a 
model that describes the possible phases that patients may pass through over 
time. This model is depicted in Figure 7 A.III. It distinguishes five different 
pathways: for patients who will survive their diagnosis after breast-conserving 
therapy (A), for patients who will survive their diagnosis after mastectomy (B), 
for those who will not survive their diagnosis after breast-conserving therapy, 
but do not have metastases at diagnosis (C), for those who will not survive their 
diagnosis after mastectomy, but do not have metastases at diagnosis (D), for 
those who have metastases at diagnosis and do not survive (E). For all women 
without metastasis at diagnosis the phase of diagnosis and therapy is the starting 
point and is followed by a disease-free phase. This phase is split into disease-
free with and without sequelae using the percentage undergoing mastectomy 
treatment, because we assumed that breast conserving therapy results in fewer 
and less severe sequelae than mastectomy. Non-survivors progress to the phase 
of metastasis or local recurrence after the disease-free phase, while for survivors 
it is the end stage. As we assumed women return to a state of full health after 
five years of disease-free survival following breast-conserving therapy, and to a 
more optimal state (approximated by the difference between disease-free with 
and without sequelae) following mastectomy, we added phase 6 and 7 which 
represent the extension of the disease-free phase after five years. Ml women 
enter the phase of metastasis or local recurrence immediately at diagnosis. 
Estimation of phase-specific incidence 
In order to distribute incidence over these pathways, we distinguished survivors 
from non-survivors, tumours metastasised at diagnosis (Ml) from those not 
metastasised at diagnosis, and cases undergoing mastectomy from breast-
conserving treatment. We assumed that all non-survivors in the model die of 
breast cancer and that this was always preceded by metastasis or local 
recurrence. The proportion of survivors ("the proportion cured") was estimated 
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from the ratio between mortality and incidence. Because death resulting from 
incidence at age n may occur many years later, mortality at age n can not be 
contributed to incidence at age n. Therefore, the "proportion cured" can not be 
calculated age-specifically using this ratio. We estimated the proportion cured 
using: 
c = 1-l:I,n (mortality"* EUpop12 ) I Ln (incidence"* EUpop12 )j, where c is the 
proportion of breast cancer survivors, mortality and incidence are the mortality 
and incidence rates at age group n and EUpop the European standard population 
at age group n. Incidence was then split over the five pathways using the data on 
the proportion of women undergoing mastectomy, prop_mastec, and the 
proportion Ml,prop_MI: 
incidencen.A = incidence12 * c * (1- prop_ mastectomy), 
incidencen.B = incidence" * c *prop_ mastectomy , 
Figure 7 A.lli. Different pathways that patients may follow after diagnosis. 
3. Disease-free 
after b-e therapy 
4. Disease-free 
after mastectomy 
3. Disease-free 
after b-e therapy 
4. Disease-free 
after mastectomy 
B-e therapy: breast-conserving therapy. 
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incidencen,C = ~ncidencen * (1- c- prop_ M1 )]* (1- prop_ mastectomy), 
incidencen,D = ~ncidence12 * (1- c- prop _M1)]* prop_ mastectomy, 
incidencen,E = incidence12 *prop _M1. 
Estimation of phase-specific duration 
The estimates of duration and how they were calculated are shown per phase in 
Table 7 A.III. For non-survivors duration was assumed independent of general 
mortality, because of the assumption that all non-survivors die from breast 
cancer. Survivors, nevertheless, die from other causes of mortality, and for them 
duration depends on general mortality. The duration of phase 6 and 7, are 
therefore calculated from the average total disease duration calculated from 
DisMod II [16], which takes death from other causes into account. At older ages 
the duration of phase 3 and 4 may decrease because general mortality increases. 
Table 7 A.III. Duration estimates and source of the estimates. 
Phase Duration d Source 
{pathway} 
1, 2 1 year Imposed by description. 
{A,B,C,D} 
3,4 5 year; ford 6,7 > 0 A matter of choice; 
{A,B} 5 year- d 6,7; ford 6,7 < 0 Subtract general mortality 
3,4 24 months Munich cancer registry 
{C,D} [14] 
6, 7 [dtotal- (1- c- prop_Ml) * (d 1,2 dtotal from DisMod 
{A,B} + d 3,4 {C,D} + d 5)- prop_MI *d 
5] I c- d 1,2- d 3,4 {A,B} 
5 34months- d 1,2 = 22 months Munich cancer registry 
{E} [14] 
d 1,2; d 3,4; d 5 is duration of phase 1 and 2 ; 3 and 4; and phase 5, respectively. 
dtotal is the average total disease duration estimated from DisMod II. 
c is the proportion cured. 
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CHAPTERS 
Introduction 
In Chapter one we introduced the research questions of this thesis. We argued 
that, as health policy decisions are mostly taken at the level of diseases and risk 
factors, disease-specific summary measures of population health are more useful 
than generic ones, at least in theory. In practice their use may be limited by their 
extensive data requirements. To calculate these measures two types of data are 
required, both of which pose specific problems to the use of disease-specific 
summary measures. On the one hand disease-specific epidemiological frequency 
data are needed. Unfortunately, these data are not always readily available, and 
can be of dubious quality. On the other hand disease-specific health status 
valuations ("disability weights" in the DALY methodology) are required to 
weigh the years lived with a disease. These weights should refer to the same 
severity level of the disease as the epidemiology data, which is not always 
straightforward to achieve. 
Two specific research questions were formulated: 
1) To what extent are causal disease models valid and useful to check the 
consistency of epidemiological frequency data and to supplement them? 
2) How can disease-stage specific health status valuations be tailored to 
epidemiological frequency data? 
With respect to these two research questions, the main findings of this thesis 
were: 
1) Causal disease models can be used to detect consistency problems in the 
epidemiological data and to supplement them, but time trends complicate 
their use. 
2) Different methods can be used to tailor stage-specific health status 
valuations to the epidemiology. 
Overall, we concluded from this that it is possible to construct useful disease-
specific summary measures of population health in practice. These findings will 
be discussed in the following sections, and focussing mainly on the DALY 
measure. We start with reporting the main findings of this thesis. Next we 
address the two research questions. Finally, we will draw some conclusions and 
give some recommendations. 
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Main findings 
In part A of this thesis we studied the validity and usefulness of disease models. 
The main findings of this part were: 
1. The validity of incidence-prevalence-mortality (IPM) models was supported 
by a check against artificial data. 
2. Both data inconsistencies and trends can cause model outcome and data to 
be discrepant. For breast cancer, a large part of the discrepancy between 
model outcome and data could be explained by underestimation of the 
prevalence data and a trend of increasing incidence. 
3. Application of a disease model to data for Major Depression (MD) required 
a complex model, but allowed the estimation of lifetime prevalence, a 
parameter that is difficult to measure. 
Part B concerned the tailoring of disability weights (DWs) to epidemiological 
data. The main findings of this part were: 
1. On the basis of disability data three clusters of MD could be distinguished: 
"mild" MD, "moderate to severe" MD and MD "with psychotic features". 
2. Newly derived DWs for these three clusters, and the overall DW in which 
they are combined, were very similar to other studies. One exception was 
the overall DW used in the Dutch Burden of Disease Study, which was 73% 
lower due to a different estimate of the proportional prevalence of the 
clusters. 
3. The estimated burden of breast cancer was most sensitive to cross-national 
variation in disease epidemiology. Variation in disability weights and 
uncertainty in epidemiological data had smaller effects. 
Usefulness of disease modelling 
To get around some of the problems with the availability and validity of the 
epidemiological data, disease models have been developed that formalise the 
relations between the different epidemiological parameters. These models can be 
seen as a form of bookkeeping of individuals, as they keep track of all the 
transitions that individuals make between states in the natural course of a disease 
process. Figure 8.1 shows that in the natural course of a disease, incidence 
always has to precede prevalence, and mortality can only follow from having the 
disease. Thus, when an initially disease-free cohort is followed over time and all 
transitions from healthy to diseased (incidence), diseased to death (case-fatality) 
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and diseased to healthy (remission) are taken into account, the number of cases 
(prevalence) can be calculated. This simple way of bookkeeping forms the basis 
of IPM models (incidence, prevalence, mortality models). These models, of 
which the DisMod model [1, 2] is an example, have been used both to calculate 
missing data and to check the internal consistency of data [3-5]. When for 
example prevalence data are not available, it can be calculated from incidence, 
remission and cause-specific mortality data. When prevalence is also available 
and applied to the model, inconsistencies between the data will appear as 
discrepancies between model outcome and data. In this way inconsistencies can 
be detected and one can choose to adjust the observed data for the 
inconsistencies. IPM models use only three parameters, with remission 
sometimes being zero. The validity and usefulness of these models in checking 
the consistency of data and supplementing them is subject of the first part of this 
thesis. 
We studied the validity and usefulness of IPM models by testing them 
against data sets for different types of cancer: two complete and consistent 
artificial data sets and four high quality empirical data sets. The artificial data 
were used to check the appropriateness of the Markov assumption in the models. 
Like every model, IPM models are a simplification of reality. One of the 
assumptions that is made in simple IPM models like DisMod is the Markov 
assumption of a random process whose future probabilities are determined by its 
most recent values [6, 7]. In other words, in the disease model the probability of 
transition to a next state is assumed to be determined only by the value of the 
previous state. The advantage of this premise is that the model does not have to 
keep track of transitions in the past: there is no need for memory in the model. 
Figure 8.1. The natural course of a disease 
Case-
I 
SUSCEPTIBLES incidence CASES I fatality CAUSE-SPECIFIC I (S) ,.. (C) I DEATHS (F) 
remission 
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However, this also means that the often-occurring relationship between mortality 
from a disease and the time lived with this disease can not be taken into account. 
We therefore tested the model against artificial data sets that were generated by 
a model that does include time-dependence of cancer mortality. This model was 
constructed and extensively tested for the evaluation of cancer screening 
programmes (MISCAN) [8]. Applying the artificial data to the IPM models gave 
no evidence that the Markov assumption was invalid at a population level: the 
IPM models reproduced the artificial data very well. 
To test the usefulness of IPM models in practice, we next used four 
presumably high quality empirical data sets. The results of this analysis casted 
some doubts on their usefulness: even though empirical data for different types 
of cancer are of high quality, large discrepancies between measurements and 
calculations occurred. It is well known that not only data inaccuracies, but also 
past trends in incidence or mortality can cause such discrepancies. Time trends 
may cause the data to appear inconsistent in steady state models, while in fact 
they are not. This is caused by the fact that prevalence is a stock variable: it is 
the accumulation of incident cases from the past. As a result, it cannot react 
instantaneously to changes in incidence and case-fatality, but only with a certain 
delay. Although it is possible to account for the effects of time trends in a 
dynamic model, this requires additional input data on the nature and size of the 
trends, which are not available for most diseases. Often, we do not even know 
whether a trend is present or not, and the researcher faces a dilemma what to do 
with the discrepancies. Adjusting observed data for apparent inconsistencies that 
are in fact the consequence of past trends would rather defeat the purpose of 
IPMmodels. 
We tried to throw some light upon this dilemma using the fact that for 
breast cancer in the Netherlands there is a tentative estimate of the trend in 
incidence [9] and several of the data problems are known. With this information 
we quantified the relative contribution of trends and known data problems on the 
discrepancy for breast cancer. Two factors had a major effect in this analysis: an 
underestimation of the 1993 prevalence data from the Regional Cancer Centre 
South (IKZ), and a trend of increasing incidence. Together, they accounted for a 
major part (60%) of the discrepancy. The underestimation of the prevalence 
results from the fact that before 1970 incident cases were not registered, and 
could thus not be included in the prevalence figures. Although prevalence of 
breast cancer is not a very useful epidemiological measure and this particular 
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underestimation will furthermore decrease when time progresses, this analysis is 
important as it shows the ability of the IPM models to detect data problems. 
While it is a known fact that the registration in the Southern part of the 
Netherlands was complete since 1970, the effect of this on the prevalence data 
for breast cancer had not been assessed earlier. 
The results of the analyses, however, also indicated that trends can have 
a large effect on the model results. The trend in incidence could have such a 
large effect on the model for breast cancer by the combination of two factors. 
First, the trend was present for a long time allowing the increase in incidence to 
build up. Second, the outflow from prevalence to mortality is not very fast for 
breast cancer, causing prevalence to reflect a range of incidence rates from the 
present to many years ago. The effect of trends for diseases with a high case-
fatality rate will thus be smaller. Nevertheless, even for these cases the problem 
remains that this effect can not be quantified unless there are data on the size and 
nature of the trend. Because, unlike for breast cancer, for most diseases these 
data are not available, there always remains the need for careful interpretation of 
the modelling results. 
After applying the models to these high quality data for breast cancer, 
we confronted them with the less well monitored epidemiology of Major 
Depression (MD). Prevalence and incidence data for MD in the Netherlands 
were available from the Netherlands Mental Health Survey and Incidence Study 
(NEMESIS). In this study the information was obtained with reference to several 
time frames. Prevalence was assessed in the past month, year and life (lifetime 
prevalence), first-incidence (of a first episode) in the past life, and total 
incidence (both first and recurrent episodes) in the past year. Simple IPM 
models, nonetheless, can solely link epidemiological parameters referring to one 
time frame at a time. Sufficient data were available only to model the lifetime 
perspective, as the study provided no data on remission (remission from lifetime 
prevalence is by definition zero). Lifetime prevalence measured in a cross-
sectional way may, however, be largely underestimated by recall problems [10, 
11]: to obtain lifetime prevalence in a cross-sectional surveys, respondents have 
to recall the presence and timing of symptoms retrospectively over their past 
life. A simple inspection of the NEMESIS lifetime data suggested that recall 
bias could indeed be present in these data. Examining the data by age showed a 
decrease after age 45 that could be due to recall bias, although also excess 
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mortality and trends could explain a decrease at older ages. A quick application 
of the lifetime data to DisMod furthermore showed that they were only 
consistent with an unrealistically high excess mortality that far exceeded the 
relative risks (RR) reported in the literature [12]. Despite the fact that, once 
more, DisMod identified a data problem, IPM models can not help to improve 
the epidemiological estimates of MD: the lifetime data were unreliable, and 
there were insufficient data to model other time frames. 
For this reason we applied a more complex disease model to Major 
Depression. We chose to construct a model using a micro simulation approach. 
This is a flexible technique that allows the use of parameters from different time 
frames as input and is able to take into account the large heterogeneity of MD. 
Microsimulation describes the disease process of an individual in terms of 
probabilities and their distributions [13]. Individual life histories are generated 
by random drawings from these distributions. Adding a large number of life 
histories creates a population from which community-based epidemiological 
measures, such as lifetime prevalence and number of episodes, can be derived. 
Using a microsimulation model we estimated lifetime prevalence of MD from 
the NEMESIS month and year prevalence data. The results pointed at two 
causes that result in an underestimation of the NEMESIS lifetime prevalence 
data: a cross-sectional setting and recall problems. To start with the first, the 
model estimates that approximately 30% of men and 40% of women suffer from 
one or more episodes of MD during their life. In a cross-section of age-groups 
similar to NEMESIS, nevertheless, only 20% and 30% of the modelled life 
histories were MD positive. The potential for recall bias is then indicated by the 
difference between these cross-sectional estimates and the NEMESIS data, 
which were 38% lower. The recall bias in these data may thus be considerable, 
posing questions at the usefulness of the empirical measurement of lifetime 
prevalence. Again, models appear to be useful, this time not only in consistency 
checking, but also in supplementing data: the model also provided us with an 
(indirect) estimate for a study in which this estimate was not measured 
empirically (the Australian Mental Health and Wellbeing Survey). This 
modelling exercise furthermore showed that for the complex epidemiology of 
depression a more complex disease model was required. It is likely that simple 
IPM models will be inadequate also for other diseases with a complex 
epidemiology, such as other psychiatric disorders, with problems similar to MD, 
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or several diseases of the locomotor system (e.g. low back pain and RSI). 
However, following the principle of parsimony (Occam's razor) these models 
should only be used when simple IPM models are not sufficient. 
Disability, disability weights and burden 
Disease-specific health status valuations, or Disability Weights (DW) in the 
DALY methodology, should be tailored to the epidemiological case-definition: 
to prevent over- and underestimation of the summary measure both should refer 
to the same severity level of a disease. The tailoring of DWs is facilitated by 
some refinements that were made to the original DW methodology of the Global 
Burden of Disease Study (GBD) by a Dutch group of researchers. In the Dutch 
Disability Weights Study (DDW) [14] researchers added a formal health status 
description in EuroQol to each health state and, where previously only one 
weight was available per disease, they derived weights for several distinguished 
disease-stages. The formal health status description gives an explicit indication 
of the severity level of the disease (or disease-stage), which before was implicit. 
This information can be used to match DWs and epidemiology (if health status 
information is also available for the epidemiological data). For example, in the 
Australian Burden of Disease Study disability information (SF-12) that was 
collected together with the prevalence data for MD was used to match DW s and 
epidemiology [4]. 
The stage-specific weights can be combined into a range of disease-
specific weights, by applying different estimates of the proportional prevalence 
of the stages. As a result, a disease-specific DW can be adapted in response to 
improvements in therapy or to a change in the used diagnostic instrument, or 
case-definition. However, the division into stage-specific weights also has a 
downside. To combine them into an overall DW for a specific disease, 
information is needed on the proportional distribution of the disease across the 
stages. This information is difficult to obtain. Epidemiological data are often not 
available per disease-stage, and if they are, the disease-stage descriptions used in 
epidemiology may differ from the ones used in the valuation. For example, the 
TNM-staging used in cancer epidemiology is not adopted here to distinguish the 
health-states for valuation, because they do not provide sufficiently different 
levels of health. How to tailor the stage-specific DWs to the epidemiological 
data was our object of study in part two of this thesis. Also, some attention was 
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given to the sensitivity of the summary measure to DWs, to assess the 
importance of this tailoring to the overall summary measure. 
For Major Depression (MD), data from the Netherlands Mental Health 
Survey and Incidence Study (NEMESIS) provided a good opportunity to tailor 
DWs to the epidemiology. The NEMESIS database contains information on both 
epidemiology and health status/ disability by different classes (type and severity) 
of MD. From the DDW study [14] weights for depression were available per 
severity class. However, the weights from this study seem to be oriented towards 
a clinical setting rather than a population, as the provided health status 
descriptions were based on expert opinion (medical doctors) and diagnostic 
criteria. Because the weights have to be combined with epidemiological data 
from population surveys, and these may include milder cases of depression than 
those found in clinical settings [15], the DDW weights do not match the 
epidemiology. Therefore, tailoring the DWs for MD requires both: 1) deriving 
new stage-specific DWs for tailored health status descriptions, and 2) combining 
the weights into an overall DW using a tailored proportional distribution of the 
disability levels. 
Therefore we first set out to construct stages and their descriptions, and 
derive DWs. Using the NEMESIS data we examined how disability differed by 
severity class and type (single or recurrent) of MD. Only three levels of 
disability were distinguished: "mild", "moderate to severe" and "severe with 
psychotic features". This shows that type of MD is not needed to describe 
different disability levels, and that only three severity classes are needed, one 
less than in the DDW study. The disability information per disease-stage was 
less severe in NEMESIS than the descriptions used in the DDW, but the new 
stage-specific DWs for these descriptions were not significantly different from 
DDW weights. Apparently, the disease-stage label is much more important than 
the health status description in the health status valuation. This could be used as 
an argument against including the disease label in the health status description. 
Omitting this label, would ensure that what is valued is the health status 
description. However, one may also reason that the disease label is very 
important. It adds information to the formal description on domains that are not 
represented in the EuroQol system. Without a disease label the DW could be 
applied to another disease-stage with similar EuroQol levels, and would thus no 
longer be disease-specific. For this reason we believe the disease label should be 
included, although other people may argue differently. 
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In the second part of the tailoring we combined the new stage-specific weights 
into an overall DW using the proportional distribution from NEMESIS. Because 
this distribution was very different from the one used previously in the 
Netherlands (based on expert opinion, Dutch 1994 National Burden of Disease 
Calculation [16]), our resulting overall DW was very different (73% higher). 
This shows the importance of the quantitative epidemiological data in the burden 
of disease calculations. The overall DW for depression seems more sensitive to 
the distribution of disability across the depressed population, than to differences 
in the descriptions of the health status. Unfortunately, information on the 
proportional distribution is often lacking. This study shows one way to derive 
such information, but depends on the availability of a database with both 
epidemiological data and information on disability and stages. 
For breast cancer, no such database was available. Epidemiological data 
for types of cancer are registered according to stages (TNM classification) that 
are very different from the ones for which DWs are derived (phases in the course 
of the disease). Thus, information on the proportional distribution has to be 
derived by other means than using the epidemiological databases. We used a 
modelling approach developed by Meise et al. [ 17, 18] that was also used in the 
Australian Burden of Disease Study [4, 19]. The model describes different 
pathways that incident breast cancer patients may pass through time. Each 
pathway consists of one or more of the discerned phases. Using some additional 
information to divide incidence over the different pathways (e.g. proportion of 
different therapy given in each country) and information on the duration of the 
phases [20] it was possible to quantify the proportional distribution across the 
phases. 
Using this information we calculated the burden of breast cancer in six 
different European countries and assessed its sensitivity to different sources of 
variation. The major part of the burden (more than 70%) was caused by 
premature mortality. As a result, the highest burden of breast cancer was found 
in those countries that reported the highest mortality rates, casting doubt on the 
usefulness of a composite health indicator such as the DALY to compare 
diseases with a high mortality component. Not surprisingly, the estimated 
burden was also most sensitive to cross-national variation in disease 
epidemiology (read: mortality), while the country-specific DWs had the smallest 
impact. We believe this conclusion can be extrapolated to many other diseases, 
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as many diseases have a large mortality component. For these diseases the 
influence of DW s will be small. 
On the other hand, for a disease that causes mainly morbidity, such as 
depression, the effect of variation in DWs may be larger. However, even for 
depression the effect of the DWs on the overall summary measure will be 
limited, because of the value of the DW itself. For disorders that induce mainly 
morbidity, the relative effect that variation in the DWs has on a summary 
measure depends on the size of the DWs. In the severe range of disability the 
relative variation resulting from, for instance, a difference of 0.1 is much smaller 
than in the mild range of disability. For example, adding 0.1 to the DW for 
depression (DW = 0.46, see chapter five) infers a change of 20% while for visual 
impairments (DW = 0.1 [16]), the difference is 100%. Because some diseases 
with a low DW are highly prevalent, the effect of variation in this DW on a 
population measure may be extensive. The major concern of tailoring the DWs 
is thus for highly prevalent diseases with a relatively low DW. 
Conclusions 
The first part of this thesis addressed the question: to what extent are causal 
disease models valid and useful to check the consistency of epidemiological 
frequency data and to supplement them. IPM models were shown to be valid and 
useful: even in the case of the high-quality data for breast cancer data problems 
could be detected. However, inconsistencies may also be caused by trends in 
incidence and! or mortality, requiring careful interpretation of the result of 
models. Furthermore for some disorders, like depression, more complex models 
are needed. These also proved useful, both to detect data inconsistencies and to 
supplement missing data. We therefore conclude that causal disease models can 
be used to detect consistency problems in the epidemiological data and to 
supplement them, but that the presence of trends complicates their use. 
The question: how can disease-stage specific health status valuations be 
tailored to epidemiological frequency data, had more than one answer. If 
available, epidemiological databases that contain both information on 
epidemiology and health status/ disability can be used both to provide a tailored 
disease-stage description (to derive new disability weights if desired) and to 
estimate the proportional distribution of the stages. In the case of depression 
such data were available and used. For breast cancer such data were not 
151 
CHAPTERS 
available, and instead the proportional distribution was estimated using a 
modelling approach. Thus, there are different ways to tailor stage-specific health 
status valuations to the epidemiology of a disease. 
In conclusion, useful disease-specific summary measures can be 
constructed in practice. Modelling provides a useful and valid tool to tackle 
some of the problems concerning the epidemiological data. Also, several ways 
were found to tailor the disability weights (DWs) to the epidemiological data. 
Nevertheless, the disease-specific summary measures are not very precise and 
should not be interpreted as such. They are useful to policy makers because they 
provide a ranking of diseases taking into account both morbidity and mortality 
and, furthermore, identify gaps in knowledge. The estimates should, however, 
not be interpreted as more than an indication of the importance of the disease. 
Recommendations 
Our research stressed the importance of the epidemiological data in the 
calculation of these disease-specific summary measures. Research in this field 
should therefore focus on obtaining sound epidemiological data more than on 
the DWs. Improvement of the epidemiological data input in summary measures 
could best be effectuated using both modelling and data collection. Until now, 
models have not been adopted frequently. The application of models to specific 
areas can improve the epidemiological input, as shown in the example of the 
depression model. More and better data collection, however, remains the most 
important, as models can not answer all the questions, especially when trends are 
present. Registration of the available information in a central database that is 
regularly updated would greatly facilitate the construction of summary measures 
and also the assessment of health impacts. In part, such a database already exists 
in the Netherlands at the Netherlands Institute of Public Health and the 
Environment (department of Public Health Status and Forecasting), but it could 
be extended to include more studies, more diseases, and the results of modelling. 
The DWs were shown to be often a less important source of uncertainty 
in the calculation of disease-specific summary measures. With respect to the 
impact of the DWs on the summary measure, three groups of diseases can be 
discerned. The first group, diseases with a large mortality burden (like breast 
cancer), is relatively insensitive to variation in DWs. The second category, 
diseases causing mainly morbidity and having a DW in the severe range of 
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disability (such as depression), is sensitive to variation m the proportional 
distribution, but the relative variation in the stage-specific DWs remains limited. 
For diseases of these two groups, the relative variation in the DWs thus has 
limited consequences (unless different methods to derive the weights are 
applied), and research should focus mainly on the proportional distribution of 
the disease-stages. The inclusion of disability measures, such as the EuroQol, in 
national epidemiological surveys (such as for example in the second Dutch 
National Study on General Practice) would greatly facilitate the estimation of 
the proportional distribution. On the other hand, the third group of diseases is 
both sensitive to variation in the distribution as well as to variation in the stage-
specific DWs. This group encompasses high prevalent disorders that produce 
mainly mild morbidity. Having a low DW, the relative variation in these weights 
may be large, while on the low side of the disability range the derived DWs may 
be imprecise [14]. For this type of diseases attention should therefore also be 
given to improving the stage-specific DWs themselves. More reliable DWs may 
be obtained by deriving them in relation to another mild to moderate disease 
instead of in relation to optimal health. 
Finally, the abundance of diseases will restrict the practical application 
of disease-specific summary measures. Tailoring DWs and modelling disease 
epidemiology is time-consuming work that can only be done for a limited 
number of diseases. The intended use of the measure should therefore determine 
how much effort should be put in obtaining consistent epidemiological data and 
DWs. For simple comparison goals, generic summary measures may suffice, 
while the evaluation of interventions will require disease-specific information 
for some specific diseases at least. In the same line, there may be good reasons 
to adapt the design of the summary measure to the aim of its use. Monitoring 
health states in developing countries, for example, using a gap measure based on 
the same ideal life expectancy as in Western countries, will obscure small 
improvements in life expectancy. It may even be proposed to return to use the 
infant mortality rate for this kind of purpose [21]. Summary measures can have 
many different designs and the researcher should carefully choose the one that 
best suits the intended use. 
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om mary 
SUMMARY 
Summary measures of population health combine information on mortality with 
information on non-fatal health outcomes. Over the past decades, the interest in 
and use of these measures has increased, and different types have been 
constructed. One distinction that can be made is between summary measures that 
use disease-specific epidemiological input and those that are based on generic 
morbidity and mortality data. As health policy decisions are mostly taken at the 
level of a disease or its risk factors, disease-specific summary measures of 
population health are in theory more useful than generic ones. However, in 
practice their use may be limited by their extensive data requirements. This 
thesis focuses on two practical data problems that may restrict the construction 
of disease-specific summary measures. 
Firstly, disease-specific epidemiological frequency data are needed, 
which are not always readily available and can be of dubious quality. To remedy 
some of these data problems, disease models such as incidence-prevalence-
mortality (IPM) models have been constructed. However, their validity and 
usefulness has not been studied yet. Secondly, disease-specific health status 
valuations (or disability weights, DWs) are required that match the severity level 
of the epidemiological data. Dividing diseases into stages facilitates adapting the 
DWs to the epidemiology, but introduces the problem of combining the stage-
specific DWs into a disease-specific one. Two specific research questions were 
investigated: 
1) To what extent are the causal disease models valid and useful to check for 
the consistency of epidemiological frequency data and to supplement them? 
2) How can disease-stage specific health status valuations be tailored to 
epidemiological frequency data? 
These questions were explored on the basis of empirical data for breast cancer 
and Major Depression (MD) in the Netherlands, both important health problems 
that allow us to study the research questions from different perspectives. 
Part A of this thesis addresses the first research question. In chapter two we 
studied the validity and usefulness of IPM models, using data sets for different 
types of cancer. The validity of the model was supported by a check against 
complete and consistent artificial data. However, high-quality empirical data 
could not be replicated well. There is evidence that this is not only caused by 
data inaccuracies, but also by past trends in incidence or mortality. Although 
trends can be accounted for in a dynamic model, this requires additional input 
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data on the nature and size of trends, which are often not available. Thus, we 
often cannot distinguish between the effects of data problems and trends, 
complicating the use of IPM models in improving disease estimates. 
In chapter three we compared the extent to which trends and data 
problems affected the model outcome for breast cancer. Two factors had a major 
effect: an underestimation of the 1993 prevalence data from the Regional Cancer 
Centre South (IKZ), and a trend of increasing incidence. Other known data 
problems had relatively smaller effects. Furthermore, part of the difference 
between model and data remained unexplained. We concluded that IPM models 
can be useful for checking data inconsistencies and supplementing incomplete 
data, but in both cases there remains the need for careful interpretation of the 
results: unknown data problems and trends may affect the outcome in unknown 
directions. In the all too common situation where, unlike for breast cancer, no 
data on the size and nature of trends are available, expert opinion is 
indispensable to assess whether models improve data quality or, inappropriately, 
remove the effect of trends. 
In chapter four we estimated lifetime prevalence of major depression 
(MD) for the Netherlands and Australia from current prevalence data using a 
microsimulation model, and quantified the underestimation in the empirical 
estimate for the Netherlands. For both countries, we found that around 30% of 
men and 40% of women suffer from one or more episodes during their life. 
Lifetime rates reported from cross-sectional surveys are much lower for two 
reasons: 1) they ignore cases that become incident after the survey, and 2) self-
reported symptoms and their timing may be biased by recall problems. Recall 
bias was shown to underestimate the Dutch empirical estimate by at least 35%. 
Modelling allowed an indirect estimation of the lifetime prevalence of 
depression, which is useful in the absence of direct measurement, but also 
indicates that the direct estimate is severely underestimated. 
Part B of this thesis concerns the tailoring of the DWs. In chapter five we 
examined the associations of depression "severity" and type (a single or 
recurrent episode) with disability in the Dutch general population. Higher 
"severity" classes were associated with more disability, but "moderate" and 
"severe" MD were not significantly different. The difference between non-
depressed and "mild" MD had a larger effect size -than between successive 
"severity" classes. Recurrent MD was not associated with more disability than 
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single episode MD. We concluded that three clusters of MD can be used to 
describe the distribution of disability in the depressed population: "mild", 
"moderate to severe" and "severe with psychotic features". A simplification of 
the DSM "severity" classes could be considered, while the marked difference 
between "mild" and no MD suggests that "mild" cases should be considered 
relevant. 
We studied whether disability of MD was overestimated in previous 
burden of disease calculations in chapter six. Previously used DWs seem to 
reflect a clinical situation rather than the population one from which the 
epidemiological data are derived. We derived DWs for the three disability 
clusters of MD ("mild", "moderate to severe" and "severe with psychotic 
features") and calculated its burden. An overall DW was based on the 
proportional prevalence of the clusters in the Dutch population. Our new DWs 
were mostly similar to previous studies, providing no indication that DW s and 
burden were overestimated in the past. One exception was the lower overall DW 
applied in the 1994 Dutch Burden of Disease Study, which was based on a 
proportional distribution based on the opinion of experts, who estimated a much 
higher proportion of cases to be "mild" than were detected in a survey of the 
Dutch population. This research shows the importance of the epidemiological 
frequency data and supports previous high estimates of the burden of MD. 
Finally, its results suggest that health status descriptions have only little effect 
on the valuation, and the disease-stage label is much more important. 
In chapter seven the burden of breast cancer was compared for six 
European countries and its sensitivity to different sources of variation examined. 
The major part of the burden (more than 70%) was caused by premature 
mortality and the largest burdens were found in Denmark and the Netherlands, 
countries with the highest mortality rates. Cross-national variation in disease 
epidemiology was the largest source of variation, while variation in the disability 
weights, in demography and uncertainty in epidemiological data had smaller 
effects. To compare the burden of breast cancer in different countries a simple 
inspection of the mortality rates would have sufficed. We believe this conclusion 
can be extrapolated to many other diseases, as many have a large mortality 
component. Using country-specific DWs will add little information to the 
comparison of the burden for these diseases. 
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Chapter eight, the general discussion, integrates and discusses the results from 
the six studies. The research showed that disease models can be used to detect 
consistency problems in the epidemiological data and to supplement them, 
although trends complicate their use. Furthermore, different ways were found to 
tailor stage-specific health status valuations to the epidemiology. On these 
grounds we conclude that useful disease-specific summary measures can be 
constructed in practice. Nevertheless, disease-specific summary measures should 
not be interpreted as being very precise and their practical application is 
restricted by the abundance of diseases. 
The results of the studies stressed the importance of obtaining sound 
epidemiological data for the calculation of disease-specific summary measures. 
Research should therefore focus on obtaining consistent epidemiological data, 
supplementing empirical data collection by modelling exercises. The DWs on 
the other hand, were shown to be often of less influence on the final summary 
measure. Efforts to improve them should focus mainly on combining the stage-
specific weights into an overall disease-specific one. Finally, the abundance of 
diseases will restrict the application of summary measures. Therefore the 
intended use of a measure should guide the choice between a generic or disease-
specific measure, and the design of the measure in general. 
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SUMMARY IN DUTCH 
Samengestelde volksgezondheidsmaten vatten gegevens over sterfte en ziekte 
samen in een getal. In de afgelopen decennia is de belangstelling voor en het 
gebruik van deze maten sterk toegenomen en zijn er verschillende varianten 
ontworpen. We onderscheiden onder andere samengestelde volksgezondheids-
maten die worden berekend op basis van ziektespecifieke epidemiologische 
gegevens en maten die gebruik maken van generieke informatie over sterfte en 
ziekte. Aangezien beleidsbeslissingen in de gezondheidszorg meestal gericht 
zijn op specifieke ziekten of risicofactoren, zijn ziektespecifieke samengestelde 
volksgezondheidsmaten beter bruikbaar dan generieke, tenminste in theorie. In 
de praktijk wordt het gebruik van deze maten beperkt door de vele gegevens die 
nodig zijn om ze te berekenen. Dit proefschrift richt zich op twee praktische data 
problemen die de constructie en het gebruik van samengestelde 
volksgezondheidsmaten kunnen belemmeren. 
Ten eerste zijn ziektespecifieke epidemiologische frequentie gegevens 
nodig. Deze zijn niet altijd voorhanden, en zijn bovendien vaak van 
twijfelachtige kwaliteit. Om dit soort data problemen te verhelpen zijn ziekte 
modellen zoals incidentie-prevalentie-mortaliteit (IPM) modellen ontworpen. De 
validiteit en bruikbaarheid van deze modellen zijn nog niet onderzocht. Ten 
tweede zijn ziektespecifieke waarderingen voor gezondheidstoestanden ( ofwel: 
wegingsfactoren) nodig, die precies aansluiten op de epidemiologische data. Het 
verdelen van ziekten in ziektestadia maakt het makkelijker om wegingsfactoren 
op de epidemiologische gegevens te laten aansluiten, maar veroorzaakt een 
nieuw probleem: hoe deze stadiumspecifieke wegingsfactoren te combineren tot 
een ziektespecifiek gewicht? In dit proefschrift worden twee onderzoeksvragen 
bestudeerd: 
1) In hoeverre zijn ziektemodellen valide en bruikbaar om de consistentie van 
epidemiologische gegevens te testen en om deze gegevens aan te vullen? 
2) Hoe kunnen waarderingen voor de gezondheidstoestand van patienten in 
specifieke ziektestadia worden afgestemd op epidemiologische frequentie 
gegevens? 
Deze vragen werden bestudeerd aan de hand van empirische data voor 
borstkanker en depressie m Nederland. Beide ZIJn belangrijke 
gezondheidsproblemen die door hun verschillen het mogelijk maken de 
onderzoeksvragen vanuit verschillende perspectieven te bestuderen. 
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Deel A van dit proefschrift richt zich op de eerste onderzoeksvraag. In hoofdstuk 
twee bestudeerden we de validiteit en bruikbaarheid van IPM modellen, door 
gebruik te maken van gegevens voor verschillende soorten kanker. De validiteit 
van het model werd bevestigd door het te testen met artificiele gegevens die per 
definitie volledig en consistent zijn. Daarentegen kon het model kwalitatief 
goede empirische gegevens niet reproduceren. Dit wordt niet aileen wordt 
veroorzaakt door inconsistenties in de gegevens, maar ook door trends over tijd 
in incidentie of sterfte. Alhoewel in een dynamisch model rekening gehouden 
kan worden met tijdstrends, zijn daarvoor extra gegevens nodig over de aard en 
grootte van de trend. Deze zijn vaak niet beschikbaar. Voor veel aandoeningen 
kan er dus in het model geen onderscheid gemaakt worden tussen effecten van 
data problemen en van trends. Dit compliceert het gebruik van IPM modellen 
om gegevens te verbeteren. 
In hoofdstuk drie vergeleken we in hoeverre tijdstrends en data 
problemen de modelberekeningen voor borstkanker be'invloeden. Twee factoren 
hadden een groot effect: een onderschatting van de borstkanker prevalentie en 
een stijging van de incidentie in de onderzochte periode. Andere data 
problemen die bekend waren hadden een relatief kleinere invloed. Daarnaast 
kon een deel van het verschil tussen modelberekeningen en gegevens niet 
verklaard worden. We concludeerden dat IPM modellen nuttig kunnen zijn om 
inconsistenties in gegevens op te sporen en incomplete gegevens aan te vullen, 
maar dat de modelberekeningen voorzichtig moeten worden ge'interpreteerd: 
onbekende data problemen en trends over de tijd kunnen de uitkomsten in 
onbekende richting bemvloeden. In de meeste gevallen zijn geen gegevens 
beschikbaar over de aard en grootte van trends. In die gevallen is het oordeel 
van experts onmisbaar om te beoordelen of het model, zoals gewenst, de 
kwaliteit van de data verbetert of, ten onrechte, het effect van trends corrigeert. 
In hoofdstuk vier schatten we met behulp van een microsimulatie model 
de lifetime prevalentie (ooit depressie gehad) van depressie in Nederland en 
Australie. V oor beide landen vonden we dat ongeveer 30% van de mannen en 
40% van de vrouwen ooit een episode van depressie hebben gehad. De 
percentages die in cross-sectionele studies worden gerapporteerd zijn veellager 
om twee redenen: 1) mensen die een depressie krijgen na het onderzoek worden 
niet meegeteld, 2) zelfrapportage van symptomen en het moment waarop die 
aanwezig waren kan door herinneringsproblemen aan bias onderhevig zijn. De 
berekeningen toonden aan dat de empirische schatting van lifetime prevalentie 
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m Nederland met ten minste 35% onderschat wordt ten gevolge van deze 
"herinnerings-bias". Dit zet vraagtekens bij de empirische meting van lifetime 
prevalentie. Ret modelleren maakte het mogelijk om een indirecte schatting van 
de lifetime prevalentie van depressie te verkrijgen. Dit is waardevol wanneer 
empirische gegevens uit langdurige follow-up studies ontbreken. 
Deel B van dit proefschrift heeft betrekking op het afstemmen van de 
wegingsfactoren op de epidemiologie. In hoofdstuk vijf onderzochten we de 
associaties van de ernst van depressie en het type depressie ( eenmalige en 
recidiverende depressie) met functionele beperkingen in de Nederlandse 
algemene bevolking. Hogere ernstklassen waren geassocieerd met meer 
beperkingen, zij het dat "matige" en "ernstige" depressie niet significant van 
elkaar verschilden. Het verschil tussen niet-depressief en "licht" depressief was 
groter dan verschillen tussen de opvolgende ernstklassen. Recidiverende 
depressie was niet geassocieerd met meer functionele beperkingen dan 
eenmalige depressie. We concludeerden dat drie clusters van depressie gebruikt 
kunnen worden om de verdeling van beperkingen in de depressieve populatie te 
beschrijven: "lichte", "matige tot ernstige" en "ernstige depressie met 
psychotische kenmerken". Ben vereenvoudiging van de DSM ernst categorieen 
zou kunnen worden overwogen. Ret aanzienlijke verschil in functionele 
beperkingen tussen "licht" depressief en niet depressief suggereert dat "lichte" 
depressie als relevant dient te worden beschouwd. 
Of de ziektelast van depressie werd overschat in eerdere ziektelast 
berekeningen bestudeerden we in hoofdstuk zes. Berder gebruikte 
wegingsfactoren voor depressie lijken meer de klinische situatie te 
weerspiegelen dan de situatie in de populatie, waaruit de epidemiologische 
gegevens zijn afgeleid. We leidden wegingsfactoren af voor de drie clusters van 
beperkingen voor depressie ("licht", "matig tot ernstig" en "ernstig met 
psychotische kenmerken") en berekenden de ziektelast van depressie. Ben 
gemiddelde wegingsfactor voor depressie werd berekend op basis van de 
proportionele prevalenties van de drie clusters in de Nederlandse bevolking. De 
nieuwe wegingsfactoren waren over het algemeen gelijk aan eerdere studies, 
zodat er geen aanleiding was om te veronderstellen dat de ziektelast in eerdere 
studies werd overschat. Ben uitzondering hierop was de gemiddelde 
wegingsfactor uit de Nederlandse Ziektelast Studie 1994. Deze was gebaseerd 
op expert schattingen van de proportionele prevalenties van de clusters. Het 
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aandeel van "lichte" depressie was in deze schattingen veel hoger dan in een 
steekproef van de Nederlandse bevolking. Dit onderzoek laat zien hoe 
belangrijk de epiderniologische frequentie gegevens zijn in ziektelast 
berekeningen en ondersteunt eerdere hoge schattingen van de ziektelast van 
depressie. 
In hoofdstuk zeven vergeleken we de ziektelast van borstkanker in zes 
Europese landen en onderzochten we de gevoeligheid van de schatting van de 
ziektelast voor verschillende bronnen van variatie. Ret grootste deel van de 
ziektelast (meer dan 70%) werd veroorzaakt door vroegtijdige sterfte. De 
grootste ziektelast werd dan ook gevonden in Denemarken en Nederland: de 
landen met de grootste sterfte aan borstkanker. V ariatie in de epiderniologische 
frequentie gegevens tussen landen was de grootste bron van variatie, terwijl 
variatie in wegingsfactoren, in demografie, en de onzekerheid in de 
epiderniologische gegevens kleinere effecten hadden. Hieruit concludeerden we 
dat om de ziektelast van borstkanker in de verschillende landen te vergelijken 
een simpele inspectie van de sterfte gegevens voldoende was. We gel oven dat 
dit ook voor veel andere ziekten zal gelden, aangezien veel ziekten een hoge 
sterfte component hebben. Ret gebruik van verschillende wegingsfactoren per 
land zal voor die ziekten weinig informatie toevoegen aan de vergelijking van de 
ziektelast. 
Hoofdstuk acht integreert en bespreekt de resultaten van deze zes studies. Ret 
onderzoek laat zien dat ziektemodellen gebruikt kunnen worden om problemen 
in epiderniologische gegevens op te sporen en om deze aan te vullen, alhoewel 
tijdstrends hun gebruik bemoeilijken. Daarnaast werden verschillende manieren 
gevonden om stadiumspecifieke wegingsfactoren aan te laten sluiten op de 
epiderniologie. Op deze gronden concluderen we dat het in de praktijk vaak 
mogelijk is om bruikbare ziektespecifieke samengestelde volksge-
zondheidsmaten te berekenen. Ziektespecifieke maten zijn echter niet erg 
nauwkeurig en hun praktische toepassing voor de beschrijving en vergelijking 
van de totale volksgezondheid in populaties wordt beperkt door de grote 
hoeveelheid ziekten. 
De resultaten van de studies benadrukken het belang van het verzamelen 
van betrouwbare epiderniologische gegevens voor het berekenen van 
ziektespecifieke samengestelde volksgezondheidsmaten. Onderzoek moet zich 
richten op het verkrijgen van consistente epiderniologische data, door empirische 
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data verzameling, en aanvullend daarop het gebruik van modellen. Ook werd 
aangetoond dat wegingsfactoren minder invloed op de uiteindelijke 
samengestelde maat hebben. Inspanningen om wegingsfactoren te verbeteren 
zouden zich met name moeten richten op het combineren van stadiumspecifieke 
wegingsfactoren. 
Tot slot, samengestelde volksgezondheidsmaten die zijn opgebouwd uit 
alle in een populatie voorkomende relevante ziekten, stellen extreem hoge eisen 
aan de beschikbaarheid en betrouwbaarheid van de epidemiologische gegevens. 
Het beoogde gebruik van een maat moet bepalend zijn voor het aantal op te 
nemen ziekten en de mate van detaillering, evenals voor het verdere antwerp 
ervan. Het ontwikkelen van samengestelde volksgezondheidsmaten blijft 
"maatwerk", waarbij het uiteindelijke doel en de beschikbaarheid van gegevens 
maatgevend zijn. 
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